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ABSTRACT 
The thesis entitled "Analysis of Cardiovascular Drugs in 
Pharmaceutical Formulations" is comprised of five chapters. The first 
chapter describes a general introduction of the subject matter. The very 
relevant matters include: 
• a brief history of drug and its relation with our daily life 
• importance of drug analysis and its role in testing the medicine before 
it is made available to the public 
• a note on drug impurity profiling 
• a brief description of various analytical techniques and its 
applications in the quantitation of drug in pharmaceuticals and 
biological fluids 
• a description on process monitoring and validation 
• importance of statistical treatment of calibration data in order to 
facilitate the selection of parameters which are relevant to the 
performance and suitability of the given analytical procedure. 
A description of the classification of drugs based on 
pharmacological action on human organs is included and finally a brief 
literature and chemical structures of the four drugs, i.e., metoprolol 
tartrate, enalapril maleate, labetalol hydrochloride and amiodarone 
hydrochloride are presented. An abundant and well-composed list of 
references is given at the end of this chapter taken from the world's 
leading scientific journals in the field. 
The Second chapter describes a kinetic spectrophotometric 
method for the determination of metoprolol tartrate in commercial 
dosage forms. The procedure is based on the reaction of the drug with 
1-chloro-2,4-dinitrobenzene (CDNB) in dimethylsulfoxide (DMSO) at 
100 ± 1°C. The reaction is investigated by measuring the change in 
absorbance with time at 420 nm. Fixed-time (AA) and equilibrium 
methods are chosen for obtaining the calibration curves. Both the 
calibration curves were found to be linear over the concentration range 
of 5 - 60 pg mL"\ The regression analysis of calibration data resulted 
into the linear regression equations: 
AA = -1.608x 10-^ +3.96.x 10"^  C 
and ' 
A = 7.31 X 10"^+1.90x10-^0 
for fixed-time (AA) and equilibrium methods, respectively. The limit of 
detection (LOD) for fixed-time (AA) and equilibrium methods are 1.16 
and 0.415 |jg m L \ respectively. The method has been successfully 
applied to the quantitation of metoprolol tartrate in commercial dosage 
forms. Statistical comparison of the results shows that there is no 
significant difference between the proposed methods and El-Ries's 
spectrophotometric method. 
In chapter three, four simple, rapid and sensitive 
spectrophotometric methods have been described for the determination 
of enalapril maleate in pharmaceutical formulations. The first method is 
based on the reaction of carboxylic acid group of enalapril maleate with 
a mixture of potassium iodate (KIO3) and iodide (Kl) to form yellow 
coloured product in aqueous medium at 25 ± 1°C. The reaction is 
followed spectrophtometrically by measuring the absorbance at 352 nm. 
The second, third and fourth methods are based on the charge transfer 
complexation reaction of the drug with p-chloranilic acid in 1,4-dioxan-
methanol medium; 2, 3-dichloro 5, 6-dicyano 1, 4- benzoquinone (DDQ) 
in acetonitrile-1,4-dioxan medium and iodine in acetonitrile-
dichloromethane medium. Under optimized experimental conditions, 
Beer's law is obeyed in the concentration ranges of 2.5 - 50, 20 - 560, 
5 - 7 5 and 10 - 200 pg mL"\ respectively. All the methods have been 
applied to the determination of enalapril maleate in pharmaceutical 
dosage forms. Results of analysis are validated statistically. 
The fourth chapter includes two simple and sensitive 
spectrofluorimetric methods for the determination of labetalol 
hydrochloride. In method A, the native fluorescence was measured at 
432 nm after excitation at 312 nm. The second method (method B) is 
based on the formation of a ternary complex between zinc (II), eosin 
and labetalol. The fluorescence intensity of the ternary complex was 
measured at 452 nm after excitation at 317 nm. Optimum conditions for 
the determination were also investigated. The linear range and 
detection limit for methods A and B were found to be 1.25 - 30.0 pg mL" 
^ 0.24 pg mL"^  and 0.5 - 4.0 pg mL"^ 0.08 pg mL"\ respectively. The 
proposed methods are simple, practical and relatively free of 
interference from coexisting substances. The methods have been 
applied to assay labetalol in commercial tablets and human uhne 
samples. The results show good accuracy and precision. 
The last chapter describes two optimized and validated 
spectrophtometric methods for the determination of amiodarone 
hydrochlohde in commercial dosage forms. Method A is based on the 
reaction of tertiary amino group of the drug with N-bromosuccinimide in 
methanol-acetone medium resulting in the formation of yellow coloured 
product, which absorbed maximally at 353 nm. Method B involves the 
formation of coloured chloroform extractable ion-pair complex of the 
drug with bromothymol blue (BTB) at pH 2.32 absorbing maximally at 
400 nm. Beer's law is obeyed in the concentration ranges 50 - 600 and 
2 - 55 fig mL"^  with molar absorptivity of 1.58 x 10^ and 1.50 x 10'^  L 
molVm^ for methods A and B, respectively. The regression analysis 
yields the calibration equations: 
A = 4.012 X lO- '^+l . iex 10~^C 
and 
A = 9.612 X 10"^+2.198 X 10^^C 
for methods A and B, respectively. The application of the proposed 
methods to the analysis of commercial dosage forms is presented. 
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Chapter 1 
gwm^AL im9(pcDVcno9{ 
The need to provide adequate medicines has been present for as long as humanit\ 
can trace its roots. Since antiquity people have tried to cure diseases by eating, drinking 
or applying substances; often plant extracts that are now referred to as herbal medicines 
Originally, the attempts to discover new drugs and new cures were based on intuition and 
empirical observation, while any successfiil results were more likely to be the product of 
fortunate accidents. Over the last century however, the search for new drugs has changed 
dramatically. Advances in the understanding of human biology, new technolog}. and 
more recently market considerations have altered the way drugs are being discovered. 
Pharmaceutical organizations have developed into large corporations, which are not 
prepared to rely upon 'fortunate accidents', nor can they afford to. This has resulted in 
pharmaceutical organizations seeking different strategies to optimize the efficiency of 
their drug discovery process. This endeavour to optimise the drug discovery process has 
resulted in the progressive replacement of the highly serendipitous process of drug 
discovery with a process dominated by new technology where scientists can almost 
statistically predict the outcome of their research. This change was primarily the result of 
the strategic imperative and significant technology changes that occurred during the last 
fifty years [1]. 
Drug Development Process 
The development of a pharmaceutical product requires a broad spectrum ot 
scientific expertise to lead it through the complex pathway from discovery through 
characterizadon of quality, efficacy and safety, which are the hallmarks of a successful 
drug product. A company must be highly proactive in setfing targets for appraising and 
selecting a compound that has the highest probability of success. In addition, the 
compound and its therapeutic use must be consistent with the research and marketing 
goals of the company in order to leverage existing resources and experience. To ensure 
scientific and commercial success, it is critical to understand the drug development 
process (Fig. 1.1) and the myriad tasks and milestones that are vital to a comprehensive 
development plan. 
Drug Development Phases 
There are three major phases in drug development: 
1. Pre-clinical research and development 
2. Clinical research and development 
3. After the compound is on the market, a possible "post-marketing" phase 
The pre-clinical phase represents bench (in vitro) and then animal testing, 
including kinetics, toxicity and carcinogenicity. In the U.S., an investigational new drug 
application (IND) is submitted to the Food and Drug Administration seeking permission 
to begin the heavily regulated process of clinical testing in human subjects. The clinical 
research (IND) phase-representing the time from beginning of human trials to the new 
drug application (NDA) submission that seeks permission to market the drug - is by far 
the longest portion of the drug development cycle and can last from 2 to 10 years. 
Phase I trials, sometimes called, "first in human" trials, are generally conducted 
on relatively small groups (typically 10 to 30) of healthy volunteers (except for oncology 
drugs or other potentially toxic compounds) in specialized units resembling small 
hospitals with 20 to 50 monitored beds. The "impatienf portion of Phase I trials usually 
lasts from a day or two to a week (though follow up can last up to about a month), and 
are designed to assess the safety of a compound and study its pharmacokinetics 
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(Pk - what the body does to the drug) and pharmacodynamics (Pj - what the drug does to 
the body). 
In some cases, human metaboHsm can differ markedly from animals so that a 
drug with a half life of a few hours in dogs may turn out to have a half life of several days 
in humans, or compound with no animal toxicity may cause elevation in liver functions in 
humans. A rough idea of the maximum safe or tolerated dose, as well as a general side 
effect profile is obtained during Phase I trials. Many compounds never make it past Phase 
I, as they are found to have unacceptable side effects. Assuming a compound is shown to 
be safe for healthy subjects and survives Phase I, then development proceeds to a series 
of Phase II trials. These trials typically enroll anywhere from about 20 or 30 patients up 
to a few hundred at most. These patients usually have a relatively "pure" form of the 
disease for which the drug is intended. In other words, they suffer from as little other 
intercurrent disease as possible, and the list of concomitant medications they can be 
taking is usually restricted. For example, patients with newly diagnosed, but untreated, 
diabetes, with no evidence of end organ damage, would be used to test a new antidiabetic 
agent. 
Phase II trials tend to last only a few weeks to, at most, a few months. Initials 
Phase II trials (sometimes called, Ila) are pilot trials to determine dose range. They tend 
to be conducted at specialized centers, like university medical centers, by specialized 
investigators, such as medical school faculty. Subsequent Phase II trials (often called, lib) 
are aimed at elucidating dose response relationship, safety and, for the first time, efficacy, 
of the compound treating the disease or condition for which it is intended. 
Drug - drug interactions are also studied carefully during Phase II as well as P|, 
and P(i in diseased patients, which can sometimes differ markedly from what was 
observed in healthy volunteers. 
Phase II can encompass anywhere from a few to 20 or more clinical trials, and the 
"development plug" can be pulled - and frequently is - after any of them. Once again. 
assuming the drug shows sufficient evidence of efficacy and no major safety concerns -
whether purely from drug effect, or fi'om drug - drug interactions - a go/no go decision 
will be made to proceed to Phase III. 
Phase III is where the "rubber meets the road." At least two pivotal Phase 111 trials 
demonstrating efficacy and safety in large numbers of pafients, including special 
populations with all forms of the disease or condition to be treated, who may be on 
multiple other medications, are required for regulatory approval in the U.S. Few drugs 
have been approved with data from less than two pivotal trials, and, if so, generally 
require post - marketing commitments to ensure that safety and efficacy is validated after 
marketing. 
In addition to the two successful pivotal Phase III trials needed before an NDA 
can be filed, numerous additional special trials are usually demanded by regulatory 
agencies throughout the course of the IND clinical development period encompassing 
Phase I through III. 
The results from all the Phase I, II and III studies are submitted to the FDA (in the 
USA) and other regulatory authorities in other territories for review. If the regulators 
agree that the data proves the efficacy and safety of the drug, and that it provides 
sufficient benefit over exisfing therapies, then the drug is granted New Drug Approval 
(NDA) status and can be marketed and the new medicine becomes available for 
physicians to prescribe. The company must continue to submit periodic reports to FDA. 
including any cases of adverse reactions and appropriate quality control records. 
It is usually a long way from the very early synthesis of a molecule to the successful 
submission for registration of a new drug. Many hurdles have to be taken and many pitfalls 
may arise. One of the well-known complications in this respect may be the gradual change 
of the route of synthesis during development and therefore the possible change in the 
impurity profile. Such a change may have major consequences, in particular for the 
interpretation of toxicological and clinical studies [2]. The presence of impurities in an 
active pharmaceutical ingredients (API) can have a significant impact on the quality and 
safety of the drug products. The International Conference on Harmonisation (ICH) 
guidelines [3, 4] achieved a great deal in harmonizing the definitions of the impurities m 
new drug substances. It is necessary to perform all the investigations on appropnate 
reference standards of drug and impurities to get meaningfiil specifications. In order to 
meet the challenges to ensure high degree of purity of drug substances and drug products, a 
scheme (Fig. 1.2) is proposed for profiling drug impurity. Finally, analytical methods based 
on analytical instrumentation must be employed to quantitate drug substance and its 
impurides. 
Identification by TLC, HPTLC, HPLC, GC or CE 
Matching of retention parameters with 
authentic samples of potential impurities 
Identified ? 
Yes 
No 
Unidentified imourities 
Preparative 
TLC 
Preparative 
HPTLC 
Preparative 
HPLC 
* IR,NMR,MS 
HPLC (CE 
or GC) / MS 
Information sufficient ? 
No 
HPLC/ NMR 
Yes 
Suggested 
Synthesis 
Identification by 
TLC/ HPLC 
Determination Identified 
impurities 
Fig. 1.2: Proposed chart for profiling drug impurity. 
Sources of impurities 
There are three important sources of impurities. 
1. Synthesis-related impurities 
Impurities in a drug substance or a new chemical entity originate mainly during 
the synthetic process from raw materials, solvents, intermediates, and by-products. The 
raw materials are generally manufactured to much lower purity requirements than a drug 
substance. Hence, it is easy to understand why they can contain a number of components 
that can in turn affect the purity of the drug substance. 
Similarly, solvents used in the synthesis are likely to contain a number of 
impurities that may range from trace levels to significant amounts that can react with 
various chemicals used in the synthesis to produce other impurities. Intermediates are 
also not generally held to the purity level of the drug substance-hence the remarks made 
for the raw materials apply. It is not reasonably possible to theorize all by-products; as a 
result, any such products that may be produced in the synthesis would be hard to monitor. 
The "pot reactions," i.e., when the intermediates are not isolated, are convenient, 
economical, and time saving; however, they raise havoc in terms of the generation of 
impurities because a number of reactions can occur simultaneously. Incidentally, this 
problem of numerous reactions occurring simultaneously can also be encountered in 
single reactions where intermediate is isolated. 
The final intermediate is generally controlled in the pharmaceutical synthesis by 
conducting regulatory impurity testing. This typically entails residual solvents (that are 
not used in further downstream processing) or process impurities (in cases where they 
conclusively demonstrate that these moieties are not also degradation products). It is 
important to remember that this step is the last major source of potential impurities, 
therefore, it is very desirable that the methods used for analysis at this stage be rigorous 
It should be remembered that base-to-salt or acid-to-salt conversions could also generate 
new impurities. Furthermore, thermally labile compounds can undergo decomposition it 
any further processing involves heating. 
2. Formulation-related impurities 
A number of impurities in a drug product can arise out of interactions with 
excipients used to formulate a drug product. Furthermore, in the process of formulation, a 
drug substance is subjected to a variety of conditions that can lead to its degradation or 
other deleterious reactions. For example, if heat is used for drying or for other reasons, it 
can facilitate degradation of thermally labile drug substances. 
Solutions and suspensions are potentially prone to degradation that is due to 
hydrolysis or solvolysis. These reactions can also occur in the dosage form in a solid 
state, such as in the case of capsules and tablets, when water and another solvent has been 
used for granulation. Not only can the water used in the formulation contribute its own 
impurities, it can also provide a ripe situation for hydrolysis and metal catalysis. Similar 
reactions are possible in other solvents that may be used. Oxidation is possible for easily 
oxidized materials if no precautions are taken. Similarly, light-sensitive materials can 
undergo photochemical reactions. 
3. Degradation-related impurities 
A number of impurities can be produced because of API degradation or other 
interactions on storage. Therefore, it is very important to conduct stability studies to 
predict, evaluate, and ensure drug product safety [5]. Stability studies include evaluation 
of stability of API, prefonnulation studies to evaluate compatibility of API with the 
excipients to determine its stability in the formulation matrix, accelerated stabilitv 
evaluations of the test or final drug product, stability evaluation via kinetic studies and 
projection of expiration date, routine stability studies of drug products in marketed 
sample or dispensed package under various conditions of temperature light, and 
humidity. 
The stability studies under various exaggerated conditions of temperature, 
humidity, and light can help us determine what potential impurides can be produced by 
degradation reactions. It is important to establish a viable stability programme to evaluate 
impurifies. A good stability programmme integrates well the scientific considerations 
with regulatory requirements. 
It is incumbent upon the chemist to perform some kinetic studies to predict 
stability of a drug substance and to evaluate degradation products. However, it is also 
important to recognize the limitations of such predictions. ICH guidelines [3, 4] for the 
identification and qualification threshold of impurities and degradation products are 
provided in Table 1.1. As can be seen fi-om the data in Table 1.2, ICH treats the 
degradation products slightly differently than impurities even though for all intents and 
proposes the degradation products are impurities. 
Table 1.1: Thresholds for reporting impurities. 
i : 
Maximum 
daily dose 
Reporting 
Threshold 
Identification 
Threshold 
Quantification 
Threshold 
Less or equal 
to 2 g/day 
> 2 g/day 
0.05% 
0.03% 
0.10%or l.Omg/day 0.15% or 1.0 mj^day 
(whichever is lower) (whichever is lower) 
0.05% 0.05% 
Table 1.2: Threshold for reporting degradation products in a new drug product. 
Maximum daily dose Threshold 
I g 
> l g 
0.1% 
0.05% 
ANALYTICAL TECHNIQUES 
From the beginnings of official pharmaceutical analysis, the aim of including 
assay methods in compendial monographs has been to characterise the quality of bulk 
drug materials by setting limits for their active ingredient content. The analytical 
techniques used in drug analysis are given in Table 1.3, based on the recent editions of 
European [6] and US [7] Pharmacopoeias. 
Titrimetric methods 
It is apparent trom Table 1.3 that in the majority of cases the titrimetric methods 
are still used, especially in European Pharmacopoeia. Advantages of these methods are 
saving time and labour, high precision and the fact that there is no need of using 
reference standards. Non- aqueous titration methods are frequently used in drug analysis, 
which can be extended to weak acids and bases. In majority of the cases, the end point is 
detected potentiometrically and thus, improving the precision of the method. In the case 
of titrimetric methods the lower and upper limits of assay are usually 98.0 - 99.0% and 
100.5 - 102.0%, respectively (most typically 99.0- 101.0%). Recently, titrimetric 
methods have been used for the determination of salbutamol sulphate [8], ranitidine [9]. 
ciprofloxacin [10] and atenolol [11] in commercial dosage forms. 
High performance liquid chromatography 
HPLC methods appeared for the first time for the assay of bulk drug materials in 
1980 [12]. HPLC is widely used both in drug research and development and also 
pharmaceutical manufacture. Applications in research and development include purity 
control of new drug synthesis, separation of products during stability testing of drugs and 
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Table 1.3: Proportion of various analytical methods prescribed for the assay of bulk 
drug materials in Ph. Eur. 4 |6] and USP XXVII [7|. 
Method 
HPLC 
GC 
Titration 
Acid-base 
Aqueous mixtures 
Indicator 
Potentiometric 
Non-aqueous 
Indicator 
Potentiometric 
Redox (lodometry, Nitritometry, ( 2tC.) 
Other (complexometry, argentometry, etc.) 
UV-vis spectrophotometry 
Microbiological assay (antibiotics) 
Other (IR, NMR, polaremetry, 
absorption spectroscopy, polarograj 
fluorimetry, 
3hy, gravimetry 
atomic 
etc.) 
Ph. Eur. 
(%) 
15.5% 
2 % 
69.5 % 
57.5 % 
21 % 
6.5 % 
14.5 % 
36.5 % 
9.5 % 
27% 
6.5 % 
5.5 % 
9.5 % 
3 % 
0.5% 
4 USP 27 
(%) 
44% 
2.5 % 
40.5 % 
29.5 % 
5.5 % 
4.5 % 
1 % 
24% 
14% 
10%) 
5.5 % 
5.5 % 
8.5 % 
2.5 % 
2 % 
formulations, and pharmacokinetics, i.e. the determination of drugs and metabolites m 
biological fluids during metabolism and clinical investigations. In phamiaceuticai 
manufacture, HPLC is widely used in the quality control of both raw materials and 
finished dosage forms. As seen in Table 1.3, this has become the predominant method in 
USP XXVII [7] and - although to a lesser extent- it is one of the most widely used 
methods also in Ph. Eur. 4 [6]. Fig. 1.3 shows the pie diagram indicadng the percent 
usage of various chromatographic techniques from which it becomes very clear that 
HPLC has been the main technique used for analysis of impurities in drugs. The choice ot 
proper detection mode is crucial to ensure that all the components are detected. With UV 
detection, this problem could be overcome by using a multiple wavelength scanning 
programme which is capable of monitoring several wavelengths simultaneously. It 
provides assurance that all the UV-absorbing components are detected, if present m 
sufficient quantity. Photodiode-array detectors are useful in determining the purity of 
enantiomeric drugs by HPLC. Most workers used the reversed-phase mode with UV 
absorbance detection whenever appropriate, because this provided the best available 
reliability, analysis fime, repeatability and sensitivity. In fact, this technique has set the 
standard against which others are compared (Fig. 1.4.) Several drugs have been assayed 
in pharmaceutical formulations [13 - 17] and in biological fluids [18-20] using HPLC. 
Thus, HPLC provides a major service in answering many questions posed by 
pharmaceutical industry. However, the limitations of HPLC include the cost of columns, 
solvents and a lack of long term reproducibility due to the proprietary nature of column 
packing. Liquid chromatography combined with mass spectrometry (LC-MS) is 
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GC 
7% 
HPTLC 
9% 
LC-MS 
8% 
GC-MS 
2% 
MEKC 
HPL( 
53% 
Fig. 1.3: Pattern of use of different chromatographic techniques employed for 
analysis of impurities in drugs. 
UV- Ultra Violet detector 
EL- Evaporative Light Scattering detector 
FL- Fluorescence detector 
EC- Electro Chemical detector 
IE- Ion Exchange detector 
UV 
94% 
Fig. L4: Usage of different detectors for HPLC analysis of drugs. 
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considered as one of the most important techniques of the last decade of 20'^  century 
[21]. It became the method-of-choice for analytical support in many stages of qualit\ 
control and assurance within the pharmaceutical industry [22, 23]. Recently HPl.C-MS 
has been used for assay of drugs [24 - 29]. 
Gas chromatography 
Gas chromatography is a dynamic method for separation and detection of volatile 
organic compounds. Gas liquid chromatography commands a significant role in the 
analysis of pharmaceutical product [30]. The advent of high-molecular weight products 
such as polypeptides, or thermally unstable antibiotics limits the scope of this technique. 
Its principal limitation rests in the relative non-volatility of the drug substances. 
Therefore, derivatization is virtually mandatory, but the techniques for producing volatile 
derivatives of drugs are legion. Recently, gas chromatography has been used for assay of 
drugs such as isotretinion [31], fluoxetine, fluvoxamine, clomipramine [32] and nicotine 
[33]. Due to insufficient volatility and thermal stability of the majority of drug materials, 
gas chromatography can also be used for their assay in a limited number of cases only, as 
reflected by the figures in Table 1.3. 
Capillary electrophoresis 
The term 'capillary electrophoresis' describes a family of related techniques in 
which separations are carried out in narrow bore capillaries under the influence of an 
electric field [34]. Capillary electrophoresis has rapidly become a powerful separation 
technique for large and small molecules, which can be organic or inorganic, and has 
found several applications in different fields, such as environmental, clinical, forensic, 
biochemical and pharmaceufical analysis. Compared with other techniques, CE has 
several advantages: the high resolving power, low consumpfion of sample, solvent and 
chiral selector, as well as its high flexibility in choosing and changing types of selectors 
CE can be applied in aqueous and non aqueous media and can be coupled with several 
detectors [35]. Moreover, owing to the large efficiencies obtained in CE, this technique 
exhibits impressive results for the separation of enantiomers. 
Numerous review papers have summarized the applications of chiral CE in 
different groups of analytes, including pharmaceutical compounds. A review on CE 
analysis of pharmaceuticals was pubUshed recently, in which chiral CE applications were 
also summarized [36]. In an overview of CE analysis of small molecules, Altria and Elder 
also discussed in detail some chiral CE applications on pharmaceutical compounds [37]. 
Stereoselective peptide analysis and enantioselective analysis of 2-propionic acid 
nonsteroidal anti-inflammatory drugs were also reviewed [38, 39]. 
Thin layer chromatography 
The invention and rapid spread of thin layer chromatography (TLC) in the 1960s 
created an entirely new situation in the field of drug analysis. TLC is a powerful tool for 
screening unknown materials in bulk drugs [40]. It provides a relatively high degree of 
assurance that all possible components of the drug are separated. The high specificity of 
TLC has been exploited to quantitative analytical purpose using spot elution followed by 
spectrophotometric measurement. TLC has been utilized for the determination of several 
antihypertensive drugs (Captopril, Enalapril, Lisonopril, Qunopril, Ramipril, and 
Cilazapril) from the group of angiotensin converting enzyme inhibitors [41]. 
High performance thin layer chromatography 
Now a days high performance thin layer chromatography (HPTLC) is becoming a 
routine analytical technique due to its advantages of low operating cost, high sample 
throughput and need for minimum sample clean up. The major advantage of HPTLC is 
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that several samples can be run simultaneously using a small quantity of mobile phase 
unlike HPLC, thus lowering analysis time and cost per analysis. HPTLC has been used 
for the detennination of a number of drugs in pharmaceutical preparations [42-45]. 
However, the impurities detected by HPTLC are limited to 0.1%. 
Flow injection analysis 
Flow injection analysis (FI) is a well-established automated technique with 
numerous and widespread applications in quantitative chemical analysis. In brief, a 
typical FI setup involves injection of a defined volume of the sample into a moving 
stream of a solution which serves as a carrier and propelles the sample zone to a flow 
through detector. Between the injection and detection points, the analyte of interest is 
chemically or physically transformed to detectable specie. FI is generally a simple and 
inexpensive technique employing common instrumentation such as peristaltic pumps and 
low-pressure injection valves. Compared to batch methods it offers increased sampling 
rate, lower reagents consumption, better precision and high versatility. 
The above-mentioned advantages of FI have led to a continuously increasing 
interest in pharmaceutical analysis and quality control applications [46]. Apart from the 
monograph published by Calatayud in 1996 [46], recent reviews on the application of FI 
to pharmaceutical analysis cover the topics of multicomponent determinations [47] and 
amperometric detection [48]. Recent applications of FI in pharmaceutical analysis 
include the determination of levofloxacin [49], levodopa and benserazide [50]. 
paracetamol [51, 52] and isoproterenol [53]. 
UV-Visible spectrophotometry 
Another group of methods in pharmacopoeias are spectrophotometric methods 
based on natural UV-VIS absorption and visual (VIS) spectrophotometric methods based 
on chemical reactions [54]. The advantages associated with these methods are low time 
and labour consumption. The precision of these methods is also excellent. The 
colourimetric methods are usually based on the following aspects: 
• Complex-formation reaction 
• Oxidation-reduction process 
• A catalytic effect 
The Encyclopedia of Analytical Science [55] contains several sections on ultraviolet and 
visible spectrophotometry discussing theory and instrumentations, techniques and 
applications. It is worth mentioning that colourimetric methods are frequently used for 
the assay of bulk materials. For example, the blue tetrazolium assay is used for the 
determination of corticosteroid drug formulations [56, 57] and is included in the recent 
edition of US Pharmacopoeia «351) "Assay for steroids" [7]). The colourimetric method 
is also utilized for the determination of cardiac glycosides and is presented in recent 
edition of European Pharmacopoeia [6]. Several approaches using spectrophotometry for 
determination of active pharmaceutical ingredients in bulk drug and formulations have 
been reported and details of these methods are recorded in Table 1.4 [58 - 100]. 
Table 1,4: Quantitative analysis of drugs in pharmaceutical formulations by I \ -
visible spectrophotometric procedures. 
Name of drug Reagents used ^Mnaxinni) Ret'erenct 
Acelamiiiopheii m-Cresol 640 58 
Amiodarone HCl p-Chloranilic acid 535 59 
2,3-DicliIoro 5,6-dicyano 575 59 
1,4- benzoqiiinone 
Amiodipine bcsylatc p-Chloranilic acid 540 60 
Ninhydrin in DMF medium 595 61 
2,3-Dichloro 5,6-dicyano 580 62 
1,4- benzoqiiinone 
Ascorbic acid 530 62 
Amoxycillin & KIO^ 520 63 
ampicillin 
Ampicillin. amoxycillin Folin ciocalteau phenol 
& carbcnicillin 
Ascorbic acid l-Cliioro-2,4-dinitrobenzene 
Diltiazcm HCl Sodium metavanadate 
Bromothymol blue 
Bromophenol blue 
750,770 
&750 
380 
750 
415 
415 
64 
65 
66 
67 
67 
Famotidine 
Irbesartan 
Lisinopril 
Labetalol HCl 
Losartan potassium 
Levodopa 
Methyldopa 
L-dopa 
Menadione 
Bromocresol green 
KMn04 in alkaline medium 
Ninhydrih 
p-Chloranilic acid 
Ninhydrin 
Ascorbic acid 
N-Bromosuccinimide 
Chloranil 
Sodium nitroprusside & 
hydroxylamine hydrochloride 
4-amino benzenesulfonic acid, 
sodium nitrite and sodium 
bicarbonate 
KMn04 in alkaline medium 
Ce(rV) nitrate in H2SO4 medium 
Ce(IV) nitrate in H2SO4 medium 
NaOH 
NaOH in the presence of amine 
415 
610 
590 
Potassium iodate and iodide in 352 
aqueous medium 
7,7,8,8-Tetracyanoquinodimethane 743 
525 
595 
530 
353 
520 
695 
395 
67 
68 
69 
7(1 
71 
71 
72 
73 
73 
74 
75 
603 
510 
550 
300 
450 
76 
77 
77 
78 
79 
Metoprolol tartrate KMn04 in alkaline medium 610 8f) 
Nalidixic acid 
Nicorandil 
Nifedipine 
Norfloxacin 
Pantoprazole sodium 
Ninhydrin 
Persulphate in alkaline medium 
595 81 
320,390 82 
Brucine-sulphanilic acid in H2SO4 410 83 
medium 
3 -Methyl -2 -benzothiazoline 
hydrazone HCl-metol 
560 
N-(l-naphthyl) Ethylenediamine 525 
Dihydrochloride 
KMn04 in neutral medium 
4-Methyl amino phenol and K2Cr207 525 
Bromocresol green 
Bromophenol blue 
Bromothymol blue 
Eriochrome Black T 
KOH in dimethylsulphoxide 430 
Ammonium molybdate 830 
KMn04 in alkaline medium 603 
Potassium ferricyanide and 725 
ammonium ferric sulphate 
3^ 
530 
415 
415 
415 
520 
85 
86 
87 
87 
87 
87 
89 
90 
Perindopril erbumine 1 -Chloro-2,4-dinitrobenzene in 420 91 
Ramipril 
Silymarin 
Trimethoprim 
Thyroxine 
dimethyl sulphoxide 
Potassium iodate and potassium 352 
iodide in aqueous medium 
1-Chloro-2,4 dinitrobenzene 420 
KMn04 in neutral medium 530 
3-Methyl-2-benzothiazoline 430 
hydrazone & potassium persulphate 
Persulphate in alkaline medium 355 
Nitrous acid 420 
93 
94 
95 
96 
97 
Verapamil HCl Chloramine T 
N-Bromosuccinimide 
Potassium metaperiodate 
425 
415 
425 
98 
99 
100 
Tropaeolin 000 No. 400 100 
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Derivative spectrophotometry 
Derivative spectrophotometry (DS) has been used for the quantitative analysis 
because of its great sensitivity and selectivity as well as its relativity low cost. Derivati\e 
spectra normally contain more apparent spectral detail than the normal spectra (zero 
derivatives). DS is an analytical technique of great utility for resolving drug mixtures 
with overlapping spectra. Moreover, DS has been applied successfiilly to the 
determination of drugs in the presence of their degradation products. In determination ot 
an individual drug, drug additivities and drug decompositions both interfered. Therefore, 
utilizing DS for the assay of individual drug allowed elimination of undesirable 
interferences as compared with normal spectrophotometry. Moreover, Table 1.5 
illustrates the analytical characteristics of derivative methods for determination of 
pharmaceutical compounds [101-108]. 
Fluorimetry 
The luminescence phenomenon, which involves the emission of electromagnetic 
radiation by chemical species, is one of the most active current research fields, as shown 
by the increasing number of papers, reviews and monographs published on this topic each 
year. Fluorescence is the luminescent phenomenon most frequently used in the different 
fields of Analytical Chemistry including pharmaceutical analysis. The spectrofluorimetry 
involves measurement of an enhanced or quenched fluorescent signal. Regarding 
fluorimetric methodologies, some methods involve chemical reactions, while others are 
based on the native fluorescence of the analytes. The fluorimetric technique applied to 
pharmaceutical analysis provides analytical methodologies which improve one or more of 
the basic properties of the analytical process, namely sensitivity, selectivity, precision and 
Table 1.5: Anahtical characteristics of derivative procedures for determination of 
pharmaceuticai compounds. 
Compound 
Ambroxol 
Bifonazole 
(isanride 
^ridoxinc 
Dcriv. 
Order 
1st 
2nd 
Isl 
2nd 
I'iucona/ole 1st 
Mcloxicam 1st 
2nd 
Nifedipine 1st 
1st 
Tlion/A iamine 1 st 
llCl 
"-max' 
nm 
255 
241.5 
276, 290 
271.6 
387 
306 
494 
Linear range/ Application remark Rt 
|.ig mL 
5.0-35.0 
1.5 to 15 
264.300 2-12 
Tablets 
Commercial cream 
formulation 
Commercial tablets 
and suspension 
126.0-462.0 Syrups 
2 - 10 
1 - 10 
5-30 
2.5-30.0 
Tablets 
Pharmaceutical 
preparations 
Multivitamin 
preparations 
l ioi i 
[1021 
11031 
[104| 
fl05| 
|106| 
11071 
8 - 20 Tablet and nasal drops 1108] 
rapidity. It has been used for the direct detennination of psychoactive drugs [109|. 
diclofenac sodium [110], labetalol HCl [111] and ramipril [112]. 
Near-Infrared spectroscopy 
The near-infrared (NIR) region (780-2500 nm) is situated between the red band of 
the visible light and the mid infrared (mid-IR) region. The NIR signal (spectrum) is a 
consequence of the absorbance of light due to molecular vibrations (overtones and 
combinations of fundamental vibrations) of hydrogen bonds like C-H, N-H, 0-H. It is a 
very fast technique: with the most modem instruments (Fourier transform (FT)-NIR), a 
spectrum can be recorded in only a few seconds. The most interesting advantage of the 
technique is the non-destructive character of the analysis: a sample can be analysed 
without or with only minimal sample preparation, in this way avoiding important steps 
responsible for error sources. This also allows in many cases the sample to be reused after 
the measurement. It is even possible to measure packaged samples through the package 
material. General aspects of NIR analyses are also described in the Ph.Eur. [113] and the 
USP [114]. An interesting document, entitled "Guidelines for the development and 
validation of NIR spectroscopic methods" has been written by the Pharmaceutical 
Analytical Sciences Group [115]. Several other international institutions are also aware of 
the potential of the NIR technique in quality control and process monitoring in the 
pharmaceutical industry. 
NIR spectroscopy can also be used to perform quantitative determinations of 
specific compounds in complex matrices, like, for instance, a pharmaceutical preparation. 
Quantitative NIR analysis of active ingredients in tablets has been reported and reviewed 
in the literature. Within the last 10 years, the number of publications describing 
quantitative NIR measurements of active ingredients in intact tablets has increased 
tremendously [116 - 130]. 
Nuclear magnetic resonance spectroscopy 
NMR spectroscopy can be used for the identification of a drug substance, the 
identification and quantification of impurities arising from the synthesis pathway and 
degradation, or residual solvents as well as the determination of the content in the assay. 
The intensity I of NMR signal is directly proportional to the number of nuclei N 
evoking the signal. Hence, the intensities of NMR signals (= areas under specific signals) 
can be taken for quantitative analysis. The linear relationship between signal intensity I 
and the number of observed nuclei (in case single pulse excitation) is given by: 
I = Cs X N 
The proportionality constant Cs results from parameters of the spectrometer, termed 
"spectrometer constant", and the sample. 
NMR spectroscopy is widely used in pharmaceutical analysis to identify a drug 
and the accompanying impurities; NMR can be used in drug analysis in order 
(1) to evaluate the level of impurities, to elucidate their structure and/or to observe the 
course of degradation resulting in the related impurities; 
(2) to evaluate the content of residual solvents; 
(3) to determine the isomeric composition, i.e. the ratio of diastereomers and the 
enantiomeric excess (ee) by means of chiral additives; 
(4) to determine molar ratios of (protonated) basic drugs and (deprotonated) organic acids 
in respective salts. 
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The United States Pharmacopoeia 26 (2003) gives detailed infonTiation about 
procedures to be applied for both qualitative and quantitative purposes. In the section toi 
qualitative analysis, the correlation between chemical shifts and coupling constants, on 
one hand, and the structure of a molecule, on the other hand, is stressed. For quantitative 
applications, an absolute method utilizing an internal standard and a relative method is 
given. Consequently, the NMR spectroscopy is used in the USP for qualitative and 
quantitative purposes more frequently. In the assay of amyl nitrite, the absolute method 
using benzyl benzoate as an internal standard was applied in USP 26. 
Mass spectrometry 
Over the past 15 years, Mass spectrometry (MS) has resulted in remarkable 
progress in the fields of biomedical and biological research, in particular drug discovery 
[131]. The ability to apply MS to these areas has been brought about principally by the 
development of electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI). Currently, MS combined with different chromatographic 
methods, provides some of the most powerful techniques available for pharmaceutical 
analysis. With its capability of speed, sensitivity and high throughput, MS has evolved to 
be a mainstay of drug discovery [132]. In particular, LC-MS has been one of the most 
prominent and valuable techniques for the analysis of pharmaceuticals and has been 
applied to drug metabolism studies (both in vitro and in vivo), high-throughput analysis 
of drugs and metabolites, analysis and identification of impurifies and degradation 
products in pharmaceuticals, and analysis of chiral impurities [133]. 
Electrochemical methods 
The application of electrochemical techniques to the analysis of daigs and 
phannaceuticals has increased greatly over the last few years. The renewed interest in 
electrochemical techniques can be attributed in part to more sophisticated instrumentation 
and to increased understanding of the technique themselves. Here the application of the 
various electrochemical modes in the analysis of drugs and phannaceuticals are presented 
in Table 1.6 [134- 147]. 
Table 1.6: Determination of drug by various electrochemical techniques. 
Technique Drugs determined Remark Reterence 
Voltammetry Isoniazid 
Danazole 
Ethinylestradiol 
Lamotrigine 
Using overoxidized poly pyrrole 
glassy carbon modified electrode 
Square wave adsorptive 
stripping voltammetry 
.34 
135 
Performed 
electrode 
at a mercury 
Performed at a mercury 137 
electrode 
Nitroxynil At glassy carbon electrode 138 
Lamivudine 
Polarography 
Amperometry 
Potentiometry 
Performed at a hanging mercury 139 
drop electrode 
Bisoprolol fiimarate 
Artemether 
Josamycin 
Psycho-active drugs 
Salbutamol 
Verapamil 
Chlorpromazine 
Clobutinol HCl 
Using single-wall 
nanotubes modified 
carbon electrode 
carbon 
glassy 
140 
141 
142 
143 
144 
145 
146 
147 
Kinetic methods 
The kinetic methods rely on the measurements of concentration changes (detected 
via signal changes) in a reactant (which may be the analyte itselt) with time after the 
sample and reagents have been mixed manually or automatically. There are several 
approaches that can be used for the determination of single components in the absence of 
any kinetic interference (Table 1.7). However, fixed-time and initial rate methods have 
been used more frequently for the determination of drugs in pharmaceutical formulations 
and biological fluids [148-150]. Kinetic automatic techniques are generally based on 
open systems among the most popular of which are stopped flow system [151] and the 
continuous addition of reagent (CAR) technique [152-154]. Several drugs have been 
determined by using the CAR technique with photometric [155,156] and fluorimetric 
detection [157]. 
Multicomponent kinetic determinations, often called as differential rate methods, 
are also receiving popularity in the field of pharmaceutical research [158,159]. Two new 
approaches i.e. kinetic wavelength pair method [160] and H-point standard addition 
method [161] have been proposed for dealing with overlapping spectra of components m 
the binary mixtures. 
M 
Table 1.7: Several kinetic approaches for determination of single component. 
A. Direct-computation methods B. Curve-fitting methods 
1. Integral methods 
a. Fixed-time 
i. One-point 
ii. Two-point 
iii. Multipoint 
b. Variable-time 
i. One-point 
ii. Two-Point 
2. Rate methods 
a. Initial-rate 
b. Intermediate-rate 
3. Integrated-signal methods 
1. Integral methods 
a. Linear responses 
b. Non-linear response 
i. Direct computation 
ii. Predictive (extrapolation) 
2. Rate methods 
METHOD VALIDATION 
Validation of an analytical technique is a procedure aimed at obtaining 
experimentally justified evidence of the ability of this technique to give results 
characterized by the required accuracy and precision [162-168]. All analytical techniques 
used for the development of pharmaceuticals and for the determination of their quality 
characteristics have to be validated. 
In 1987, the United States Food and Drug Administration (FDA) issued practical 
guides on the main principles of validation [166] and on the presentation of samples and 
analytical data pertaining to the validation of methods [167]. In 1993, the International 
Conference on Harmonization (ICH) developed generalized recommendations on the 
validation of analytical procedures; these documents were published in 1994 and treated 
in more detail in 1995 [162-164]. In 1994, the US FDA Center for Drug Evaluation and 
Research (CDER) issued a guide on the validation of chromatographic methods [165]. 
These documents and some review papers and monographs [169-173] provided a basis 
for extensive implementation of the procedure of validation of analytical methods. 
Validation studies are most frequently conducted under the following 
circumstances [ 174, 175]: 
• when a new analj^ical procedure is being developed, 
• when widening the range of applicability for a given procedure is investigated, 
e.g. for determining the same analyte, but in different matrix, 
• when the results of the Quality Control protocol suggest that validation 
parameters vary in time, 
• when a given analytical procedure is going to be used in another laboratory. 
• when different measuring equipment will be used, 
• when measurements will be conducted by another person, 
• when the new analytical procedure is being compared with the known standard 
procedure. 
A number of parameters that form a basis of the validation process depend on 
many factors, such as: 
• type of analytical studies which will be conducted with the application of given 
analytical procedure (e.g. qualitative or quantitative analysis or routine analytical 
work), 
• requirements posed for a given analytical procedure, 
• time consumption and costs associated with conducting the validation process. 
Table 1.8 contains the parameters which, according to the recommendations of ICH 
[162, 164] and USP [176], should be included in the validation process. 
Table 1.8: List of the analytical procedure parameters that should be validated 
according to the recommendations of ICH (162, 164j and USP [176|, 
Parameter ICH USP 
+ 
Precision 
- repeatability 
- intermediate precision 
- reproducibility 
Accuracy 
Limit of detection 
Limit of quantification 
Specificity/selectivity 
Linearity 
Measuring range 
Robustness 
Ruggedness 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
3N 
Besides the estimation of validation parameters, the following basic-
characteristics of an analytical procedure should be defined before proceeding with the 
validation [174]: 
• type of the measured component (analyte), 
• analyte concentration level, 
• analyte concentration range, 
• type of sample matrix, 
• presence of interfering substances, and whether they should be determined, 
• existing legal regulations and requirements which the analytical procedure should 
fulfill, 
• type of the obtained information, i.e. quantitative or qualitative, 
• required limits of detection and quantification, 
• expected and required accuracy (precision and correctness) of the procedure, 
• required robustness of the procedure, 
• necessary measuring equipment (i.e. does a given procedure require the use of a 
precisely specified measuring device or any of the similar type?), 
• possibility to apply the validated procedure in other laboratory. 
The validation steps of an analytical procedure can be conducted in any order. However, 
after considering the sequence in which specific parameters are determined it seems most 
logical that the order should follow a flow chart presented in Fig. 1.5 [ 174]. 
T,<^} 
Selectivity determination 
(analysis of standard samples) 
^' 
Determination of linearity, 
LOD, LOQ and measuring range 
^' 
Determination of repeatability 
ir 
Determination of intermediate precision 
1 r 
Selectivity determination 
(analysis of real samples) 
^ ' 
Accuracy determination 
(analysis of reference materials) 
1 r 
Determination of robustness 
(e.g. interlaboratory comparisons) 
1 ' 
VALIDATION REPORT 
Fig. 1.5: The sequence in which validation parameters are determined (174|. 
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Specificity and Selectivity 
The first validation parameter that should be detennined is selectivity. It is onlv 
logical to make sure, before proceeding with the characterization of an analyte based on 
the measured analytical signal, that this signal has been exclusively a result of the 
analyte's presence in the sample. 
It is quite common to confuse selectivity with specificity and vice versa, however, 
both terms differ in a significant way. According to lUPAC recommendation [177]. 
selectivity should be defined as follows: "Selectivity of a method refers to the extent to 
which it can determine particular analytes under given conditions in mixtures or matrices, 
simple or complex, without interferences from other components." Moreover, lUPAC 
stated that "specificity is the ultimate of selectivity", and the term specificity should be 
used preferentially. 
Selectivity, therefore, is the capability of a method to distinguish a given analyte 
fi-om other substances. This feature is mainly a fiancdon of the described measuring 
technique; however, it might vary with the type of compound or matrix. A method can be 
called specific when it shows the highest selectivity. On the other hand, Valcarcel [178] 
gives a different definition of selectivity: "it is the capability of an analytical process to 
receive signals whose size almost entirely depends on the content of the measured analyte 
present in a sample". 
The following practical definition can also be proposed [179] 
"specificity/selectivity is a capability of accurate and precise determination of the 
occurrence and content of analyte/group of analytes in the presence of other components 
in the real sample under given measuring conditions." Therefore selectivity is one of the 
main parameters that characterizes and describes an analytical procedure, particularly m 
the case of trace analysis [180]. The selectivity of the analytical method must be 
demonstrated by providing data to show the absence of interference with regard to 
degradation products, synthetic impurities and the matrix (excipients present in the 
formulated product at their expected levels). 
Linearity 
Linearity characterizes the ability of a proposed analytical procedure to give 
(within the suitability range) a response signal with the magnitude Y directly proportional 
to the amount C (concentration) of a drug to be determined. 
According to ICH recommendations [164], the linearity in practice is first visually 
estimated from the linear appearance of the plot of Y versus C. If the plot appears linear, 
this relation is studied by methods of regression analysis in terms of the linear equation 
Y = a + be. 
For the analytical procedures for determining the content of a parent compound. 
CDER recommends establishing the criterion of linearity at a level of the correlation 
coefficient r not lower than 0.999 [165]. However, even such a high level of correlation 
may be accompanied by significant deviations from linearity in the regions of high and 
low drug concentrations [173]. For this reason, ICH [164] recommends that the linearity 
be validated by a plot of the difference Y-C showing deviations (residuals) of the 
calculated values yi = a + bC from the measured Yj values as the function of the 
concentration C,. The "outbursts" of the points (xi, yi) relative to the regression model can 
be determined by calculating the parameter 'fusing the formula [181] 
y.-Y 
m . 11+ + 
1 i^^.-yy 
Here, y, and Yj are the calculated and experimentally measured values of the response, 
respectively; J^  = ^ .V, / A' ; N is the total number of experimental points (xi, y,), and 
sn = , ^ i ^ i i i sD.-^^^y'-y''' 
N-1 ' ' \ N-\ 
The calculated t value is compared to tabulated values of the Student criterion t (P = 95%, 
f = N - 2). If the calculated parameter is greater than the tabulated value, the given pomt 
can be considered as deviating from the adopted regression model with a 95% confidence 
probability. In practice, validation of the procedures of determination of the content of 
impurities with respect to linearity is sometimes performed proceeding from a correlation 
ofr = 0.98[173]. 
The linearity should be validated based on the analysis of at least five solutions 
with various concentrations covering the entire suitability range of a proposed analytical 
procedure [182]. According to ICH recommendations [164], the linearity can be 
demonstrated directly by using the reference parent substance (dilutions of a standard 
solution) and/or model artificial mixtures including components of the drug studied. The 
most adequate approach consists in taking thoroughly weighed aliquots of the drug 
components and preparing solutions according to the proposed procedure, since all 
operations of the analyst should correspond strictly to those stipulated in the description. 
In practice, however, an "immediate" approach recommended by ICH [164] is frequently 
employed. According to this, solutions are partly prepared using weighed aliquots of the 
drug components and other are obtained by diluting these stock solutions. It should be 
emphasized that the linearity of a proposed analytical procedure should be confirmed in 
the course of validation of the accuracy, which reduces expenditures and saves time. The 
usual procedures are as follows. 
(a) For the analysis of parent compounds, it is common practice to prepare a 
reference solution of the compound with a concentration at or above the upper limit ot 
the expected concentration interval (suitability range of the proposed procedure). Then, a 
series of dilutions is prepared so as to cover the entire range. 
(b) For the analysis of ready-to-use drugs, the linearity is frequently checked in 
the same way as for parent compound (i.e., using solutions of the parent compound as 
described in (a)). However, it is incorrect to ignore the possibility that auxiliary 
components (placebo) may influence the results. Therefore, it is more correct to validate 
the linearity using model mixtures of the parent compound and placebo. 
Limit of detection (LOD) 
The limit of detection (LOD) is determined as the minimum concentration ot 
analyzed substance in the sample, which (i.e., the corresponding response) can be 
detected under preset conditions [164, 165, 168]. 
According to USP-26 [168], it is usually not necessary to determine the actual 
LOD of the analyzed substances (except for analytical procedures intended tor 
monitoring the cleanness of technological equipment). In most other cases, it is sufficient 
to show that the impurity of interest is reliably detected at a preset level. 
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According to ICH [164], the LOD value is calculated by the fomnula 
LOD = 3.3(SDa/b), 
assuming that the response - concentration relation is linear in the range from the 
maximum possible concentration of the analyzed compounds down to zero. It is 
recommended to determine the slope b of the calibration curve using reference sample 
solutions v i^th concentrations in the vicinity of the LOD. 
Limit of quantitation (LOQ) 
The limit of quantitation (LOQ) is the minimum concentration of analyzed 
substance that can be determined at an acceptable precision (repeatability, 
reproducibility) and accuracy under rated conditions of analysis by a given method [162. 
183]. 
The ICH [164] recommends determining the LOQ by the formula 
LOQ=10(SDa/b), 
where b is the slope of the calibration curve and SDa is the standard deviation of the 
response signal. 
Accuracy 
The accuracy characterizes the proximity of the experimental results, obtained 
using a proposed analytical procedure, to the "true" value in the entire suitability range of 
this procedure. The accuracy represents a combination of the random and systematic 
error. 
The accuracy of analytical procedures should be determined using homogeneous 
samples with exactly known concentrations of the compounds to be determined. For 
validation purposes a series of such solutions is prepared using the reference parent 
I N 
compound. According to ICH recommendations and USP-26 [162, 168. 18.i]. tlu 
accuracy can be expressed both in the classical form, as the difference X - / / between 
the average experimental value (X) and the true value (n) with the correspondmu 
confidence interval A A', 
( X -/.I )± AX, 
and in an alternative ( and more illustrative) form, in terms of the percentage recovery ot 
the known amount of the compound to be determined. 
(^ found content^ 
p.= X 100% 
introduced content) 
The ICH Methodology Guideline [164] suggests that accuracy should be assessed 
using a minimum of nine determinations over a minimum of three concentration le\els 
covering the specified range (e.g., three concentrations/three replicates each of the total 
analytical procedure) If only three concentration levels were to be used thev should bt-
the mean and two samples representing the extremes of the range. The ICH Methodolouv 
Guideline [164] goes on to suggest that accuracy should be reported as the percentauc 
recovery by the assay of known added amount of analyte in the sample or as the 
difference between the mean and accepted true value together with the confidence 
intervals Several approaches regarding the accuracy have been discussed in ICH 
tzuidelines and are summarized in Table 1.9. 
4(> 
Table 1.9: Quantitative approaches to demonstrate accuracy according to ICH 
11641. 
Drug Substance Application of the analytical procedure to a reference material 
Comparison of the results with those of a second, well 
characterised procedure 
Drug Product Application of the analytical procedure to synthetic mixtures 
of drug product components 
Spiking of analyte to drug product 
Comparison of the results with those of a second, well 
characterised procedure 
Impurities (quantitative) Spiking of the impurity to drug substance or product 
Comparison of the results with those of a second, well 
characterised procedure 
Measuring range 
Linearity and LOQ determinations allow to define the measuring range. 
Measuring range is the range of values (analyte concentrations) within which the 
instrumental error is below the assumed value. In practice, it ranges from the LOQ value 
to the highest analyte concentration for which the instrument displays an increase of 
analytical signal. It should also be underlined that the higher limit of a measuring range 
can be (or rather ought to be) assumed to be the maximum concentration of analyte in 
standard solution for which the calibration curve had been plotted. Fig. 1.6 shows the 
graphic representation of definitions of linearity, measuring range, LOD and LOQ [184]. 
Precision 
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of experiments obtained fi-om multiple sampling of 
the same homogenous sample under the prescribed conditions. Precision may be 
considered at three levels: repeatability, intermediate precision and reproducibility. 
Precision should be investigated using homogenous, authenfic samples. However, if it is 
not possible to obtain a homogenous sample it may be invesfigated using artificially 
prepared samples or a sample solufion. The precision of an analytical procedure is usually 
expressed as the variance, standard deviation or coefficient of variation of series of 
measurements. 
4S 
o 
-a 
,2 
measuring range 
linear range ^^-^^^ 
slope = sensitivity 
(slope of calibration curve) 
LOQ 
/ ^ LOD 
y intercept 
J w 
Amount (e.g. concentration) 
Fig. 1,6: Graphic representation of the definitions of linearity, measuring range, 
LOD and LOQ [184]. 
4^) 
Repeatability 
Repeatability expresses the precision under the same operating conditions over a short 
interval of time. Repeatability is also termed intra-assay precision 
Repeatability should be assessed using: 
a) a minimum of 9 determinations covering the specified range for the assay (e.g.. 
three replicates of three different concentrations); or 
b) a minimum of 6 determinations at 100 % of the test concentration. 
Intermediate precision 
Intermediate precision characterizes the reproducibility of results obtained in the 
same laboratory by different analysts using various instruments during a prolonged 
period of time (not less than two days) for the same homogeneous sample or a model 
drug mixture according to the proposed analytical procedure. 
Typically, not less than six solutions are prepared with concentrations close to the 
nominal value. Each sample solution is prepared independently of the other solutions and 
analyzed at least three times. 
These solutions are characterized by the average drug content according to the 
results obtained by each of the analysts, X/and Xy(i, j = 1, , N). These data are 
Yx / 
statistically processed and characterized by generalized average values X, = -^ 'Ar and 
/N 
.s^ .. X.=^ y-j^ and corresponding standard deviations (SDj, SDj) and relative standard 
deviations (RSDj, RSDj) of particular measurements. 
First, it is required to show that the proposed procedure of determination of the 
drug content and impurity concentration provides for the statistically equivalent standard 
deviations SD, and SD, of the results obtained by different analysts. Then, it is necessarv 
to demonstrate that the average results of these (for certainty, two) analysts are 
statistically reliably (P = 95%) identical in terms of the t-criterion calculated as 
t = 
Xx-X: 
^SD, SD^ jSD.+SD', 
N, N, \ N 
where Xi, A'2 are the average results of analyses performed by analysts 1 and 2 and SDi. 
SD2 are the standard deviations in the particular series of Ni and N2 parallel 
determinations (usually Ni= N2 = N). This t value is compared to tabulated values of the 
Student criterion t (P = 95%, f = Ni + N2 - 2), where P = 95% is the confidence 
probability and f = N] + N2 - 2 is the number of degrees of freedom. If the calculated 
parameter t is lower than the tabulated value, the difference of average values can be 
considered as statistically insignificant with a 95% confidence probability. Otherwise, the 
average results differ to a greater extent than that admitted by random errors in both 
series [182]. 
It should be noted that, according to USP-26 [168], it is in most cases sufficient to 
determine only the repeatability for proper validafion of an analytical procedure, while 
the intermediate precision and reproducibility characteristics should be determined for 
procedures included in the pharmacopoeial articles. 
Reproducibility 
This characteristic is determined by comparing the results obtained upon analysis 
of the same samples in different laboratories using a proposed analytical procedure. 
In practice, however, the reproducibility is usually evaluated using two or three 
laboratories and characterized by less strict estimates. For example, validation ot a 
procedure proposed for the quantitative determination of a parent compound is perfonued 
by demonstrating the statistical equivalence of the standard deviations SD, and SD, of the 
results obtained in different laboratories (in terms of the Fisher F-criterion). Then, it is 
demonstrated that the scatter (RSD) of the results of analyses in one laboratory, 
(characterized by the maximum standard deviation SD, and SDj) relative to the average 
results of analyses in other laboratories (with lower SDj and SD, values) does not exceed 
a certain preset level [173]. The fiill - scale reproducibility of analytical procedures is 
rarely validated because (i) it is necessary to involve certified laboratories capable of 
reproducing the proposed procedure with high precision and (ii) this requires high 
organizational facilities and expenditures. 
Ruggedness and Robustness 
Robustness of a procedure is determined in order to estimate the influence of 
small fluctuations in analytical conditions on the final result. Its value has bearing on the 
measuring technique regime for a given analytical procedure [185]. As the influence of 
small changes in parameters on the final analytical result increases, it becomes mandatory 
to maintain those parameters at the constant level. Robustness is a parameter related to 
the changes in internal conditions [186-188]. 
Ruggedness, on the other hand, is a parameter that defines the suitability of a 
given analytical procedure under varying conditions; it can be estimated fi-om the 
reproducibility value [186-188]. 
Similarly to reproducibility, the robustness and ruggedness of analytical 
procedure are determined via interlaboratory comparisons. However, the evaluation of an 
impact that the changing conditions have on the analytical procedure undergoing a 
validation process can be conducted within one laboratory (e.g. influence of temperature, 
purity and type of reagents used and pH).The values of both parameters for a given 
analytical procedure can be calculated based on the analysis of the differences among 
standard deviations from a series of measurements obtained while slightly changmg the 
procedure's parameters. 
CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic and 
inorganic compounds. They can be prepared synthetically or reconstituted from natural 
sources product. All the drugs having medicinal importance can be broadly divided into 
two classes. 
Chemical classification 
The drugs are classified according to their chemical structure and properties 
without taking the pharmacological action. In this class most of the drugs are having at 
least an organic substrate; fiirther classification is done in the relevant manner. 
Pharmacological classiflcation 
In this class the drugs are divided according to their action on the organism's 
organ (viz. heart, brain, lymphatic system, respiratory system, endocrine system, central 
nervous system etc.). Hence, these drugs are called cardiovascular, narcotics, analgesics, 
antibiotics, diuretics, and anesthetics etc. Further classificafion of each group is done 
according to the therapeutic / pharmacological specificity with the relevant organ. A 
detailed classificafion of drugs based on pharmacological action on human organs has 
been given in Scheme 1.1. This thesis deals with the determination of the cardiovascular 
drugs namely metoprolol tartrate, enalapril maleate, labetalol hydrochloride and 
amiodarone hydrochloride. 
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METOPROLOL TARTRATE 
Metoprolol tartarate, 2-Propanol, l-[4-(2-methoxyethyl) phenoxy]-3-[( I-
methylethyl) amino]-, (±)-, [R-(R*, R*)]-2, 3-dihydroxybutanedioate (2:1) (salt) 
[(Ci5H25N03)2 .C4H6O6, 56392-17-7, M.W. 684.81] is known as a cardioselective beta 
adrenergic receptor blocker. It is used for the treatment of hypertension, angina pectoris. 
supraventricular and ventricular arrhythmias and to reduce the frequency and intensity of 
migraine headache, among other applications. Administration of successive large doses 
might lead to some side effects such as cardiac depression, blockade of cardiac vascular 
or bronchial B-adrenoreceptor and visual disturbance. Metoprolol is administered as a 
recimic mixture. (S)-(-)-metoprolol has been reported to be significantly greater B-
adrenergic receptor affinity by > 25-fold than (R)-(-)-metoprolol [189]. It undergoes 
extensive first pass metabolism with about 95% of the dose being metabolized in humans 
(Fig. 1.7). The hydroxylated metabolite a-hydroxy metoprolol (OH-met) results from 
oxidation of the benzylic carbon atom of metoprolol by the cytochrome P- 450 isozyme 
system in liver. There are marked interindividual differences in the pharmacokmetics 
partially due to the rate of drug oxidation by cytochrome P- 450 isozymes. B-Blockers 
(eg. metoprolol, atenolol) are misused as doping agents in sports and hence these drugs 
have been added to the list of forbidden drugs by the International Oljmipic Committee 
[190]. 
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H^/OH 
OCH3 
METOPROLOL 
0-DEMETHYLMETOPROLOL 
OCH-
a- HYDROXYMETOPROLOL 
Fig. 1.7: Major pathways of metoprolol metabolism in man. 
ENALAPRIL MALEATE 
Enalapril maleate ((S)-l-{N-[l-(ethoxycarbonyl)-3-phenyl-propyl]-L-alanyl |-L 
proline, (Z)-2-butenedioate (1: 1) is a salt of enalapril and maleic acid. Its empirical 
formula is C20H28N2O5.C4H4O4, and its structural formula is: 
HoQ O HOOC 
HO 
Enalapril maleate is a white to off-white, crystalline powder with a molecular 
weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble m 
methanol. Enalapril maleate is supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for 
oral admmistration. In addition to the active ingredient enalapnl maleate, each tabid 
contains the following inactive ingredients: lactose, magnesium state, starch, and other 
ingredients. The 2.5 mg, 10 mg and 20 mg tablets also contain iron oxides. 
Enalapril is a pro-drug; following oral administration, it is bioactivated by 
hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin converting 
enzyme inhibitor (ACE). ACE is a peptidyl dipeptidase that catalyzes the conversion ot 
angiotensin I to the vasoconstrictor substance, angiotensin II, which stimulates 
aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased 
plasma angiotensin 11, which leads to decreased vasopressor activity and to decrease 
aldosterone secretion [191]. 
•>s 
The enalapril is a widely used drug in clinical practice for various treatments such 
as arterial hypertension in all its grades, rennin-dependent hypertension and congestnc 
cardiac insufficiency. In this last disease, this substance improves the symptoms, decrease 
the mortality and diminishes the frequency of patient hospitalizations. 
On the other hand, it can be observed that enalapril is a very photosensitive drug 
and it degradates in an evident way through diketopiperazine (I) by dehydration process 
and enalaprilate diacid (II) by hydrolysis [192]. These products of degradation increase 
with temperature and pH of solution. Therefore, there is a need to develop analytical 
methods for its quantitation in commercial dosage forms. 
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LABETALOL HYDROCHLORIDE 
Labetalol hydrochloride is chemically known as 2-hydroxy-5-[l-hydroxy-2-f( 1-
methyl-3-phenylpropyl) amino] ethylj-benzamide hydrochloride (CAS No. 32780-64-6. 
M.W. 364.87). It is a white or almost white powder and soluble in water and alcohol: 
insoluble in dichloromethane and ether. A 1.0% solution (w/v) in water is clear and its 
pH varies between 4.0 and 5.0.Labetalol is unique drug with complex pharmacological 
properties exhibiting combined a] and yS- adrenoceptor antagonist properties and partial 
Jh- agonist activity [193-195]. Labetalol, an antihypertensive, has been used in the 
management of pregnancy-induced hypertension or pre-eclampsia. 
Labetalol has two asymmetric centers resulting in four stereoisomers, designated RR. 
SS, SR and RS (Fig. 1.8). The drug is supplied as an approximately equicomponent 
mixture of all four isomers. Labetalol is a weak base (pKa= 8.3) and is administered as 
the hydrochloride salt. Labetalol exerts reversible and competitive a\- and^^- blocking 
activity [196.197] and is approximately one- fourth as potent as propranolol in blocking 
^-receptors and one- tenth as potent as phentolamine in blocking a\- receptors. 
Labetalol is metabolized predominantly in the liver, the metabolites being excreted 
in the urine together with only small amounts of unchanged labetalol; its major 
metabolite has not been found to have significant a- or yS-adrenoceptor blocking effect. 
Excretion also occurs in the feaces via the bile. The elimination half-life at steady state is 
reported to be 8 hours. Following intravenous infusion, the elimination of half- life is 
about 5.5 hours. Labetalol is not removed by dialysis. 
HjNOC 
R'i 
CH.NH CH2CH2-
RR- isomer: 
SS- isomer: 
SR-isomer: 
RS-isomer: 
R 
OH 
H 
H 
OH 
Labetalol 
R' 
H 
OH 
OH 
H 
R" 
H 
CH3 
H 
CH3 
R'" 
CH3 
H 
CH3 
H 
Fig. 1.8. Structure of labetalol and proposed pharmacological activity of its 4 
stereoisomers 
b- Non- selective beta-adrenoceptor blocking activity 
b2- Selective beta2- adrenoceptor agonist activity 
ai - Selective betal- adrenoceptor blocking activity 
* Denotes chiral center 
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AMIODARONE HYDROCHLORIDE 
Amiodarone hydrochloride (AD) is a potent III antiarrhythmic drug and is 
chemically known as 2-butyl -3-benzofuranyl 4-[2-(diethyl amino) ethoxy]-3.5-
diidophenyl methanone hydrochloride. It is used to treat ventricular and supraventricular 
arrhythmias, especially when they are resistant to other conventional antiarrhythmic 
drugs [198, 199]. However, its use is sometimes complicated by serious adverse affects. 
including occasionally life threatening pulmonary fibrosis and hepatitis. Amiodarone has 
a long serum elimination of 40 to 50 d, which was attributed to its huge distribution 
[200]. Therefore, the amiodarone concentrations in patients treated with therapeutic doses 
of the drug vary considerably and therapeutic drug monitoring of amiodarone may assist 
in individualizing the dosage regimen. 
For the synthesis of AD, 2-butylbenzofuran-3-yl (4-hydroxy-3, 5-diiodophenyl) 
methanone, a key intermediate, is condensed with N-(2-chloroethyl)-N,N-dietylamine 
Hydrochloride. The unreacted intermediate appears as impurity D ((2-butyl-1-
benzofLiran-3-yl)(4-hydroxy-3,5-diiodophenyl) methanone) in the final product of AD 
(Fig. 1.9). During the synthesis of the key intermediate two more byproducts are formed 
which appear as impurity E ((2-butylbenzofiiran-3-yl)(4-hydroxy-phenyl) methanone) 
and F ((2-butylbenzofuran-3-yl)(4-hydroxy-3-iodophenyl) methanone). The impurity E 
and F may also condense with N-(2-chloroethyl)-N,N-diethylamine HCl to give impurity 
A ((2-butylbenzofuran-3-yl)[4-[2-(diethylamino)ethoxy]phenyl]methanone HCl) and 
C((2-butylbenzo{liran-3-yl)[4-[2-(diethylamino)ethoxy]-3-iodophenyl] methanone HCl). 
The authentic standards of impurity D and E are commercially available. 
6?^  
HCi 
N-(2-chloroethyl) N,N-diethylaminc HC 
Impurity D 
(2-butyl-1 -benzofuran-3-yl)(4-hydroxy-
3,5-diiodophenyl) methanone 
HCI 
Amiodarone HCI I 
(2-butylbenzofuran-3-yl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl] methanone 
hydrochloride 
Two byproducts are formed 
Impurity E 
(2-butylbenzofuran-3-yl)(4-hydroxy-
phenyl) methanone 
Impurity F 
(2-butylbenzofuran-3-yl)(4-hydroxy-
3-iodophenyl) methanone 
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Impurity E 
(2-butylbenzofuran-3-yl)(4-hydroxy-
phenyl) methanone 
HCI 
N-(2-chloroethyl) N,N-diethylaniine HC 
Impurity A 
(2-butylbenzofuran-3-yl)[4-[2-(diethylamino)ethoxy]phenyl]methanone HCI 
Impurity F 
(2 -butylbenzo furan-3 -yI)(4-hydroxy-
3-iodophenyl) methanone 
N-(2-chloroethyl) N,N-diethylamine HC 
Impurity C 
(2-butylbenzofuran-3-yl)[4-[2-(diethylamino)ethoxy]-3-iodopheny]] methanone HCI 
Fig. 1.9: Proposed pathway for impurity substances of amiodarone HCI. 
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INTRODUCTION 
Metoprolol tartrate, 2-Propanol, l-[4-(2-methoxyethyl) phenoxy]-3-[(l-
methylethyl) amino]-, (±)-, [R-(R*, R*)]-2,3-dihydroxybutanedioate (2:1) (salt) 
[(Ci5H25N03)2 .C4H6O6, 56392-17-7, M.W. 684.81] is a competitive B-adrenoceptor 
antagonist. It is used in the treatment of cardiovascular disorders such as 
hypertension, angina pectoris, cardiac arrhythmias and myocardial infarction. 
The drug is officially listed in Martindale The Extra Pharmacopoeia [1]. The 
recommended assay of the drug is listed in British Pharmacopoeia, which describes a 
potentiometric titration method [2]. The various analytical methods such as thin layer 
chromatography [3, 4], high performance liquid chromatography [5-7], gas 
chromatography [8], capillary electrophoresis [9], infrared spectroscopy [10] and 
electrochemical methods [11] have been described for its determination. The above-
mentioned techniques are good and sensitive but require laborious clean up 
procedure prior to analysis of drug. Spectrophotometry in visible region is attractive 
because of their speed, no pretreatment steps and simplicity. The assay procedures 
based on spectrophotometry [12-16] were published in reputed journals. The 
literature citation revealed that charge transfer complexation reactions [17, 18] of 
metoprolol with s-acceptor such as iodine and p-acceptors such as 7,7,8,8-
tetracyanoquinodimethane; 2,3-dichloro-5,6-dicyano-l,4-benzoquinone; 
tetracyanoethylene; 2,3,5,6, tetrabromo-l,4-benzoquinone; 2,3,5,6-tetrachloro-1.4-
benzoquinone and 2,5 dichloro-3,6-dihydroxy-l,4-benzoquinone have been exploited 
for its estimation in commercial dosage forms. The quantitation of metoprolol 
SI 
tartrate was done based on the reaction of the drug with ammonium metavanadate 
[19], FeCl3 [20], N-bromosuccinimide [21] and potassium dipertellurato cuprate(Ill) 
[22]. Extractive spectrophotometric methods have also been utilized for the 
quantification of metoprolol tartrate in pharmaceutical formulations based on 
chlorofonn extractable ion pair complexes of the drug with bromophenol blue, 
bromocresol purple, bromocresol green [23] ; benzyl orange [24] ; bromothymol 
blue [25]; and carbon disulfide-copper chloride [18]. Two kinetic 
spectrophotometric methods based on the reaction of metoprolol tartrate with 
ninhydrin in dimethyl formamide [26] and KMn04 in alkaline medium [27] have 
been reported. The literature is still running with few analytical procedures based on 
kinetics for the quantitation of metoprolol tartrate in dosage forms. Therefore, there 
is a need for another kinetic approach to quantitate the drug in commercial dosage 
forms. 
The present chapter reports an optimized and validated kinetic 
spectrophotometric method for the determination of metoprolol tartrate m 
commercial dosage forms. The method is based on the reaction of metoprolol tartrate 
with l-chloro-2,4-dinitrobenzene (CDNB) in dimethylsulfoxide (DMSO) at 100 ± 
o 
1 C. The absorbance of the coloured product measured at 420 nm increases as a 
function of heating time. Therefore, fixed time (AA) and equilibrium methods are 
applied for the quantitation of metoprolol tartrate in commercial dosage forms. 
N2 
EXPERIMENTAL 
Apparatus 
Shimadzu (UV-1240, Shimadzu Corporation, Kyoto, Japan) and Milton Roy 
Company (2()D", USA) spectrophotometers were used for absorbance measurements. 
A water bath shaker (NSW 133, New Delhi, India) was used to control the heating 
temperature for colour development. 
Reagents and standards 
All chemicals used were of analytical reagent grade. Metoprolol tartrate 
reference standard was procured from Sigma Chemical Company, St. Louis, MO. 
USA. Tablet formulations of metoprolol tartrate such as Betaloc 25 (AstraZeneca 
Pharma India Ltd., Bangalore, India), Metapro 25 (Cardicare, Bangalore, India) and 
Metolar 25 (Cipla, Mumbai, India) were purchased from local drug stores. 
Standards solutions: 
• CDNB (9.87 X 10"^  M, Fluka Chemie AG, Germany) solution was prepared in DMSO 
(Merck, India). 
• 0.05% metoprolol tartrate (7.30 x 10"* M) was also prepared in DMSO (Merck. 
India). 
Proposed procedure for the determination of metoprolol tartrate 
Into a series of boiling test tubes, different volumes (0.05 - 0.6 mL) of 
standard metoprolol tartrate (0.5 mg mL"') solution corresponding to 5 - 60 \ig mL'' 
were pipetted. To each test tube, 1.7 mL of 9.87 x 10"^  M CDNB was added, mixed 
well and heated on water bath at 100 ± TC for a preselected fixed time. After 
cooling at room temperature, the contents of the test tube were transferred to a 5 mL 
N3 
volumetric flask and the volume was completed with DMSO. The absorbance of the 
yellow coloured product was measured at 420 nm against the reagent blank as a 
function of time. 
The following two methods were adopted for constructing the calibration graphs: 
• Fixed-time method (AA): The change in absorbance (AA) between the times, ti (5 
min) and ti (10 min) was computed and plotted against the initial concentration ot 
metoprolol tartrate. 
• Equilibrium method: The equilibrium was attained at 44 min of heating. The 
absorbance measured at 46 min of heating was plotted against the initial 
concentration of metoprolol tartrate. 
Alternatively, regression equations were also developed to determine the metoprolol 
tartrate. 
Analysis of commercial dosage forms 
To determine the content of metoprolol tartrate in tablet formulations (label 
claim: 25 mg), the contents of 4 tablets were weighed and finely powdered. A 
portion of the powder equivalent to 50 mg metoprolol tartrate was stirred with 25 mL 
DMSO and let stand for 10 min. The residue was filtered on Whatmann No. 42 filter 
paper (Whatmann International Limited, Kent, UK) and washed well with DMSO for 
complete recovery of the drug. The filtrate and washings were diluted to 100 mL 
with DMSO. This solution was subjected to the proposed procedure for the 
determination of metoprolol tartrate. 
N4 
Procedure for reference method [18] 
Aliquots (0.2 - 3.5 mL) of 0.05% metoprolol tartrate were pipetted into a series of 
10 mL standard volumetric flasks. To each flask, 2.0 mL of 5 x 10 ' M 
tetracyanoethylene was added and the mixture was diluted to volume with acetonitrile. 
The reaction mixture was allowed to stand for 15 min at 25 C. The absorbance was 
measured against the reagent blank at 415 nm. The amount of the drug in a given sample 
was computed from the calibration graph. 
Method validation 
Solution stability 
The stability of reference metoprolol tartrate and quality control sample 
solutions at room temperature was evaluated with the help of UV-visible spectra and 
thin layer chromatography using TLC plates coated with silica gel G (Merck, 
Mumbai, India) and chloroform-methanol- 2.89 M ammonia (v/v/v/: 40:10:1) as 
mobile phase. 
Specificity and selectivity 
The specificity and selectivity of the proposed method was evaluated by 
estimating the amount of metoprolol tartrate in the presence of common excipients 
such as sodium stearyl fiimarate, magnesium stearate, starch, lactose and talc. 
Linearity 
The linearity of the fixed-time (AA) and equilibrium methods was ascertained 
by taking metoprolol tartrate at seven concentration levels: 5, 10, 20, 30, 40, 50 and 
60 (jg mL' . Each concentration was independently analyzed for five times. 
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Accuracy and precision 
The accuracy and precision of the fixed-time (AA) and equiHbrium methods 
were evaluated within the Hnearity range based on the analysis of metoprolol tartrate 
in pure at 10.0, 30.0 and 50.0 |ig mL"' and in quality control samples at 50.0 |ag mL' 
. Five independent analyses were performed at each concentration level within one 
day (intra day precision) as well as for five consecutive days (inter day precision) 
too. 
Recovery studies 
Recovery experiments were carried out by standard addition method. For this, 1.0 
mL (or 3.0 mL) of reference metoprolol tartrate solution (0.5 mg mL' ) was transferred 
into a 50.0 mL volumetric flask followed by 2.0 mL of sample solution (0.5 mg mL' ) 
and volume was completed up to the mark with DMSO. The total amount was 
determined by the proposed procedure. 
Determination of stoichiometry 
The stoichiometry of the reaction was studied by mole ratio method. For this, 
1.0 mL of 4.94 x 10"^  M metoprolol tartrate was treated with varied volumes (0.05 -
0.8 mL) of 4.94 x 10"^  M CDNB and the absorbance was recorded at 420 nm. The 
absorbance was plotted against the mole ratio of [CDNB] / [metoprolol tartrate]. 
Equivalence testing 
The bias has been evaluated by means of point and interval hypothesis tests 
[28, 29]. In interval hypothesis the proposed method is accepted when the true mean 
is within ± 2% of that of the true reference method (method 1), i.e. 
- 0.02 m<(n2-m)< 0.02 m 
The above equation can also be written as: 
0.98<H2/m < 1.02 
which can be generalized to 
where 9L and Ou are lower and upper acceptance limits, respectively. The limits of 
this confidence interval can be calculated as the two roots of the following quadratic 
equation. 
where x, and x, are mean values based on ni and n2 measurements, respectively. Sp is 
the pooled standard deviation and ttab is the student's t-value with ni + n2 -2 degrees of 
freedom at 95% confidence level. 
Setting 
(3 = X| 
b = - 2x, Xj 
_ 2 P ^lab 
n. 
The lower limit BL and upper limit 9u of the confidence interval are obtained as: 
-b-
-b-
-^b'-
2a 
i-^b'-
-4ac 
-4ac 
OL = 
la 
RESULTS AND DISCUSSION 
Mechanism and stoichiometry of the coloured species 
The interaction of polynitroaromatic and halopolynitroaromatic compounds 
with a variety of Lewis and Bronsted bases has resulted in the fonnation of brightly 
coloured solutions which provided a means for determining their quantity. It was 
reported that the addition of secondary amines [30] such as dimethylamine and 
diethylamine to DMSO solutions of 1,3,5-trinitrobenzene yielded an adduct i.e. 
Meisenheimer complex. In this reaction 2 moles of amine were utilized with one 
mole of 1,3,5-trinitrobenzene. Metoprolol contained a secondary amino group was 
found to react with CDNB in DMSO at 100 ± 1°C, resulting in the formation of 
intense yellow colour due to the adduct formation which absorbs maximally at 420 
nm. The blank consisting of CDNB in DMSO has a characteristic band at 345 nm. 
The absorption spectra are shown in Fig. 2.1. 
The stoichiometry was established by mole ratio method. The results are 
shown in Fig. 2.2. It is apparent from the figure that the combining molar ratio 
between metoprolol and 1-chloro 2,4-dinitro benzene is 2:1. The apparent formation 
o 
constant and standard Gibbs free energy (AG) were calculated and found to be 4.85 
X 10 and -43.85 kJ mol" , respectively. This stoichiometric ratio is similar to those 
obtained for interaction of 1,3,5-trinitrobenzene with diethylamine in DMSO. On 
the basis of our experimental findings and literature background [31], the reaction 
sequence is presented in Scheme 2.1. 
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Fig. 2.1: Absorption spectra of (a) 2.92 xlO" M metoprolol tartrate (200 ^g mL 
') in DMSO (b) Blank solution: 9.87 xio"* M CDNB in DMSO (c) Sample 
solution: 3.36 xlO"^ M CDNB + 7.30 xlQ-^ M metoprolol tartrate (50 ^g mL ') in 
DMSO. 
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Fig. 2.2: Mole ratio plot for stoichiometric ratio between metoprolol tartrate 
and CDNB in DMSO (2:1). 
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Solution stability 
The solution stability was ascertained from UV spectra of reference standard and 
quality control samples. The reference standard of the drug showed an absorption peak at 
277 nm. The standard and quality control sample solutions were kept at room temperature 
for five days and it was observed that there was no change in the absorption spectra of 
these solutions. The solution stability was also ascertained by applying the standard and 
quality control samples on TLC plates coated with silica gel G (Merck Limited, Mumbai. 
India) and developed in chloroform-methanol-2.89 M ammonia (v/v/v/: 40:10:1) solvent 
system. The plates were air-dried and spots were detected in the iodine chamber. In both 
the cases, a single spot was observed with Rf = 0.6 corresponding to metoprolol tartrate. 
Optimization of reaction conditions 
The optimum conditions affecting the formation of Meisenheimer complex 
were examined. 
Effect of heating time 
The effect of reaction time on the maximum absorbance of the product m 
DMSO was studied at lOCC. In this process, 0.5 mL of 7.30 x lO""* M metoprolol 
tartrate and 1.7 mL of 9.87 x 10"^  M CDNB were added and kept on water bath at 
100 ± 1 C for varied time. The maximum intensity of colour was obtained at 44 min 
of heating and remained constant up to 48 min. Therefore, 46 min of reaction time 
was used throughout the quantitation process in equilibrium method (Fig. 2.3). 
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Fig. 2.3: Effect of heating time on the absorbance of the Meisenheimer complex 
-3 between metoproloi tartrate (50 fig mL"') and CDNB (3.36 x 10 " M) in DMSO. 
Effect of the concentration ofCDNB 
The effect of CDNB concentration on the absorbance of yellow coloured 
Meisenheimer complex was studied in the range of 9.87 x 10"^  - 3.95 >;10" M. It was 
found that the maximum absorbance was obtained in the range 2.76 X 10"^-3.95 xlO"' VI 
CDNB (Fig. 2.4). Therefore, the optimum concentration of 3.36 x 10'^  M CDNB was 
chosen for the further work. 
Robustness 
The robustness of fixed-time (AA) and equilibrium methods relative to each 
operational parameter was checked and investigated. The operational parameters 
were as follows: 
• heating temperature, 100 ± 1 °C 
• reaction time, 5 - 25 min for fixed-time (AA) and 46 ± 2 min for equilibrium 
methods, respectively. 
• volume of 9.87 x lO'^MCDNB. 1.7 ±0.3 ml. 
The robustness of the fixed-time (AA) and equilibrium methods was assessed by 
analyzing the active metoprolol tartrate in Metolar 25. The quality control sample 
solution containing 50 \ig mL"' of the drug was assayed. The percent recoveries ± RSD 
for fixed-time (AA) (100.02 ± 0.09) and equilibrium methods (100.05 ± 0.08) were found 
to be appreciable, indicated that the proposed methods are robust. 
Ruggedness 
For the evaluation of ruggedness of fixed-time (AA) and equilibrium methods, the 
contents of metoprolol tartrate (lVIetolar-25; Cipla) at 50 fig mL"' was assayed following 
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Fig. 2.4: Effect of the molar concentration of CDNB on the absorbance of the 
coloured product keeping 7.30 xlO"^ M metoprolol tartrate (50 |xg mL"'). 
the recommended procedure using Spectronic 20D^ and Shimadzu UV 1240 
spectrophotometers. The percent recoveries ± RSD resuhed from Spectronic 201)' 
spectrophotometer (100.03 ±0 .14 and 100.01 ±0 .17 for fixed-time (AA) and 
equilibrium methods, respectively) and Shimadzu UV 1240 (100.04 ±0.13 and 99.^ )9 
±0.16 for fixed-time (AA) and equilibrium methods, respectively) were compared. 
The results agreed well within the acceptable limits with permissible bias. 
Analytical performance: Fixed-time (?A) method 
At room temperature, the reaction did not take place; hence the reaction leading to 
the formation of Meisenheimer complex was carried out at 100 ± 1°C. The absorbance of 
the Meisenheimer complex was measured at 420 nm as a function of time and was 
utilized to develop a fixed-time (AA) method for the quantitafion of metoprolol tartrate 
(Fig. 2.5). The change in absorbance (AA) between 10 and 5; 15 and 5; 20 and 5; 25 and 
5 was computed and plotted against the initial concentration of metoprolol tartrate at 
seven concentration levels. The corresponding linear regression equations with 
coefficient of correlations are summarized in Table 2.1. It is evident from the table that 
the most acceptable linearity was obtained when the change in absorbance between 5 and 
10 min (i.e. AA = Aio - A5) was plotted against the initial concentration of metoprolol 
tartrate (^g mL" ). This fixed time was selected for the quantitation of metoprolol tartrate 
in commercial dosage forms. 
96 
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Fig. 2.5: Absorbance-time curves for the reaction between metoprolol tartrate 
and CDNB in DMSO: 1.7 mL of 9.87 x 10"^  M CDNB and (a) 5, (b) 10, (c) 20, (d) 
30, (e) 40, (f) 50 and (g) 60 |j,g mL"' metoprolol tartrate. Each set is diluted to 5 
mL standard flask with DMSO. 
Table 2.1: Summary of calibration equations at different fixed times. 
AA Calibration equation r S;, Sb 
A10-A5 AA = -1.61x lO-^  + S.QGx 10"- C 0.9996 8.22x10'^ 2.28x10"'* 
A,5-A5 AA = -5.76x 10-V6.12X 10''C 0.9995 2.64x10"' 7.31x10"' 
A20-A5 AA = -6.52x 10"-V8.14x 10"'C 0.9993 2.06x10"' 5.71x10"-
A25-A5 AA =-5.72 x 10"V 1.11 x 10"^  C 0.9999 2.51x10"- 6.96x10"' 
08 
Equilibrium method 
The reaction between metoprolol tartrate and CDNB required 44 min to complete. 
Therefore, in equiHbrium method, the absorbance of the coloured product at 420 nm was 
measured after 46 min of heating. The absorbance was plotted against the initial 
concentration of metoprolol tartrate (|Lig mL" ). 
The linear dynamic range, molar absorptivity, regression equation, correlation 
coefficient, confidence limits for slope and intercept, limits of detection and quantitation, 
and variance of calibrafion line for fixed-time (AA) and equilibrium methods are 
summarized in Table 2.2. The high values of correlation coefficient indicated the 
excellent linearity of the calibration graphs. The small values of confidence limit of slope 
and intercept pointed towards good reproducibility of the fixed-time (AA) and 
equilibrium methods. 
Table 2.2: Summar> of optical and regression characteristics of fixed-time (AA) and 
equilibrium methods. 
Parameters 
Linear dxiiamic range (|.ig 
Molar absorptivitN (L mol 
Regression equation 
± t S , 
± t S h 
Correlation coefficient (r) 
LOD(^gmL^) 
LOQ(MgmL ') 
niL ') 
' cm ') 
Variance (S , ) of calibration line 
Fixed time i 
5 - 60 
-
AA = -5.72 
6.45 X 10 ' 
1.79 ' 10^ 
0.9999 
1.04 
3.16 
1.23 X {(}-' 
method (AA) 
X ur '+ 1 l. l l X lO-C 
Hquilibnum .\lctli.>.; 
5 - 60 
1.30 X 10^  
A = 7.31 10 ^ • ! ^'" 
4.42 - 10 
1.22 10" 
0.9999 
0.415 
1.26 
5.71 - (.1' 
±t S, and ±t Sb are confidence limits for intercept and slope, respectiveh . 
100 
Accuracy and precision 
The intra day and inter day precisions in pure and quality control samples were 
evaluated and the results are summarized (Table 2.3 and 2.4). As can be seen from Table 
2.3 and 2.4 that the percent relative error and relative standard deviation by intra day 
precision were in the ranges 0.01 - 0.11 %; 0.15 - 0.76 and 0.01 - 0.04%; 0.12 - 0.58 for 
fixed-time (AA) and equilibrium methods, respectively. Also, the percent relative error 
and relative standard deviation by inter day were found to be 0.01 - 0.07%; 0.21 - 0.90 
and 0.01 - 0.07%; 0.10 - 0.60 for fixed-time (AA) and equilibrium methods, respectively. 
The results showed that the percent relative error (= 0.11 %) and relative standard 
deviation (= 0.90 %) found in intra and inter day assays can be considered to be 
satisfactory. 
Recovery studies 
The accuracy of the fixed-time (AA) and equilibrium methods was 
ascertained by recovery studies using standard addition method. The results are 
summarized in Table 2.5. The mean recoveries ± RSD for fixed-time (AA) and 
equilibrium methods were in the ranges 99.92 ± 0.15 - 100.02 ± 0.50 % and 99.98 ± 
0.14 - 100.06 ± 0.32 %, respectively. The results agreed well within the acceptable 
limits of ± 2%. There is no interference fi-om excipients present in tablet 
formulations. 
Table 2,3: Summary of accuracy and precision results of the proposed methods in 
pure form. 
Proposed methods 
Fixed time (A A) 
Intra day assay 
Inter day assay 
Equilibrium method 
Intra day assay 
Inter day assay 
Amount 
((.igmL"') 
Taken 
10.0 
30.0 
50.0 
10.0 
30.0 
50.0 
10.0 
30.0 
50.0 
10.0 
30.0 
50.0 
Found ± SD' 
10.01 ±0.08 
30.02 ± 0.06 
50.01 ±0.10 
9. 99± 0.09 
29.99 ±0.08 
49.99 ±0.12 
10.00 ±0.06 
30.00 ± 0.07 
50.01 ±0.08 
9.99 ±0.06 
29.99 ±0.09 
49.99 ±0.10 
RSD 
(%) 
0.76 
0.21 
0.21 
0.90 
0.27 
0.24 
0.58 
0.23 
0.17 
0.60 
0.29 
0.19 
RE 
(%) 
0.11 
0.07 
0.02 
0.07 
0.02 
0.01 
0.04 
0.01 
0.03 
0.07 
0.02 
0.01 
SAi;' 
0.03 
0.03 
0.05 
0.04 
0.04 
0.05 
0.03 
0.03 
0.04 
0.03 
0.04 
0.04 
C.L; 
0.09 
0.08 
0.1.^ 
0 1 1 
0 10 
0 i? 
0.()7 
0 09 
0 10 
008 
Oil 
0.12 
'^ Mean for 5 independent analyses. 
^ SAE, standard analytical error. 
'' C.L., confidence limit at 95 % confidence level and 4 degrees of freedom (t = 2.776). 
lo: 
Table 2.4: Summary of accuracy and precision results of the proposed methods in 
dosage forms. 
Proposed methods 
Fixed time (A A) method; 
Intra day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Inter day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Equilibrium method : 
Intra day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Inter day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Amount 
(Mg mL') 
Taken 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
Found ± SD' 
50.01 ±0.08 
49.99 ±0.08 
49.99 ±0.10 
50.01 ±0.10 
49.98 ±0.11 
49.99 ±0.12 
49.99 ± 0.06 
50.00 ±0.07 
50.01 ±0.08 
49.98 ±0.10 
49.99 ±0.14 
49.97 ±0.10 
RSD 
(%) 
0.16 
0.15 
0.20 
0.21 
0.22 
0.24 
0.12 
0.14 
0.17 
0.19 
0.28 
0.20 
RE 
(%) 
0.02 
0.01 
0.01 
0.02 
0.05 
0.01 
0.01 
0.01 
0.03 
0.03 
0.01 
0.06 
SAE' 
0.04 
0.03 
0.04 
0,05 
0.05 
0.05 
0,03 
0.03 
0,04 
0.04 
0.06 
0.05 
( I . , 
0.1(1 
0,09 
0.12 
0,13 
0,12 
0.15 
0.08 
0,09 
0.10 
0.12 
0 . 1 7 
0.13 
^ Mean for 5 independent analyses. 
'' SAE, standard analytical error. 
" C.L., confidence limit at 95 % confidence level and 4 degrees of freedom (t 2.776) 
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Application 
The proposed procedures have been successfully appHed to quantitate metoprolol 
tartrate in commercial dosage forms. The assay of the same batch of samples was als. 
completed by El-Ries"s spectrophotometric method [18], The results of the fixed-time 
(AA) and equilibrium methods were compared with those obtained by E!-Ries N 
spectrophotometric method in terms of mean recovery. RSD, 9i,, Or. t- and F- values 
(Table 2.6) As can be seen from Table 2.6 that the assay results showed good agreement 
between proposed methods and the reference method as t- and F- values were less than 
the theoretical ones at 95 % confidence level and 0i, and Q\ were less than ^ 2 0 '^ ' , 
indicating the compliance of the regulatory authorities [28]. 
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INTRODUCTION 
Enalapril maleate is chemically described as 1-[N-[(S) - 1 -carboxy- 3-
phenylpropyl] L - proline 1'- ethyl ester, maleate (1:1). Its molecular weight is 492.53 
Enalapril is a prodrug; following oral administration, it is bioactivated by hydrolysis ot' 
ethyl ester to enalaprilat, which is the active angiotensin converting enzyme inhibitor. It 
lowers peripheral vascular resistance without causing an increase in the heart rate. It is an 
ideal drug for hypersensitive patients who are intolerant to beta-blockers. The drug is 
used for treating high blood pressure or hypertension in adults and children and 
congestive heart failure. The drug and their tablets are official in USP 24 [1], which 
describes HPLC method for its quantitation. 
The therapeutic importance of enalapril was behind the development of numerous 
methods for its determination. The methods adopted to the analysis of enalapril maleate 
include high-performance liquid chromatography [2-9], capillary electrophoresis [10], 
liquid chromatography- tandem mass spectrometry [11], polarography [12]. atomic 
absorption spectrometry [13] and membrane selective electrodes [14]. 
Few spectrophotometric methods have also been reported for the determination of 
enalapril maleate in commercial dosage forms. The cited drug after dissolving in distilled 
water exhibits an absorbance maximum at 207 nm and this property has been exploited to 
develop a UV method for its quantitation [15]. Enalapril maleate reacts with 2. 4-
dinitroflurobenzene at pH 9 yielding a coloured product which absorbs maximall> at 356 
nm forming a basis for its determination [12]. Spectrophotometric methods based on the 
ternary complex formation between copper (II), eosin [13]; palladium (II), eosin [16] and 
enalapril maleate have been reported. The spectrophotometric methods reported for 
no 
analysis of enalapril maleate in commercial dosage fornis suffered disadvantage of 
heating at 100 C [12] and long analysis time [16]. Considering this drawback, there was 
a need to develop more advantageous spectrophotometric methods for its detennination 
in commercial dosage fonns. 
This chapter describes four sensitive, fast, simple and economical methods for the 
determination of enalapril maleate in dosage forms. The first method is based on the 
reaction of carboxylic acid group of enalapril maleate with a mixture of potassium iodate 
and iodide. The second, third and fourth methods are based on the charge transfer 
complexation reaction of the drug with p-chloranilic acid (pCA) in 1, 4-dioxan-methanol 
medium, 2,3-dichloro 5,6-dicyano 1,4-benzoquinone (DDQ) in acetonitrile-1,4-dioxan 
medium and iodine in acetonitrile-dichloromethane medium. 
EXPERIMENTAL 
Apparatus 
Spectral runs were made on Spectronic 20D^ Spectrophotometer (Milton Roy 
Company, USA) with 1 cm matched glass cells. 
Materials and reagents 
• Enalapril maleate was kindly provided by Sunij Pharma Pvt. Ltd., Ahmedabad, India 
and was used as received. 
• Pharmaceutical preparations of enalapril maleate such as enapril (Intas 
Pharmaceuticals Pvt. Ltd., India), envas (Cadila Pharmaceuticals Ltd., India) and 
enace (Nicholas Primal India Ltd.) were purchased from local market. 
• Potassium iodide (s.d. Fine-Chem Ltd, Mumbai, India) solution was prepared as 5.0 
X 10"^  M soludon in disfilled water. 
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• Potassium iodate (Central Drug House (P) Ltd. New Delhi. India) solution was alsc 
prepared as 3 0 < 10"^  M solution in distilled water 
• pCA (Central Drug House (P) Ltd, New Delhi, India) was prepared as 0 2% iw \ \ 
solution in L4-dioxan 
• DDQ (Fluka Chemie AG, Germany) was prepared as 0 1% (w/v) solution in L 4 
dioxan 
• Iodine (Merck Limited, Mumbai, India) was prepared as 0 1% (w/v) solution m 
dichloromethane 
Standard drug solutions 
Knalapril maleate standard solutions were prepared as 0 5 mg mL"' solution in 
distilled water for Method A, 2.0 mg mL'' in methanol for Method B, 0 5 mg ml ' m 
acetonitrile for Method C and 1.0 mg mL"' in acetonitrile for Method D 
Procedure for determination 
Method A 
Aliquots of enalapril maleate standard solution (0.5 mg mL' ) containing 2*^  • ^ i^ > 
(.ig were transferred into a series of 10 mL volumetric flasks. To each flask, 1 mL of 3 0 
X lO'"* M potassium iodate and 1.5 mL of 5.0 > 10'" M potassium iodide were added and 
diluted to volume with distilled water. The reaction was allowed to proceed at 25 ± 1 ( 
and absorbance was measured as a function of time at 352 nm against reagent blank 
prepared simultaneously. The calibration curve was constructed by plotting the \ .\ 
(absorbance measured at 8.0 min- absorbance measured at 2 min) against the initial 
concentration of enalapril maleate. The content of enalapril maleate was calculated either 
from the calibration curve or corresponding regression equation. 
Method B 
Into a series of 5 mL volumetric tlasks, volumes of enalapril maleate standard 
solution (2.0 mg mL ' ) equivalent to 0.1-2.8 mg of the drug were transferred. To each 
flask, 2.5 mL of 0.2 % pCA was added and brought up to the volume with 1,4-dioxan . 
The coloured product formed immediately at room temperature (25 ± 1 C") and 
absorbance was measured after 2 min of mixing at 510 nm against the reagent blank 
prepared similarly omitting the drug. 
Method C 
The aliquots of enalapril maleate standard solution (0.5 mg mL"' ) equivalent to 
25 - 375 (ag of the drug were transferred into a series of 5 mL volumetric flasks. To each 
flask, 1.4 mL of 0.1% DDQ was added and brought up to the volume with acetonitrile. 
The colour developed immediately at room temperature (25 ±1 C) and the absorbance 
was measured after 3 min at 565 nm against the reagent blank prepared similarly omitting 
the drug. 
Method D 
The volumes of enalapril maleate standard solution (1.0 mg mL'') corresponding 
to 50 - 1000 )jg of the drug were transferred into a series of 5 mL flasks. 1.2 mL of 0.1 % 
iodine was added in each flask at room temperature (25 ±1 C) and diluted up to the mark 
with dichloromethane. The absorbance was measured after 2 min at 365 nm against the 
reagent blank. 
Analysis of pharmaceutical formulations 
Twenty tablets (claming for 2.5 mg of enalapril maleate per tablet) were tineK 
powdered and extracted separately into sufficient volume of water, methanol or 
acetonitrile with shaking. The residue was filtered on Whatmann filter paper No. 42 and 
the filtrate was diluted to 50 mL with water, methanol or acetonitrile, as the case may be. 
It was further diluted according to the need and then analyzed following the proposed 
procedures. 
RESULTS AND DISCUSSION 
Reaction with a mixture of iodide and iodate 
It has been reported in the literature [17] that iodine is formed as a result of the 
interaction of a mixture of iodide and iodate with inorganic or organic acid in accordance 
with the equation: 
5 / " + / o r + 6 / / " ^3H.O + 3L 
In aqueous solution, the iodide ions react with the liberated iodine to yield triiodide ion 
(Ij +1' ^ /, ) which absorbs maximally at 290 nm and 360 nm. We thought that this 
reaction would be helpfiil for developing a spectrophotometric method for determination 
of enalapril maleate as it contains -COOH group in its moiety. Keeping this in mind, a 
mixture of potassium iodide and potassium iodate was allowed to react with enalapril 
maleate which yielded iodine. Then the liberated iodine reacted with the excess of iodide 
ion resulting in the formafion triiodide ion with Ama\ at 352 nm. The reaction 
sequence is shown in Scheme 3.1. 
HOOC 
Enalapril 
Aqueous medium 
V 
10," 51 
H^C O •ooc X / ^ ' V ^ O CH 
+ 31, + 3HX) 
h+l'^h 
Scheme 3.1 
Reaction with s -acceptor 
The absoq3tion spectmm of iodine in dichloromethane showed only one peak with 
maximum absorption at 500 nm. The colour of iodine changes to yellow upon reaction 
with enalapril maleate. This is due to charge transfer complexation reaction between 
enalapril maleate and iodine. The absorption spectrum of enalapril maleate-iodine 
reaction product showed absorption peaks at 290 and 365 nm. The stoichiometry of the 
reaction was studied by Job's method of continuous variations. It was observed from the 
Fig. 3.1 that the combining molar ratio between enalapril maleate and iodine is 1:1. It has 
been reported that the charge-transfer complex between drug and iodine [18] would ha\e 
an ionized structure Dl^. . .I3". The absorption spectrum of this charge-transfer complex is 
identical to that of I3' in dichloromethane as it also absorbed at 290 nm and 360 nm. On 
the basis of our experimental findings and the literature background, the reaction 
mechanism is proposed and given in Scheme 3.2. 
Reaction with p-acceptors 
The interaction of enalapril maleate with p-acceptors such as pCA and DDQ at 
room temperature was found to yield coloured charge transfer complexes. In polar 
solvents, complete electron transfer from enalapril maleate (D), as an electron donor, to 
the acceptor moiety (A) takes place resulting in the formation of intensely coloured 
radical anions. The reaction sequence can be shown as: 
D + A 
• -
(D - A) 
complex 
Polar solvent 
D^ + A " 
radical ions 
A 
b 
s 
o 
r 
b 
a 
n 
c 
e 
0.0 0.2 0.4 0.6 0.8 1.0 12 
Mole fraction of drug ( Enalapril maleate) 
Fig. 3.1: Job's plot for stoichiometric ratio between enalapril maleate and pCA 
(4.06 X 10'^  M each), DDQ (2.03 x 10"^  M each) or Iodine (3.94x10'^ M each). 
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H.C O. HOOC \y^\^o CH, 
HX. O HOOC \ / ^ X ^ 0 CH 
HX. O. HOOC X/^^^O CH 
I. 
H,C D. HOOC \ y ^ \ ^ 0 CH 
r + I, 
H.C 
'^\/°N^° CH 
HOOC 
XI O 
Tri- iodide ion pair 
Scheme 3.2 
The absorption spectra of enalapril maleate - p-acceptor reaction mixtures showed 
absorption peaks which were similar to the maxima of the radical anions of the p-
acceptors obtained by the iodide reduction method [19]. 
The literature reveals that pCA exists in three forms: (i) H2A at very low pH 
which is yellow-orange in colour, (ii) HA", dark purple, which is stable at pH 3, and (in) 
colourless A"' which is stable at high pH. The interconversion of these species can be 
represented as: 
H2A -^  H' + HA" (violet) 
HA" "^^  H + A" (colourless) 
The interaction of enalapril with pCA in methanol-1,4-dioxan solvent system 
resulted in the formation of violet coloured charge transfer complex and the absorption 
spectrum exhibited maximum absorption at 510 nm. The reaction stoichiometry between 
enalapril maleate and pCA was evaluated by applying Job's method of continuous 
variations. The Job's plot (Fig. 3.1) reached a maximum value at a mole fraction of 0.5 
which suggested a donor (enalapril) to acceptor (pCA) ratio of 1:1, On the basis of 
reaction stiochiometry and literature background, the reaction mechanism is presented in 
Scheme 3.3. 
The interaction of enalapril maleate with DDQ resulted in the formation of 
coloured charge-transfer complex. The dissociation of charge-transfer complex was 
promoted by the high ionizing power of the acetonotrile-1, 4-dioxan solvent system 
where complete electron transfer from enalapril maleate to the DDQ moiety takes place. 
This is followed by the formation of the DDQ radical anion as predominant chromogen 
HOOC O 
HO I C: 
Enalapril 
n - n 
Complexation 
cr OH 
O 
H^C P 
p-chloranilic acid 
HOOC 
HO CI 
n - 7t complex 
in methanol -1,4-dloxan solvent 
0" 
H.Q ^°\^o 
HOOC 
O. 
p-chloranllic acid radical anion 
(coloured species) 
Scheme 3.3 
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which absorbed maximally at 430, 535 and 565 nm. In order to avoid the maximum 
interference from the blank, the absorption band at ?L„ia\ 565 nm was chosen tor 
analytical studies. The Job's plot (Fig. 3.1) indicated a donor to acceptor ratio of 1:1. On 
the basis of this study and literature survey, the formation of DDQ radical anion is shown 
in Scheme 3.4. 
The association constants and apparent molar absorptivities of pCA-enalapnl 
maleate, DDQ-enalapril maleate and iodine-enalapril maleate charge transfer complexes 
have been calculated using Ross and Labes equation [20], which depends on the 
experimental condition that acceptor concentration should not low enough to be 
considered negligible with respect to donor concentration. 
[^][Q] , 1 _ ' , ^ ^± (1) 
[A] + [D] A, Ke, [A] + [D] e, 
where [A] and [D] are total concentrations of the acceptor and donor, respectively. A, 
and e> are the absorbance and apparent molar absorptivity of the complex at wavelength 
A,. K is the association constant of the charge transfer complex. 
X — is plotted against (Fig. 3.2) which gave a straight line. The [A] + [D] A, [A] + [D] 
intercept and slope were calculated and equation (1) is transformed into the following 
equations: 
for pCA - enalapril maleate system 
i^ J^^  ] x ^ = 2.173x10'^ X J + 8.313x10^ (2) 
[A] + [D] A, [A] + [D] ^ ' 
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HOOC 0 
n - J: 
Complexation 
N = ( 
N = 
0 
DDQ 
CI 
CI 
HQC. P 
H-.C. P 
HOOC 
N ^ C C = N 
n - 71 complex 
HOOC 
in acetonilrile-1,4-dioxan solvent 
o. 
DDQ radical anion 
(coloured species) 
Scheme 3.4 
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.\D Fig. 3.2: Plot of l/|DoJ vs [AoJ/A"" for Methods B, C and D 
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for DDQ - enalapril maleate system 
- M ^ . , , X = 3.202x10 «x ^ +1.641x10^ (3) 
[A] + [D] A, [A] + [D] 
for Iodine - enalapril maleate system 
[^It^] x —-8.889x10 '^x ^  + 1.371x10"^ (4) 
[A] + [D] A, [A] + [D] 
The association constants and molar absorptivities were found to be 3.826 xlQ^ and 
1.203x10^ Lmof' cm" for/7CA-enalapril maleate complex from equation (2), 5.124 ^10 
and 6.095 xio^ Lmof^cm' for DDQ-enalapril maleate complex from equation (3) and 
1.543x10^ and 7.291x10^ Lmor'cm' for iodine- enalapril complex from equation (4). 
respectively. The free energy change was also calculated and found to be -20.44 KJmol 
forpCA-enalapril maleate complex, - 21.17 KJmof' for DDQ-enalapril maleate complex 
and - 18.19 KJmof' for iodine- enalapril maleate complex. 
Optimizations of Variables 
The different parameters affecting the colour development were extensively 
studied to determine the optimum conditions for the assay procedures. The optimum 
values of the variables were maintained throughout the determination process. 
Method A 
Effect of the concentration of potassium iodate 
The effect of the volume of 3.0 xlO' M potassium iodate on the absorbance of the 
product was studied in the range of 0.2 -1.2 mL. The absorbance increases with increase 
in the volume of KIO3 and became constant at 0.8 mL. Further addition of KIO3 does not 
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change the absorbance and therefore, 1.0 mL of 3.0 xlO" M KIO3 was chosen as an 
optimum value (Fig.3.3). 
Effect of the concentration of potassium iodide 
The effect of the volume of 5.0 x 10' M potassium iodide on the intensity of the 
coloured product was studied in the range of 0.2-1.8 mL, keeping the constant 
concentrations of enalapril maleate (50 \xg mL"') and KIO3 (3.Ox lO'* M) .The maximum 
absorbance was obtained with 1.2 mL; fiarther addition caused no change in the 
absorbance. Thus, 1.5 mL of 5.0 x 10' M potassium iodide was used throughout the 
experiment (Fig. 3.4). 
Method B 
Effect of reaction Time 
Optimum reaction time was evaluated by monitoring the colour development at 
room temperature. It was observed that the reaction got stabilized within 2 min. The 
developed colour remained stable at room temperature for about a further 1 h. 
Effect of pCA concentration 
To study the effect of the volume of the reagent on the absorbance of the charge 
transfer complex, varying volumes of 0.2% pCA was mixed with 1.5 mL of 0.2% drug in 
a 5 mL standard flask and diluted to volume with 1,4-dioxan. The results (Fig. 3.5) 
showed that the highest absorbance was obtained with 2.2 mL, which remained 
unaffected by further addition of pCA. Hence, 2.5 mL of the reagent was used for the 
determination. 
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Volume of 3 X 10" M potassium iodate (mL) 
Fig 3.3: Effect of the volume of 3,0 x 10"^  M potassium iodate on the absorbance 
of the product (enalapril maleate 50 |ag mL"'; 1.5 mL of 5.0 xlO"^ KI). 
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Volume of 5 X 10' M potassium iodide (mL) 
Fig 3.4: Effect of the volume of 5.0 xlO' M potassium iodide on tiie absorbance 
of tlie product (enalapril maleate 50 i^g mL '; 1.0 mL of 3.0 xlO ^ KIO3). 
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0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3 0 
Volume of (a) 0.2 % pCA (b) 0.1 % DDQ (c) 0.1 % iodine (mL) 
Fig 3.5: Effect of the volume of 0.2% pCA , 0.1% DDQ and 0.1% Iodine on the 
absorbance (600 |ig mL'' enalapril maleate for pCA, 50 ng mL"' enalapril 
maleate for DDQ and 100 ^g mL" enalapril maleate for iodine). 
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Method C 
Effect of reaction time 
The interaction of DDQ with enalapril maleate resulted in the formation of 
coloured product which stabilized within 2 min. The developed colour remained stable at 
room temperature for about a further 2 h. 
Effect of DDQ concentration 
To establish the optimum experimental condition, enalapril maleate (250 pg) was 
allowed to react with different volumes (0.05-1.8 mL) of 0.05% DDQ. The results (Fig. 
3.5) showed that the highest absorbance was obtained with 1.0 mL, which remained 
unaffected by further addition of DDQ. Hence, a volume of 1.4 mL of the reagent was 
used for the determination. 
Method D 
Effect of reaction time 
In method D, the coloured product was formed immediately and remained stable 
at room temperature for about 1 h. The absorbance was measured after 2 min of mixing 
the reagent. 
Effect of Iodine concentration 
In order to study the effect of the volume of O.I % iodine on the absorbance of 
the charge transfer complex, varying volumes (0.05-1.2 mL) were treated, separately with 
500 ^g of enalapril maleate.The results are shown in Fig. 3.5 which indicated that 0.8 mL 
of 0.1% iodine gave the maximum absorbance and remained constant by further addition 
of iodine. Therefore, a volume of 1.2 mL was chosen as an optimum value for the 
determination. 
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Validation of proposed methods 
Under the optimum experimental conditions, the cahbration graphs were 
constructed by plotting AA (A A = absorbance measured at 8.0 min- absorbancx 
measured at 2 min) or absorbance as a fijnction of initial concentration of enalapni 
maleate for methods A; and B, C and D, respectively. The method of least square \\a^ 
applied to yield the regression equations. Resuhs are summarized in Table 3 1 it is 
apparent from the Table 3.1 that the sensitivity of the proposed methods follows the 
order: A>C>D>B. In all cases, calibration plots (n = 11) were linear with small intercepts 
(1.32 X 10"^+ 6.52 y \0'\ (9.36 x 10"''± 2.43 x 10'^ ), (6,98 x 10"^± l.S.S x lO'") and (-
8.76 ' I0"^  + 4 12 ' 10"^ ) and good correlation coefficients ( 0 9998 - 0.9999 ) The LOD 
values obtained for methods A, B, C and D were 1.13. 3.07, 0.39 and 3 20 ug ml, 
respectively The small values of the variance 2.13 x I0~\ 3.03 x 10'', I 04 « 10" and 
9,06 X 10^' |.rg mL" for methods A, B, C and D, respectively (Table 3 1) confirmed the 
small degree of scatter of experimental data points around the line of regression. 
Accuracy and precision 
The within day precision was evaluated through replicate analysis (n = ."^ ) of 
quality control samples; 20, 35 and 50 |.ig mL'' for method A and 120, 280 and 440 ug 
mL"' for method B and 20, 40 and 60 \xg mL"' for method C and 40, 100 and 160 (.ig mL ' 
for method D The percentage recoveries ranged from 99.96 - 100.08 % with RSD from 
0.284 - 0.845 % , 99.96 - 100.02 % with RSD from 0.122 - 0.242 %, 99.96 - 100 04 % 
with RSD from 0.250 - 0.481 % and 100.01 - 100.06 % with RSD from 0.142 - 0 440 
%for methods A, B, C and D, respectively. The interday precision was also evaluated 
through replicate analysis of the quality control samples for five consecutive davs at 
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the same concentration levels as used in within day precision. The percentage 
recoveries for methods A, B, C and D ranged from 99.98 - 100.11 % with RSD from 
0.482 - 1.098%, 99.91 - 99.96 % with RSD from 0.184 - 0.373 %, 99.89 - 100.00 % 
with RSD from 0.373 - 0.872 % and 100.01 - 100.06 % with RSD from 0.318 - 0.918 
% respectively (Table 3.2). The results in the Table 3.2 indicated the high precision of 
the proposed methods. The selectivity of the proposed methods was investigated by 
observing any interference encountered from the excipients of the tablets such as 
lactose, starch, cellulose, magnesium stearate, ferric oxide, talc and calcium carbonate 
and hydrochlorothiazide which is present with enalapril maleate in pharmaceutical 
products. It was observed that the excipients and hydrochlorothiazide did not interfere 
with the proposed methods. 
The proposed methods were applied to the determination of enalapril maleate 
in commercial tablets such as Enapril 2.5, Envas 2.5 and Enace 2.5. The same batch 
of the commercial dosage forms was also analyzed by the reference method [12]. The 
results of the proposed methods were compared with those obtained by the reference 
method. Statistical analysis of the results using Student's t-test. variance ratio F-test 
and interval hypothesis test [21] revealed revealed no significant difference between 
the proposed method ( A, B, C and D) and therefore method at 95% confidence level 
regarding accuracy and precision. The results are summarized in Table 3.3. The 
proposed methods have been extended to the determination of enalapril maleate in 
spiked human urine samples. The results of analysis of urine samples are summarized 
in Table 3.4. 
Table 3.2: Test of precision of tlie proposed methods A, B, C and D. 
Proposed methods 
Method A 
Intraday assay 
Interday assay 
Method B 
Intraday assay 
Interday assay 
Method C 
Intraday assay 
Interday assay 
Method D 
Intraday assay 
Interday assay 
Concentration, (jLig niL^ ) 
Taken 
20 
35 
50 
20 
35 
50 
120 
280 
440 
120 
280 
440 
20 
40 
60 
20 
40 
60 
40 
100 
160 
40 
100 
160 
Found ± SD 
19.99 ±0.169 
35.03 ±0.133 
50.01 ±0.142 
20.02 ±0.220 
35.00 ±0.169 
49.99 ±0.270 
119.99 ±0.290 
279.89 ±0.478 
440.10 ±0.535 
119.89 ±0.447 
279.89 ±0.610 
439.78 ±0.811 
20.00 ± 0.096 
40.01 ±0.113 
59.98 ±0.150 
19.98 ±0.174 
39.99 ±0.149 
60.00 ± 0.244 
40.02 ±0.176 
100.05 ±0.269 
160.02 ±0.228 
40.02 ±0.367 
100.05 ±0.420 
160.02 ±0.509 
Recovery 
(%) 
99.96 
100.08 
100.03 
100.11 
100.00 
99.98 
99.99 
99.96 
100.02 
99.91 
99.96 
99.95 
100.00 
100.04 
99.96 
99.89 
99.98 
100.00 
100.06 
100.06 
100.01 
100.06 
100.06 
100.01 
RSD "^ 
(%) 
0.845 
0.378 
0.284 
1.098 
0.482 
0.538 
0.242 
0.171 
0.122 
0.373 
0.217 
0.363 
0.481 
0.283 
0.250 
0.872 
0.373 
0.406 
0.440 
0.269 
0.142 
0.918 
0.420 
0.318 
SAF." 
0.076 
0.059 
0.063 
0.098 
0.076 
0.120 
0.130 
0.214 
0.239 
0.200 
0.273 
0.363 
0.043 
0.051 
0.067 
0.078 
0.067 
0.109 
0.079 
0.121 
0.102 
0.164 
0.188 
0.228 
CL' 
0.210 
0.165 
o.r6 
0.273 
0.210 
0.334 
0.360 
0.594 
0.664 
0.555 
0,757 
1.007 
0.119 
0.141 
0.186 
0.216 
0.185 
0.303 
0.219 
0.335 
0.283 
0.456 
0.521 
0.632 
a) RSD, relative standard deviations (n = 5) 
b) SAE, standard analytical error. 
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Table 3.3: Determination of enaiapril maleate in pharmaceutical preparations by 
the proposed methods A, B, C, D and reference method |12|. 
Formulations Method A 
Recovery RSD 
(%) (%) 
Method B 
Recovery RSD 
(%) (%) 
Reference 
method 
Recovery RSD 
(%) (%) 
Enapril 2.5 100.03 .159 100.16 1.014 99.92 1.206 
eL=0.993 eu=1.005 
t =0.505 F= 1.081 
01=0.992 eu=1.003 
t =1.158 F= 1.407 
2.5 
2.5 
99.93 
01=0.988 
t =0.490 
99.93 
eL=0.993 
t =0.450 
1.314 
eu= 1.002 
F= 1.106 
0.997 
eu= 1.005 
F= 1.627 
99.98 
eL=0.991 
t =0.706 
99.98 
eL=0.993 
t =0.698 
1.162 
eu=i.oo5 
F= 1.411 
0.996 
eu=1.005 
F= 1.694 
99.81 
99.83 
1.383 
1.273 
Method C Method D 
Enapril 2.5 100.06 1.048 
eL=0.993 Ou= 1.005 
t =0.219 F= 1.321 
100.13 0.959 
eL=0.985 eu=1.011 
t =1.041 F= 1.578 
99.92 .206 
Envas 2.5 99.98 1.314 
eL=0.991 9u= 1.006 
t =0.018 F= 1.023 
100.13 1.222 
eL=o.99o eu=i.oo4 
t =0.706 F= 1.272 
99.81 1.383 
Enace 2.5 100.06 1.210 
eL=0.996 eu=1.009 
t =0.964 F= 1.101 
99.92 1.177 
eL=0.993 0u= 1.006 
t =0.361 t =0.361 
99.83 1.273 
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Table 3.4: Application of the proposed spectrophotometric methods to the 
determination of enalapril maleate in spiked human urine. 
Method A 
Method B 
Method C 
Method D 
Amount added 
(^g/mL) 
10.0 
25.0 
40.0 
X 
RSD 
80.0 
320.0 
480.0 
X 
RSD 
20.0 
40.0 
60.0 
X 
RSD 
40.0 
80.0 
160.0 
X 
RSD 
Amount found 
(lag/mL) 
9.83 
24.63 
39.56 
79.14 
319.25 
474.28 
19.45 
38.78 
59.71 
39.57 
79.83 
158.70 
% Recovery 
98.30 
98.52 
98.91 
98.58 
0.31 
98.92 
99.76 
98.81 
99.16 
0.52 
97.25 
96.96 
99.52 
97.91 
1.43 
98.93 
99.78 
99.19 
99.30 
0.44 
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INTRODUCTION 
Labetalol hydrochloride is chemically 5-[l-Hydroxy-2-(l-methyl-3-henyl propyl 
amino) ethyl] salicylamide hydrochloride. Labetalol (LBT) is a mixed antagonist i.e. ai 
and non-selective B-receptor antagonist. It is used in the management of hypertension. In 
hypertension LBT is usually given in an initial dose of 100 mg twice daily. After oral 
administration it is well absorbed and extensively metabolized in liver. The metabolites 
are excreted in the urine together with small amounts of unchanged labetalol. British 
Pharmacopoeia [1] recommended non-aqueous titration for its determination whereas 
United States Pharmacopoeia [2] recommended HPLC method for LBT determination. 
The therapeutic importance of the cited drug has forced to develop assa\ 
procedures for its quantitation in commercial dosage forms and biological fluids 
Literature survey revealed that analytical techniques such as spectrophotometry [3-5]. 
HPLC [6-9], HPLC-MS [10], micellar liquid chromatography [11], capillary liquid 
chromatography [12], capillary electrophoresis [13-14], capillary isotachophoresis fl5| 
and NMR spectroscopy [16] have been employed for the determination of LBT. LBT was 
also determined in pharmaceutical preparations using an ion-selective electrode [17]. The 
determination in biological fluids normally requires the use of trace analysis techniques 
such as HPLC, LC, CE, cyclic voltammetry and hyphenated techniques like LC-MS, GC-
MS, inductively coupled plasma-mass spectrometry which normally makes the method 
much more expensive. In addition to this, these methods require long and tedious 
pretreatment of the samples and laborious clean up procedures prior to analysis. UV-
visible spectrophotometry and fluorimetry are the techniques of choice even today in the 
laboratories of research, hospitals and pharmaceutical industries due to its low cost and 
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inherent simplicity. Spectrofluorimetric methods have also been reported [18] for 
determination of LBT in commercial dosage forms and spiked human urine based on its 
interaction with ethylacetoacetate in presence of sulphuric acid and reaction between 
nitroso-derivative of LBT and 2-cyanoacetamide in the presence of ammonia [19]. 
This chapter describes two simple, sensitive and accurate spectrofluorimetric 
methods for the determination of LBT. The first method is based on the direct 
measurement of the native fluorescence of the drug at 432 nm after excitation at 312 nm. 
In the second method, the ternary complex formed between zinc (II), eosin and labetalol 
was extracted into chloroform and its fluorescence intensity was measured at 452 nm 
after excitation at 317 nm. The proposed methods were extended to the determination of 
LBT in pharmaceutical preparations and human urine. 
EXPERIMENTAL 
Apparatus 
All fluorescence measurements were made on a 'Hitachi F-2500 fluoresence" 
spectrophotometer (Tokyo, Japan) equipped with a xenon lamp. Slit widths for both 
excitation and emission monochromators were set at 5 nm and all measurements were 
made in quartz cells with path length of 1.0 x 1.0 cm. Absorbance measurements were 
made on Elico UV-Visible Spectrophotometer, model No SL-164 (India). 
Materials and reagents 
• Reference standard sample of labetalol hydrochloride was obtained from Sigma 
Chemical Co, USA. 
14(1 
Phamiaceutical preparations of labetalol such as lobet 100 (Samarth Pharma.. India). 
gravidol 100 (Mercury Lab., India) were purchased from local market. 
Eosin (Fluka Chemie AG, Switzerland) solution was prepared as 2.0 x 10'^  M 
solution in distilled water. 
Zinc (II) sulphate (Sigma Aldrich Chemie, Germany) solution was prepared as 2.0 
X 10'^  M solution in distilled water. 
• Urine samples were obtained from healthy volunteers. 
• Carbonate buffer of pH 9.4 was prepared by dissolving 26.5 g sodium carbonate and 
21.0 g sodium bicarbonate in 500 mL distilled water. 
Standard LBT solution 
A stock solution of LBT (0.25 mg mL"') was prepared by dissolving 25 mg LBT 
in distilled water in 100 mL volumetric flask. The stock solution of LBT (0.25 mg mL'') 
was used to prepare working solutions by suitable dilutions with distilled water. The 
stock solution of LBT was stable at least 10 days at room temperature. 
Procedure for determination of LBT 
Method A 
Different aliquots of stock solution (0.25 mg mL"') were transferred into a set of 
10 mL volumetric flasks and then the volume was completed to the mark with distilled 
water to produce solutions in the concentration range 1.0 - 30.0 )ig mL"'. The 
fluorescence intensity was measured at 432 nm after excitation at 312 nm. The calibration 
graph was constructed by plotting fluorescence intensity against the final concentration of 
LBT. 
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Method B 
Various aliquots of stock solution (0.25 mg mU') were pipetted into a series of 25 
mL volumetric flasks to produce working solutions in the concentration range 0.5 to 4.0 
HgmU'. To each flask, 0.8 mL of 2.0 x 10"^  M eosin and 0.7 mL of 2.0 x 10"^  M zmc (III 
sulphate were added and diluted to volume with distilled water. The contents of the flask 
were transferred into a separating funnel and extracted with 25 mL chlorofonn b\ 
shaking for 1 min. The fluorescence intensity of the organic layer was measured at 452 
nm after excitation at 317 nm. The calibration graph was obtained by plottmg the 
fluorescence intensity versus the final concentration of LBT. 
Procedure for commercial tablets 
Five tablets (claming 100 mg of LBT per tablet) were accurately weighed and 
finely powdered. A quantity of the powder equivalent to 25 mg of LBT was extracted bv 
shaking with 20 mL of distilled water, followed by another two extractions each with 10 
mL of distilled water. It was filtered on Whatmann filter paper No. 42 (Whatmann 
Intemafional Limited, Kent, UK) to remove insoluble materials. The volume of filtrate 
was diluted to 100 mL with distilled water. It was further diluted according to the need 
and then analyzed following the proposed procedures. The nominal content of the tablets 
was calculated either from the previously plotted calibration graphs or using the 
regression equafions. 
Procedure for spiked human urine samples 
Aliquot volumes of spiked human urine samples were transferred into small 
separating funnel. 5 mL of carbonate buffer pH -9.4 was added and the solution was 
mixed well. The solution was then extracted with 3 x 5 mL of diethyl ether. The ether 
14: 
extract was collected and evaporated. The residue was dissolved in 5 mL of distilled 
water and the above general procedure was then followed. The nominal content of LB 1 
was determined from the corresponding regression equation. 
Evaluation of bias 
The bias has been evaluated by means of point and interval hypothesis tests [20, 
21]. In interval hypothesis the results of the recovery experiments of proposed method 
(method A & B) were compared with those of reference method. If the true mean is 
within ± 2 % of that of the reference method, then the proposed method is accepted. 
Which can be represented as 
0.98 < 112/m< 1.02 
A generalized form can be written as 
OL < 2^ / m < Su 
where 9L and 6u are lower and upper acceptance limits, respectively. The limits of this 
confidence interval can be calculated using the following quadratic equation: 
e^ [x] - Sy I n , ) - 16x,V^ + [x] - Sy /n^ )= 0 
RESULTS AND DISCUSSION 
Aqueous solution of LBT flouresces at 432 nm with an excitation wavelength at 
312 nm (Fig. 4.1). Based on the iriherent fluorescent property, the direct determination of 
LBT was achieved in pharmaceutical preparations and urine samples. 
In the literature, spectrophotometric [22] and fluorimetric [23] methods have been 
reported based on the ternary complexes of general formula (LnMxSy). In the present 
study, a ternary complex involving LBT, Zn (II) and eosin has been formed in which 
main ligand L is LBT, the second ligand S is eosin and M is zinc (II). The ternary 
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Fig. 4.1: Excitation and emission spectra of aqueous solution of LBT. 
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complex was extracted into chloroform which fluoresces at 452 nm after excitation at 3 P 
nm (Fig. 4.2). The mixtures of LBT - eosin and LBT - Zn (II) were shaken, separately, 
with chloroform and organic layer, in both cases, did not exhibit fluorescence under the 
specified experimental condition whereas the chloroformic extract of eosin - Zn (11) 
fluoresces at 655 nm after excitation at 327 nm. Therefore, it is concluded that interaction 
of Zn (II), eosin and LBT resulted in the formation of ternary complex. 
Stoichiometry of the ternary complex 
The stoichiometry of the ternary complex was evaluated by Job's method of 
continuous variations. The combining molar ratio between Zn (II) and LBT was 
determined in the presence of excess eosin and found to be 1:1. In a similar manner, [Zn 
(II): eosin] ratio in the presence of excess LBT and [eosin: LBT] ratio in the presence of 
excess Zn (II) was found to be 1:1, in each case (Fig. 4.3). Therefore, the composition of 
ternary complex, LBT - Zn (II) - eosin, be expressed as 1:1:1. 
Optimization of reaction conditions 
Investigations were carried out to establish the optimum reaction conditions with 
respect to reaction time, reagents concentration and shaking time for extraction. 
Effect of time 
The effect of time on the development of fluorophore and its stability was 
investigated. The reaction product got stabilized immediately after mixing LBT and the 
reagents and remained stable for at least 2 h. 
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Effect of Zinc (II) sulphate concentration 
The effect of volume of 2.0 x 10"^  M Zn (II) on the fluorescence intensity of the 
ternary complex was studied over the volume range 0.015 - 0.9 mL; keeping the 
concentrations of the drug (10 )ig mL"') and eosin ( 0.8 mL of 2.0 x 10"^  M) constant. It is 
apparent from Fig. 4.4 that the maximum and constant fluorescence intensity was 
obtained over the range 0.5 - 0.9 mL of 2.0 x 10"^  M Zn (11). Thus, 0.7 mL of 2.0 x 10' M 
Zn (II) was used as an optimum volume for fiirther measurement. 
Effect of eosin concentration 
In order to examine the effect of the volume of 2.0 x 10"^  M eosin on the 
fluorescence intensity, the reaction was carried out using different volumes (0.05 - 1.0 
mL). As can be seen from the Fig. 4.5 that the maximum and constant fluorescence 
intensity was obtained at 0.8 ± 0.2 mL. Therefore, 0.8 mL of 2.0 x lO"^  M eosin was 
taken as optimum volume for the assay procedure. 
Effect of shaking time for extraction 
In order to examine the effect of shaking time for the extraction of fluorophore 
into chloroform, experiments were performed for the periods ranging from 1 - 3 min. A 
maximum and constant fluorescence intensity was obtained from one minute shaking and 
therefore, two minutes shaking time was recommended for the extraction of fluorophore. 
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Validation of proposed methods 
Under the optimum experimental conditions, the fluorescence intensity -
concentration plots for methods A and B were found to be rectilinear over the range 1.25 
- 30 |ig and 0.5 - 4 |ag mL" , respectively. Linear regression analysis of calibration data 
gave the regression equations cited in Table 4.1 with correlation coefficients close to 
unity in both the cases. Statistical analysis of regression lines were made regarding the 
standard deviation of residuals (Sx/y), standard deviation of slopes (Sb) and standard 
deviation of intercepts (Sa) and the values are summarized in Table 4.1. In both the 
spectroflourimetric methods, the values are small confirming that the proposed methods 
are precise [24]. The LOD values for methods A and B were found to be 0.24 and 0.08 
fig mL"', respectively. 
Precision 
The within day precision assays were carried out through replicate analysis (n = 
5) of LBT corresponding to 5, 15 and 25 |ag mL"' for method A and 1.0, 2.6 and 4.0 |ig 
mL"' for method B. The interday precision was also evaluated through replicate analysis 
of the pure drug samples for five consecutive days at the same concentration levels as 
used in within day precision. The results of these assays are reported in Table 4.2. As can 
be seen fi-om the Table 4.2 that RSD values for within day precision were always lower 
than 1.4 % for method A and 2.8 % for method B; RSD values for interday precision 
were lower than 1.1 % for method A and 2.95 % for method B. The precision results are 
satisfactory. 
Table 4.1: Analytical characteristic of the proposed methods. 
Parameters 
Beer's law limit (|Ag m U ) 
Linear regression equation'' 
Sa 
tSa" 
Sb 
tSb" 
Correlation coefficient (r) 
Variance (Sxy^) 
Detection limit (|ig m L ' ) 
Quantitation limit {\xg m L ' ) 
Method A 
1.25-30 
F = 1.45 + 9.99 C 
0.44 
9.74x10-' 
2.59 xlO-2 
5.77x10"^ 
0.9999 
0.54 
0.24 
0.73 
Method B 
0 . 5 - 4 
F = 10.95 X10"-- 25.49 (• 
0.38 
8.51 xlQ-' 
1 .52x10 ' 
3.39 x i o ' 
0.9998 
0.35 
0.08 
0.23 
" With respect to F = a + bC, where C is the concentration in |j,g mL" , F is fluorescence 
intensity. 
''Confidence interval of the intercept and slope at 95 % confidence level and ten degrees of 
freedom (t = 2.228). 
Table 4.2: Test of precision of the proposed methods. 
Proposed methods 
Method A 
Intraday assay 
Interday assay 
Method B 
Intraday assay 
Interday assay 
Concentration 
( M g m L ' ) 
Taken 
5.00 
15.00 
25.00 
5.00 
15.00 
25.00 
1.00 
2.60 
4.00 
1.00 
2.60 
4.00 
Found ± SD' 
5.062 ± 0.066 
15.053 ± 0.068 
25.042 ± 0.083 
4.965 ± 0.050 
14.980+ 0.083 
25.007+ 0.182 
0.998 + 0.027 
2.602 ± 0.023 
4.007+ 0.033 
1.003+ 0.030 
2.604+ 0.025 
4.006 ± 0.040 
RSD' 
(%) 
1.31 
0.45 
0.33 
1.01 
0.56 
0.73 
2.71 
0.87 
0.83 
2.94 
0.95 
1.00 
SAE" 
0.030 
0.030 
0.037 
0.022 
0.037 
0.082 
0.012 
0.010 
0.015 
0.013 
O.OIl 
0.018 
C.L. 
0.082 
0.084 
0.103 
0.062 
0.104 
0.226 
0.034 
0.028 
0.041 
0.037 
0.031 
0.050 
^Mean for five independent determinations. 
SAE, standard analytical error. 
"C.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
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Accuracy 
The proposed method A was used for estimation of LBT from tablets after spiking 
with 100, 300 and 500 % of additional pure drug. In case of method B, LBT was 
determined from tablets after spiking with 50, 150 and 250 % of additional pure drug. 
The results are reported in Table 4.3. As can be seen from the Table 4.3 that recoveries 
ranged from 99.99 - 100.13 % for method A and 99.87 - 100.16 % for method B. The 
selectivity of the proposed methods was ascertained by analyzing standard LBT in the 
presence of tablet excipients such as lactose, starch, glucose, cellulose, talc and 
magnesium stearate. It was observed that these excipients did not interfere with the 
proposed methods. 
The proposed methods were applied to the determination of LBT in its 
commercial tablets. The results of the proposed methods were compared with those 
obtained by the reference method [25] (Table 4.4). Statistical analysis of the results using 
Student's t-test and variance ratio F-test revealed no significant difference between the 
proposed methods (Method A and B) and the reference method at 95 % confidence level 
regarding accuracy and precision. 
The bias of each drug sample was also checked based on recovery experiments 
using inters'al hypothesis test. As can be seen from Table 4.4 that the true bias of all 
samples is lower than ± 2% confirming that there is no significant differences between 
the proposed method and reference method with regard to accuracy and precision at 95% 
confidence level. 
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Table 4.3: Accuracy and Recovery. 
Formulation Excess of the drug Recovery ± RSD 
added (%) 
SAE 
Method A 
Lobet 100 
Gravidol 100 
Method B " 
Lobet 100 
Gravidol 100 
100 
300 
500 
100 
300 
500 
50 
150 
250 
50 
150 
250 
100.13 ±1.16 
100.0110.45 
99.99 ± 0.26 
100.03 + 1.53 
99.99 ±0.70 
100.03 ±0.68 
100.16± 1.60 
100.06 ± 1.21 
100.05 ±1.18 
100.08 ±1.65 
100.10± 1.14 
99.87 ±0.99 
0.052 
0.041 
0.035 
0.068 
0.063 
0.091 
0.011 
0.014 
0.019 
0.011 
0.013 
0.016 
0,144 
0 112 
0 097 
0 190 
o,n5 
0.253 
0,030 
0 037 
0.051 
0 031 
0.035 
0,043 
* Initial amount taken = 5.0 [ig mL" 
** Initial amount taken = 1.0 fig mL' 
Lv-
Table 4.4: Assay results of LBT in commercial tablets using the proposed methods. 
Fomuilations 
Lobct 100 tablets 
Rccovcr\ (%) 
RSD 
t'^  
F^  
e,; 
e, '^ 
Gravidol 100 tablets 
Method A 
100.12 
1.47 
1.205 
1.519 
0.998 
1 004 
Method B Reference Method I.!51 
100.11 100.23 99.62 
0.843 1.19 1.74 
1.41K 
4.191 
0.990 
1.101 
Rccovcn (%) 100.01 100.13 100.18 W 
RSD' " 1.30 1 14 138 2 
t'^  2.201 0.437 
F'' 1043 3.717 
e, ^ 0 999 0.996 
G, ^  1004 1.000 
Mean for five independent analyses 
Theoretical t-value {x =8) and F-valuc (\' = 4.4) at 95% confidence level are 2.306 and 6 39 
rcspectiveh 
Oi = 0.98 and Oi = 1.02 arc acceptable bias, based on recover\ experiments and are within 
_ L . - ) 0 / 
± Z ,0. 
The performance of the proposed methods was compared with other existing 
spectrofluorimetric methods [18, 19]. In case of the proposed method B and reported 
method [18], the products are formed immediately after mixing the reagents but the 
precision of the reported method is somewhat poor with relatively higher LOD value. 
However, the LOD value of the other method [19] is very small but the drawback is that 
it requires 25 min of heating for reaction to complete. Therefore, the proposed methods 
were found to be simple and can compete with existing spectrofluorimetric methods \n 
determining the drug in phamiaceutical preparations. 
The proposed methods were further extended to the in vitro determination of LBT 
in spiked human urine samples. In hypertensive patients, LBT is orally given in doses of 
100 mg three times daily and consequently, it results in urine level at concentration level 
of about 2 - 4 |ig mL"' . This concentration falls well within working range of proposed 
methods. The calibration graphs were first constructed by plotting fluorescence intensity 
vs. increasing concentration of LBT in spiked human urine samples over the 
concentration ranges 1.25 - 30 p.g mL'' for method A and 0.5 - 4.0 ng mL'' for method B. 
The proposed methods were then applied to spiked human urine samples. These results ( 
Table 4.5) are satisfactorily accurate and precise. 
TabJe 4.5: Application of the proposed spectrofluorimetric methods to the 
determination of LBT in spiked human urine. 
Method A 
Method B 
Amount added 
(^ ig mL ') 
1.0 
2.0 
3.0 
4.0 
5.0 
X 
RSD 
1.6 
2.0 
2.4 
2.8 
X 
RSD 
Amount found 
(Mg mL') 
0.974 
2.081 
2.993 
3.995 
5.025 
1.625 
1.990 
2.435 
2.755 
% Recovery 
97.41 
100.05 
99.78 
99.88 
100.51 
100.33 
2.39 
101.56 
99.50 
101.46 
98.39 
100.84 
1.15 
15S 
REFERENCES 
[I] The British Pharmacopoeia, Her Majesty Stationary Office, London (1998) 
p.768. 
[2] The United States Pharmacopia, Pharmacopial Convention, Rockville, National 
Formulary MD, USA, 27 (2004) p. 1060. 
[3] N. Rahman, H. Rahman, S. N. H. Azmi, J. Chin. Chem. Soc. 54 (2007) 185. 
[4] F. Belal, S. Al-Shaboury, A. S. Al-Tamrah, IL Farmaco 58 (2003) 293. 
[5] C. S. P. Sastry, D. M. Krishna, Microchim. Acta 122 (1996) 87. 
[6] D. Magali, D. Charlotte, P. Francois, D. Philippe, A. Jean-Claude, Forensic Sci 
Int. 141 (2004)23. 
[7] H, Zhao, H. Z. Li, Z. Y. Qiu, Sepu. 17 (1999) 369. 
[8] C. Ceniceros, M. I. Maguregui, R. M. Jimenez, R. M. Alonso, J. Chromatogr. B 
705(1998)97. 
[9] J. M. Dakers, D. W. Boulton, J. P. Faweett, J. Chromatogr. B 704 (1997) 215. 
[10] M. S. Lant, J. O. L. E. Martin, J. Chromatogr. A 394 (1987) 223. 
[II] S. Carda-Broch, R. Rapado-Martinez, l. Est eve-Romero, M. C. Garcia-Alverez-
Coque, J. Chromatogr. Sci. 37 (1999) 93. 
[12] C. Karlsson, H. Wikstrom, D. D. Armstrong, P. K. Owens, J. Chromatogr. A 
897 (2000) 349. 
[13] T. V. Goel, J. G. Nikelly, R. C. Simpson, B. K. Matuszewski, J. Chromatogr. A 
1027(2004)213. 
[14] S. L. Tamisier-Karolak, M. A. Stenger, A. Bommart, Electrophoresis 20 (1999) 
2656. 
159 
[15] S. Jana, P. Jozef, J. Chromatogr. A 735 (1996) 403. 
[16] M. A. iorio, A. Mazzeo-Farina, A. Doldo, J.Pharm. Biomed. Anal. 5 (1987) 1. 
[17] E. Gorodkiewicz, P. Falkowski, A. Sankiewicz, Z. Figaszewski, Central Euro. .[ 
Chem. 1 (2003) 242. 
[18] F. Belal, S. Al-Shaboury, A. S. Al-Tamrah, J. Pharm. Biomed. Anal. 30 (2002) 
1191. 
[19] D. R. EL-Wasseef, S. M. EL-Ashry, M. A. ABU-EL-Enein, M. A. A. Moustata. 
J. Food Drug Anal. 14 (2006) 133. 
[20] C. Hartmann, J. Smeyers-Verbeke, W. Penninckx, Y. V. Heyden, P 
Venkeerberghen, D. L. Massart, Anal. Chem. 67 (1995) 4491. 
[21] Canada Health Protection Branch, Drugs Directorate guidelines, Acceptable 
methods. Ministry of National Health and Welfare, Draft (1992). 
[22] E. A. Hisham, M. A. Magda, A. T. Elham, J. Pharm. Biomed Anal. 18 (1999) 
1021. 
[23] E. A. Hisham, Spectrochim. Acta Part A 66 (2007) 701. 
[24] J. C. Miller, J. N. Miller, "Statistics for Aanalytical Chemistry", John Wiley and 
Sons, New York (1983) p. 428. 
[25] The British Pharmacopoeia, Her Majesty Stationary Office, London, Vol 1 
(1993)p.373. 
I6(' 
Chapter 5 
INTRODUCTION 
Amiodarone hydrochloride (AD) is a potent III antiarrhythmic drug [1] and is 
chemically known as 2-butyl-3-benzofuranyl 4-[2-(diethyl amino) ethoxy]-3.5-
diidophenyl methanone hydrochloride. It is used to treat ventricular and supraventricular 
arrhythmias, especially when they are resistant to other conventional antiarrhythmic 
drugs [2,3].The drug is official in Indian Pharmacopoeia [4] and British Pharmacopoeia 
[5]. 
The analytical techniques that have been utilized for the quantification of this 
drug in biological fluids and pharmaceutical formulations include high performance 
liquid chromatography [6-11], high performance thin layer chromatography [12], 
liquid chromatography [13,14], infrared spectroscopy [15], enzyme linked 
immunosorbent assay and electrochemical methods [16,17]. The literature survey 
revealed that only few spectrophotometric methods are available for its 
quantification. A spectrophotometric method was presented for the assay of 
amiodarone based on reaction of the drug with citric acid - acetic anhydride [ 18] 
reagent to provide a bluish-violet colour having absorption maximum at 580 mn. 
However, the Beer's law was obeyed over the concentration range 2 -12 i^ g mL"' but 
required 45 minutes to complete the analysis. Amiodarone was found to form 
insoluble molecular complexes with iodine, ammonium molybdate (AM) or 
phosphomolybdic acid (PMA) [19] under acid conditions and spectrophotometric 
methods were developed based on the colour formation with either unreacted 
precipitant in the filtrate (I2) or released precipitant form the precipitate (AM or 
PMA) with chromogenic reagents. However, these methods are tedious to perform 
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and time consuming. Extractive spectrophotometric methods have also been 
developed based on chloroform extractable ion-association complex [20] of the drug 
with tropaeolin 00, tropaeolin 000, or wool fast blue. Amiodarone was also 
determined spectrophotometrically using the charge transfer complexation reaction 
of the drug with p-chloranilic acid [21], 2, 3-dichloro 5, 6-dicyano 1, 4-
benzoquinone [21], chloranil and iodine [22]. Spectrophotometry is the technique of 
choice even today due to its low cost and inherent simplicity. It has wide application 
in the quantitative analysis of pharmaceutical drugs in clinical and pharmaceutical 
laboratories. 
This chapter describes two simple and accurate spectrophotometric methods 
for the assay of amiodarone hydrochloride in bulk and commercial dosage forms. 
Method A is based on bromination of drug with N-bromosuccinimide whereas 
method B utilizes chloroform extracble ion-association complex of drug with 
bromothymol blue (BTB). The reaction conditions were thoroughly studied and 
under optimal experimental conditions, the procedure provides accurate 
determination of drug in commercial dosage forms. 
EXPERIMENTAL 
Apparatus 
The absorbance measurements were made on a Spectronic 20D^ 
Spectrophotometer (Milton Roy Company, USA) with 1 cm matched glass cells. A 
water bath shaker (Narang Scientific Works Pvt limited. New Delhi, India) was used 
to control the temperature. 
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Reagents and marketed tablets 
Amiodarone hydrochloride was kindly provided by Troikaa Pharmaceutical 
Ltd. India and was used as received. Commercial dosage forms of amiodarone 
hydrochloride such as Duron (Samarth Pharma Pvt. Ltd., India), Cardarone (Sanofi 
Synthelabo (India) Ltd.) and Amiodar (Cardicare, India) were purchased from local 
drug stores, labeled to contain 100 mg amiodarone hydrochloride per tablet. 
• N-Bromosuccinimide (1.12 x 10'' M; S.d. fine Chem. Ltd., India) solution was 
prepared in acetone. 
• Bromothymol blue (4.01 x 10"^  M, Loba chemie Pvt. Ltd., India) solution was 
prepared in distilled water. 
• Sodium acetate-hydrochloric acid buffer [23] of pH 2.32 was prepared by mixing 50 
mL of 1.0 M sodium acetate solution with 51 mL of 1.0 M HCI and diluted to 250 mL 
with distilled water. 
Test solutions 
(i) Amiodarone hydrochloride (1 mg mL'') solution was prepared in methanol for 
method A 
(ii) Amiodarone hydrochloride (0.5 mg mL'') solution was prepared in 
chloroform for method B. 
Proposed procedures for the determination of amiodarone hydrochloride 
Method A 
Aliquots of standard solution of amiodarone hydrochloride (1 mg mL"') 
equivalent to 0.25 - 3.0 mg were transferred into a series of boiling tubes. To each 
tube, 1.7 mL of 1.12 x 10' M N-bromosuccinimide was added and contents were 
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heated on a waterbath at 40 ± 1 °C for 10 min. After cooling at room temperature, 
the contents were transferred to 5 mL volumetric flask and volume was completed 
with methanol. The absorbance of the coloured product was measured at 353 nm 
against the reagent blank prepared simultaneously. The calibration curve was plotted 
and regression equation was developed. 
Method B 
Into a series of 50 mL separating funnels, 5 mL of buffer solution of pH 2.32 
and 3.5 mL of BTB were placed. An appropriate volume (0.04 - 1.1 mL) of 
amiodarone hydrochloride (0.5 mg mL' ) was added to each funnel and mixed well. 
The funnels were shaken vigorously with 10 mL chloroform for 2 minutes, and then 
allowed to stand for clear separation of two phases. The absorbance of the organic 
phase was measured at 400 nm against the reagent blank prepared simultaneously. 
Determination of amiodarone hydrochloride in commercial dosage forms 
Ten tablets were powdered and mixed thoroughly. For method A, an amount 
of the tablet powder equivalent to 100 mg of amiodarone hydrochloride was weighed 
accurately and extracted into 50 mL methanol with shaking. Filtration through 
Whatmann No 42 filter paper was performed. The filtrate was diluted to 100 mL 
with methanol. For method B, an amount of the tablet powder equivalent to 100 mg 
amiodarone hydrochloride was stirred well with chloroform and filtered through 
Whatmann No 42 filter paper. The filtrate and washings were diluted to volume in a 
100 mL volumetric flask. The assay was completed following the proposed 
procedures. 
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RESULTS AND DISCUSSION 
N-Bromosuccinimide is an extremely useful and versatile reagent [24]. Its 
unique brominating ability has been attributed to its almost non-polar N-bromine 
bond, as well as the favourable geometric arrangement, which exists between the N-
bromine and carbonyl function. It has been reported [25] that tertiary amine reacts 
with N-bromosuccinimide resulting in the formation of coloured intermediate, which 
on hydrolysis yields aldehydes and brominated secondary amine whereas N-
bromosuccinimide irreversibly reduced to succinimide. This can be expressed as: 
(R-CH2)3N + BrN(C0CH2)2 ^ ^ n t e r m e d i a t e " ^ ^ ^^^'^ ^ (R-CH2)2NH2Br + HN(COCH2)2 
Similarly, in the present study, the amiodarone contains tertiary amino group, which 
reacts quantitatively with N-bromosuccinimide in methanol-acetone medium resulting in 
the formation of a coloured product absorbing maximally at 353 nm. The stoichiometry 
of the reaction was studied adopting limiting logarithmic method [26]. The absorbance of 
the reaction product was alternatively measured in the presence of excess of N-
bromosuccinimide and amiodarone hydrochloride. A plot of log absorbance vs log [N-
bromosuccinimide] and log [amiodarone hydrochloride] gave straight lines; the values of 
the slopes were 1.05 and 1.00 respectively (Fig. 5.1). It is concluded that the reaction 
proceeds in the ratio of 1:1. Based on the obtained molar reactivity, the reaction pathway 
is shown in Scheme 5.1. 
At pH 2.32, the amino group of amiodarone is protonated while sulphonic acid 
group present in BTB undergoing dissociation. The colour of BTB is due to the opening 
of lactoid ring and subsequent formation of quinoid group. It is supposed that the two 
tautomers are present in equilibrium but due to strong acidic nature of the sulphonic acid 
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group, the quinoid body must predominate. Finally, the protonated amiodarone fonns 
ion-pair with BTB, which are quantitatively extracted into chloroform. The ion-pair 
complex absorbed maximally at 400 nm and the reagent blank under similar conditions 
showed no absorption at the specified wavelength. The absorption spectrum is shown m 
(Fig. 5.2). The stoichiometry was established by mole ratio method [27]. As can be seen 
from Fig. 5.3 that the molar ratio of amiodarone to BTB was 1:1. On the basis of our 
experimental findings and literature background, the reaction sequence is shown in 
Scheme 5.2. 
Optimization of variables 
The optimum conditions for the assay procedures (methods A and B) have 
been established by studying the reactions as a fianction of heating time, 
concentration of reagents, pH and nature of solvent. 
Method A 
Effect of heating time 
To investigate the optimum heating time for colour development, aliquots of 
amiodarone hydrochloride (3 mg) were transferred into a series of boiling tubes. To 
each tube, 2 mL of 1.12 x 10"' M N-bromosuccinimide was added followed by 5 niL 
of methanol. The tubes were placed on waterbath maintained at 40 ± 1 °C for 
different time intervals. The results are shown in Fig 5.4. As can be seen irom Fig. 
5.4 that the maximum absorbance was obtained at 8 min and remained constant upto 
12 min. Therefore, 10 min heating time was used throughout the experiment. 
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mL of 4.01 X lO"* M BTB + 5.0 mL of sodium acetate-HCl buffer solution of pH 
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Fig. 5.4: Effect of heating time on the absorbance of the product. 
Effect of N-biomosiiccinimide concentration 
The influence of the volume of 1.12 x 10' M N-bromosuccinimide on the colour 
development was examined in the range of 0.1 - 2.0 mL. The highest absorbance was 
obtained with 1.5 mL, which remained unchanged with higher amount of N-
bromosuccinimide (Fig. 5.5). Thus, 2.0 mL of the reagent was selected as an optimum 
value for the determination process. 
Method B 
Effect of the pH 
The influence of pH on the ion-pair formation between amiodarone and BTB 
was studied using sodium acetate-hydrochloric acid buffer in the pH range of 1.4 -
3.3 .The results are shown in Fig. 5.6. The maximum and constant absorbance was 
found between pH 1.99 and 2.64. Thus, a buffer of pH 2.32 was used in further 
studies. 
Effect of BTB concentration 
The effect of the volume of 4.01 x 10"^  M BTB was studied in the range of 
0.5 - 5.0 mL. The maximum absorbance was found with 3 mL of BTB; above this 
volume the absorbance remained unchanged (Fig. 5.7). Thus, 3.5 mL of BTB was 
used for ion-pair formation throughout the experiment. 
Choice of organic solvent and time of shaking 
A. variety of organic solvents such as benzene, toluene, hexane, chloroform, ethyl 
acetate, carbon tetrachloride and 1,2-dichloromethane were examined for extraction of 
ion-pair. However chloroform was preferred owing to selective extraction of the lon-pair 
complex from the aqueous solution. 
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Fig. 5.7: Effect of the volume of 4.01 xlO"^ M BTB on the absorbance of the ion 
pair complex (50.0 ^g mL"* amiodarone hydrochloride; 5.0 mL of buffer 
solution of pH 2.32). 
The time of shaking for complete extraction of ion-pair complex was studied m 
the range of 0.5 - 4 min. It was found that the absorbance remained constant o\er this 
time period. Thus, 2 min shaking time was used as an optimum value throughout the 
experiment. 
ANALYTICAL DATA 
Under the optimized experimental conditions, the absorbance-concentration 
plots were found to be linear over the concentration ranges 50 - 600 i^ g mL" and 2 -
55 )ig mL"' of amiodarone hydrochloride with molar absorptivity of 1.58 x 10 and 
1.50 X IC* L mol"' cm" for methods A and B, respectively. The linear regression 
analysis of calibration data gave the following equations: 
A = 4.012x lO'V L16x lO'^C r = 0.9999 formethodA 
A= 9.612 X 10"V 2.198 X 10"^  C r = 0.9999 formethodB 
Where A is the absorbance, C is the concentration in \xg niL" and r is the correlation 
coeffecient. The values of confidence limit at 95% confidence level for slopes were found 
to be 1.16 X 10"^  ± 6.87 x 10"^  and 2.198 x 10"^  ± 4.07 x 10"^  whereas for intercepts of 
calibration lines were 4.012 x 10"^  ± 2.41 x 10"^  and 9.612 x 10"* ± 1.33 x 10"^  for 
methods A and B, respectively. The good linearity of the calibration graphs and the 
negligible scatter of the experimental points were clearly evident from the values of 
correlation coeffecient and variance of calibration lines (3.24 x 10"^  and 1.06 x 10"^  |.ig 
mL" for methods A and B, respectively). Test of significance for intercepts of the 
regression lines was performed. For this, the values of t- were calculated using the 
relation t == a/Sa [28] and found to be 0.393 and 1.705 for methods A and B, respectively 
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which did not exceed the tabulated t-value (t = 2.367, v = 7) at 95% confidence level. It 
confirmed that the intercepts for the proposed methods are not significantly different 
from zero. The limits of detection for methods A and B were calculated and found to be 
5.12 and 0.16 ^gmL ' . 
Accuracy and precision 
The within day precision was evaluated through replicate analysis (n = 5) of 
quality control samples: 160, 360 and 560 i^ g mL"' for method A and 5, 25 and 50 |.tg 
mU' for method B. The percentage recoveries ranged from 99.99 - 100.00 with % 
RSD from 0.02 - 0.09 % and 99.99 - 100.18 % with RSD from 0.14 - 1.49 % for 
methods A and B, respectively. The interday precision was also evaluated through 
replicate analysis of the quality control samples for five consecutive days at the same 
concentration levels as used in within day precision. The percentage recoveries for 
methods A and B ranged fi-om 99.99 - 100.00% with RSD from 0.03 - 0.14% and 
99.99 - 100.18% with RSD from 0.20 - 2.07%, respectively (Table 5.1). The results 
in the Table 5.1 indicated the high precision of the proposed methods. The selectivity 
of the proposed methods was investigated by observing any interference encountered 
fi-om the excipients of the tablets such as magnesium stearate, talc, lactose, starch 
and gelatin. It was observed that these excipients did not interfere with the proposed 
methods. 
The standard addition method was applied to check the validity of the 
proposed methods for the determinafion of amiodarone hydrochloride in commercial 
tablets (Table 5.2). The percentage recoveries were found to vary from 99.96 -
100.20 % for method A while 100.10-100.30 % for method B. 
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Table 5.1: Test of precision of the proposed method. 
Proposed methods 
Method A 
Intraday assay 
Interday assay 
Method B 
Intraday assay 
Interday assay 
Concentration, (f.ig niL"') 
Taken 
160 
360 
560 
160 
360 
560 
5 
25 
50 
5 
25 
50 
Found ± SD 
159.98 + 0.15 
359.9910.14 
560.02 + 0.13 
159.99 ±0.22 
359.96 ±0.20 
559.98 ±0.18 
5.01 ±0.08 
25.00 ±0.06 
49.99 ± 0.07 
5.01 ±0.10 
25.00 ±0.09 
49.99 ±0.10 
Recovery 
(%) 
99.99 
99.99 
100.00 
100.00 
99.99 
100.00 
100.18 
100.02 
99.99 
100.18 
100.03 
99.99 
RSD 
(%) 
0.09 
0.04 
0.02 
0.14 
0.06 
0.03 
1.49 
0.25 
0.14 
2.07 
0.38 
0.20 
SAE 
0.066 
0.061 
0.057 
0.098 
0.089 
0.079 
0.033 
0.028 
0.032 
0.046 
0.042 
0.045 
CL 
0.183 
0.169 
0.159 
0.273 
0.246 
0.218 
0.093 
0.079 
0.089 
0.129 
0.116 
0.126 
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Table 5.2: Standard addition method for the determination of amiodarone 
hydrochloride in dosage forms. 
Formulations 
Method A 
Cardarone 100 
(Sanofi Synthelabo) 
Duron 100 
(Samarth Pharma) 
Amiodar 100 
(Cardicare) 
Method B 
Cardarone 100 
(Sanofi Synthelabo) 
Duron 100 
(Samarth Pharma) 
Amiodar 100 
(Cardicare) 
Concentration, (|.i 
Taken 
80 
80 
80 
80 
80 
80 
15 
15 
15 
15 
15 
15 
Added 
80 
160 
80 
160 
80 
160 
20 
40 
20 
40 
20 
40 
gmL' ) 
Found ± SD 
159.93 + 0.15 
239.91 ±0.14 
160.02 + 0.17 
240.03 ± 0.20 
160.03 + 0.13 
240.03 ±0.13 
35.03 ±0.10 
55.01 ±0.09 
35.01 ±0.04 
55.02 ±0.05 
35.01 ±0.05 
55.02 ±0.05 
Recovery ± RSD 
% 
99.96 ±0.10 
99.96 ±0.07 
100.01 ±0.10 
100.01 ±0.08 
100.02 ±0.08 
100.01 ±0.05 
100.10 ±0.30 
100.02 ±0.16 
100.02 ±0.13 
100.03 ±0.10 
100.02 ±0.12 
100.03 ±0.10 
SAE 
0.069 
0.061 
0.074 
0.089 
0.058 
0.058 
0.046 
0.039 
0.020 
0.024 
0.022 
0.024 
CI 
OA')] 
0J,69 
0,206 
0.246 
0.162 
0.162 
0.129 
0.109 
0.055 
0.066 
0.061 
0.066 
This study has further confirmed that the common excipients present in tablet 
formulations did not interfere with the assay. 
The proposed methods were apphed to the detennination of amiodarone 
hydrochloride in commercial tablets such as Duron, Amiodar and Cardarone. The 
same batch of the commercial dosage forms was also analyzed by the reference 
method [21]. The results of the proposed methods were compared with those 
obtained by the reference method. Statistical analysis of the results using Student's t-
test, variance ratio F-test and interval hypothesis test [29, 30] revealed no significant 
difference between the proposed method (A or B) and the reference method at 95 % 
confidence level regarding accuracy and precision. The results are summarized in 
Table 5.3. 
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Table 5.3: Determination of amiodarone hydrochloride in the commercial dosage 
forms by the proposed methods and reference method. 
Formulations Rccovcn RSD 
Co) (%) 
Method A 
Cardaronc 100 "^^ 100.01 0,022 
(Sanofi Sxnthclabo) 9 = 0.986 9^= 1.014 
t= 0.022 F=1.04 
Duron 100 100.01 0.016 
(Samarth Phamia) 9 =0 991 9,-1.008 
t -0 ,033 F=1.36 
Reference method 
Recovery (%) RSD (%) 
99,99 0,023 
99,99 0,02(,i 
Amiodar 100 
(Cardicare) 
100,01 0,022 
9 =0,985 9,= 1.015 
t =0.002 F= 1.18 
100.01 0.024 
Method B 
Cardaronc 100 
(Sanofi Sxnthclabo) 
100.00 0.122 
9 =0.988 9,= 1.012 
t =0.012 F=1.38 
99.99 0.144 
Duron 100 
(Samarth Pliarma) 
Amiodar 100 
(Cardicare) 
100.08 0.130 99.99 
9 =0.987 9,= 1.011 
t =0.189 F= 1.22 
100.03 0.133 100.00 
9=0 .987 9u= 1.012 
t = 0 111 F= 1.18 
0.143 
0.032 
Theoretical t-value (\' =8) and F-value (v = 4.4) at 95%confidence level are 2.306 and 6 3^. 
respecti\el\ 
0| = 0.98 and Or - 1 02 are acceptable bias, based on recovery experiments and are within ±2"i> 
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Kinetic Spectrophotometric Determination of Metoprolol Tartrate In 
Commercial Dosage Forms 
Nafisur Rahman,* Sk Manirul Haque and Syed Najmul Hejaz Azmi 
Department of Chemistry. Aligarh Muslim University. Aligarh-202 002, Uttar Pradesh. India 
A kinetic spectropiiotomctric method has been described for the determination of metoprolol tartrate 
in commercial dosage forms. The procedure is based on the reaction of the drug with 1 -chIoro-2,4-dinitro-
benzene (CDNB) in dimethylsulfoxide (DMSO) at 100 ± 1 °C. The reaction is investigated by measuring 
the change in absorbance with time at 420 nm. Fixed-time (AA) and equilibrium methods are chosen for 
obtaining the calibration curves. Both calibration curves were found to be linear over the concentration 
range of 5-60 |,ig mL''. The regression analysis of calibration data resulted in the linear regression equa-
tions of AA=-1.608 x 10-^  + 3.96x 10"^CandA = 7.31 x lO'V 1.90x lO'-C for fixed time (AA) and equi-
librium methods, respectively. The limit of detection (LOD) for fixed time and equilibrium methods are 
1.16 and 0.415 \xg mL"', respectively. The method has been successfully applied to the quantitation of 
metoprolol tartrate in commercial dosage forms. Statistical comparison of the results shows that there is 
no significant difference between the proposed methods and El-Ries's spectrophotometric method. 
Keywords: Metoprolol tartrate; l-Chloro-2,4-dinitrobenzene; Meisenheimer complex; Pharma-
ceutical formulations; Spectrophotometry; Validation. 
INTRODUCTION 
Metoprolol tartrate, 2-propanol, l-[4-(2-methoxyeth-
yl)phenoxy]-3-[(l-methylethyl)amino]-, (±)-, [R-(R*,R*)]-
2,3-dihydroxybutanedioate (2:1) (salt) [(Ci5H25N03)2-
C4H(,0(,. 56392-17-7. M.W. 684.81] is a competitive P-
adrenoceptor antagonist. It is used in the treatment of car-
diovascular disorders such as hypertension, angina pecto-
ris, cardiac arrhythmias and myeocardial infarction. 
The drug is officially listed in Martindale The Extra 
Pharmacopoeia.' The recommended assay of the drug is 
listed in the British Pharmacopoeia, which describes a 
potentiometric titration method.~ The various analytical 
methods such as thin layer chromatography,^''high perfor-
mance liquid chromatography,^"^ gas chromatography,** 
capillary electrophoresis,^ infrared spectroscopy,'" and 
electrochemical methods" have been described for its de-
termination. The above-mentioned techniques are good 
and sensitive but require a laborious clean up procedure 
prior to analysis of the drug. Spectrophotometry in the visi-
ble region is attractive because of its speed, no pretreatment 
steps and simplicity. The assay procedures based on spec-
trophotometry'""'^ have been published in reputed journals. 
The literature citations revealed that charge transfer com-
plexation reactions'^'"* of metoprolol with a-acceptor such 
as iodine and n-acceptors such as 7,7,8,8-tetracyanoqumo-
dimethane; 2,3-dichloro-5,6-dicyano-1,4-benzoquinone; 
tetracyanoethylene; 2,3,5,6-tetrabromo-l,4-benzoquinone; 
2,3,5,6-tetrachloro-l .4-benzoquinone and 2.5-dichl(>r(' 
3,6-dihydroxy-l,4-benzoquinone have been exploited for 
its estimation in commercial dosage forms. The quantition 
of metoprolol tartrate was done based on the reaction of the 
drug with ammonium metavanadate,'** FeCl?,"" N-bromo-
succinimide,"' and potassium dipertellurato euprate(Ill) " 
Extractive spectrophotometric methods have also been uti-
lized for the quantification of metoprolol tartrate in phar-
maceutical formulations based on chloroform extractable 
ion pair complexes of the drug with bromophenol blue. 
bromocresol purple, bromocresol green,^ ^ benzyl orange. " 
bromothymol blue," and carbon disulfide-copper chkv 
ride.'** Two kinetic spectrophotometric methods based on 
the reaction of metoprolol tartrate with ninhydrin in di-
methyl formamide^* and KMn04 in alkaline medium"" have 
been reported. The literature is still has few analytical pro-
cedures based on kinetics for the quantitation of metoprolol 
tartrate in dosage forms. Therefore, there is a need for an-
'• Corresponding author. E-mail: chtl7nr(ayahoo.co.in 
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other kinetic approach to quantitate the drug in commercial 
dosage forms. 
The present communication reports an optimized and 
validated kinetic spectrophotometric method for the deter-
mination of metoprolol tartrate in commercial dosage forms. 
The method is based on the reaction of metoprolol tartrate 
with CDNB m DMSO at 100 ± I °C. Ihc absorbance of the 
colored product measured at 420 nm increases as a function 
of heating time. Therefore, fixed time (AA) and equilib-
rium methods are applied for the quantitation of metoprolol 
tartrate in commercial dosage forms. 
EXPERIMENTAL 
Apparatus 
Shimadzu (UV-1240, Shimadzu Corporation, Kyoto, 
Japan) and Milton Roy Company (20D , USA) spectropho-
tometers were used for absorbance measurements. A water 
bath shaker (NSW 133. New Delhi, India) was used to con-
trol the heating temperature for color development. 
Reagents and Standards 
All chemicals used were of analytical reagent grade. 
Metoprolol tartrate reference standard was procured from 
Sigma Chemical Company, St. Louis, MO, USA. Tablet 
formulations of metoprolol tartrate such as Betaloc 25 
(AstraZeneca Pharma India Ltd., Bangalore, India), Metapro 
25 (Cardicare, Bangalore, India) and Metolar 25 (Cipla, 
Mumbai, India) were purchased from local drug stores. 
Standard Solutions 
• CDNB (9.87 X 10 3 M , Fluka Chemie AG, Ger-
many) solution was prepared in DMSO (Merck, India). 
• 0.05% metoprolol tartrate (7.30 x 10"* M) was also 
prepared in DMSO (Merck, India). 
Proposed Procedure for the Determination of 
Metoprolol Tartrate 
Into a series of boiling test tubes, different volumes 
(0.05-0.6 mL) of standard metoprolol tartrate (0.5 mg 
mL'') solution corresponding to 5-60 fig mL"' were 
pipetted. To each test tube, 1.7 mL of 9.87 x 10'^  M CDNB 
was added, mixed well and heated on a water bath at 100 ± 
1 °C for a preselected fixed time. After cooling at room 
temperature, the contents of the test tube were transferred 
to a 5 mL volumetric flask and the volume was completed 
with DMSO. The absorbance of the yellow colored produc 
was measured at 420 nm against the reagent blank a^  a 
function of time. 
The following two methods were adopted for nm 
structing the calibration graphs: 
• Fixed-time method (AA): The change in absorbaiKc 
(AA) between the times, t|( 5 min) and t:( 10 mini was com 
puted and plotted against the initial concentration n'' 
metoprolol tartrate. 
• Equilibrium method: The equilibrium was attamecl 
at 44 min of heating. The absorbance measured at 46 min of' 
heating was plotted against the initial concentraticm o'" 
metoprolol tartrate. 
Alternatively, regression equations were also de\ ci 
oped to determine the metoprolol tartrate. 
Analysis of Commercial Dosage Forms 
To determine the content of metoprolol tartrate m tab-
let formulations (label claim: 25 mg), the contents of 4 tab-
lets were weighed and finely powdered. A portion of the 
powder equivalent to 50 mg metoprolol tartrate was stirred 
with 25 mL DMSO and let stand for 10 min. The residue 
was filtered on Whatmann No. 42 filter paper (Whatmann 
International Limited, Kent, UK) and washed well with 
DMSO for complete recovery of the drug. The filtrate and 
washings were diluted to 100 mL with DMSO. This solu-
tion was subjected to the proposed procedure for the deter^ 
mination of metoprolol tartrate. 
Procedure for Reference Method"* 
Aliquots (0.2-3.5 mL) of 0.05% metoprolol tartrate 
were pipetted into a series of 10 mL standard \olumetric 
flasks. To each flask, 2.0 mL of 5 x 10'^  M tetracyanoethy U 
ene was added and the mixture was diluted to volume with 
acetonitrile. The reaction mixture was allowed to stand for 
15 min at 25 °C. The absorbance was measured against the 
reagent blank at 415 nm. The amount of the drug in a given 
sample was computed from the calibration graph 
METHOD AND VALIDATION 
Solution Stability 
The stability of reference metoprolol tartrate and 
quality control sample solutions at room temperature was 
evaluated with the help of UV-visible spectra and thin layer 
chromatography using TL(" plates coated with silica gel G 
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(Merck, Mumbai, India) and chiorofonTi-iTiethanol-2.89 M 
ammonia (v/v \/: 40:10:1) as mobile phase. 
Specificity and Selectivity 
The specificity and selectivity of the proposed method 
was evaluated by estimating the amount of metoprolol 
tartrate in the presence of common excipients such as so-
dium stearyl fumarate, magnesium stearate, starch, lactose 
and talc. 
cally using the following quadratic equation: 
^'{x; - S ;/,„,; / n,)+i}{-2x,x,)^ {.x; --5;;,,,; ;) , ) )^ 
where .r, and .v, are mean values based on Ui and n; iiica 
surements, respectively. Sp is the pooled standard de\ iation 
and t,abis the tabulated one-sided t-value, with Ui - n^-l tic 
grees of freedom at 95% confidence level. 
Linearity 
The linearity of the fixed-time (.\A) and equilibrium 
methods was ascertained by taking metoprolol tartrate at 
seven concentration levels: 5, ID, 20, 30, 40, 50 and 60 (ig 
mL"'. Each concentration was independently analyzed five 
times. 
Accuracy and Precision 
The accuracy and precision of the fixed-time (AA) 
and equilibrium methods were evaluated within the linear-
ity range based on the analysis of metoprolol tartrate in ref-
erence standard samples at 10.0, 30.0 and 50.0 (.ig mL' and 
in quality control samples at 50.0 |.ig mL''. Five independ-
ent analyses were performed at each concentration level 
within one day (intra day precision) as well as for five con-
secutive days (inter day precision). 
Recovery Studies 
Recovery experiments were carried out by the stan-
dard addition method. For this, 1.0 mL (or 3.0 mL) of refer-
ence metoprolol tartrate solution (0.5 mg mL"') was trans-
ferred into a 50.0 mL volumetric flask followed by 2.0 mL 
ofsample solution (0.5 mgmL ') and the volume was com-
pleted up to the mark with DMSO. The total amount was 
determined by the proposed procedure. 
Determination of Stoichiometry 
The stoichiometry of the reaction was studied by the 
mole ratio method. For this, 1.0mLof4.94x 10'^  M meto-
prolol tartrate was treated with varied volumes (0.05-0.8 
mL) of 4.94 x lO'^  M CDNB and the absorbance was re-
corded at 420 nm. The absorbance was plotted against the 
mole ratio of [CDNB] / [metoprolol tartrate]. 
Equivalence Testing 
For pharmaceutical analysis in dosage forms, a bias 
of ± 2.0% is acceptable"'* and can be calculated statisti-
RESULTS AND DISCUSSION 
Mechanism and Stoichiometry of the Colored Species 
The interaction of polynitroaromatic and halopo;\-
nitroaromatic compounds with a variety of Lewis and 
Bronsted bases has resulted in the formation of brighiK 
colored solutions which provided a means for determining 
their quantity. It was reported that the addition of second-
ary amines'' such as dimethylamine and dieth> lamine to 
DMSO solutions of 1,3,5-trinitrobenzene yielded an adduct, 
i.e. Meisenheimer complex. In this reaction 2 moles ot 
amine were utilized with one mole of 1,3,5-trinitroben-
zene. Metoprolol containing a secondary amino group w as 
found to react with CDNB in DMSO at 100 ± 1 C, result-
ing in the formation of an intense yellow colour due to the 
adduct formation which absorbs maximally at 420 nm. The 
blank consisting of CDNB in DMSO has a characteristic 
band at 345 nm. The absorption spectra are shown in Fie. ! 
The stoichiometry was established by the mole ratio 
method. The results are shown in Fig. 2. It is apparent from 
the figure that the combining molar ratio between meto-
prolol and l-chloro-2,4-dinitrobenzene is 2:1. The appar-
ent formation constant and standard Gibbs free energy 
(AG°) were calculated and found to be 4.85 •< 10 and 
-43.85 kJ mol ' , respectively. This stoichiometric ratio is 
similar to those obtained for interaction of 1,3,5-trinitro-
benzene with diethylamine in DMSO. On the basis of our 
experimental findings and literature review,^' the reaction 
sequence is presented in Scheme I. 
Solution Stability 
The solution stability was ascertained from the LA 
spectra of the reference standard and quality control sam-
ples. The reference standard of the drug showed an absorp-
tion peak at 277 nm. The standard and quality control sam-
ple solutions were kept at room temperature for five days, 
and it was observed that there was no change in the absorp-
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Scheme 1 
H3CO 
Metoprolol 
DMSO 
At 100°C 
H,CO 
H,CO 
Meisenheimer yellow complex 
-e 06 
o 
Q'i 
Fig. 1. 
240 280 320 360 400 440 480 520 6 
Wavelength (nm) 
Absorption spectra of (a) 2.92 x 10''' M meto-
prolol tartrate (200 Mg mL ' ) in DMSO (b) 
Blank solution: 9.87 x 10"^  M CDNB in DMSO 
(c) Sample solution: 3.36 x 10"^  M CDNB + 
7.30 X IQ-'' M metoprolol tartrate (50 |ig mL"') 
in DMSO. 
tion spectra of these solutions. The solution stability was 
also ascertained by applying the standard and quality con-
trol samples on TLC plates coated with silica gel G (Merck 
Limited, Mumbai, India) and developed in a chloroforin-
11 -
1.0 -
0.9 
0.8 -
0,4 ^ 
0,1 
OO 0 1 0 2 0 3 0 4 0 5 0 6 0 7 
Mole ratio [CDNBl / [Metoprolol tartrate] 
Fig. 2. Mole ratio plot for stoichiometric ratio between 
metoprolol tartrate and CDNB in DMSO (2:1). 
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iTiethanol-2.89 M ammonia (\ v v : 40:10:1) sohcnt sys-
tem. The plates were air-dried and spots were detected in 
the iodine chamber. In both eases, a single spot was ob-
served with R| = 0.6 corresponding to metoprolol tartrate. 
Optimization of Reaction Conditions 
The optimum conditions affecting the formation of 
Meisenheimer complex were examined. 
Effect of Heating Time 
The effect of reaction time on the maximum absorb-
ance of the product in DMSO was studied at 100 °C. In this 
process. 0.5 mL of 7,30 x 10"^  M metoprolol tartrate and 1.7 
mL of 9.87 x 10'^  M CDNB were added and kept on a water 
bath at 100 ± 1 °C for varied times. The maximum intensity 
of color was obtained at 44 min of heating and remained 
constant up to 48 min. Therefore, 46 min. of reaction time 
was used throughout the quantitation process in the equi-
librium method (Fig. 3). 
Effect of the Concentration of CDNB 
The effect of CDNB concentration on the absorbance 
of yellow colored Meisenheimer complex was studied in 
the range of 9.87 x 10"' - 3.95 x 10"^  M. It was found that the 
maximum absorbance was obtained in the range 2.76 x 10"^  
- 3.95 xlO"' M CDNB (Fig. 4). Therefore, the optimum 
concentration of 3.36 x lO"' M CDNB was chosen tor 
further work. 
Robustness 
The robustness of fixed-time (AA) and equilibrium 
methods relative to each operational parameter w as checked 
and investigated. The operational parameters were as fol-
lows: 
• heating temperature, 100 ± 1 °C. 
• reaction time, 5-25 min for fixed-time (AA) and 4(i 
+ 2 min for equilibrium methods, respectively. 
• volume of 9.87 X 10"-M CDNB, 1.7±0.3mL, 
The robustness of the fixed-time (AA) and equilib 
rium methods was assessed by analyzing the active meto-
prolol tartrate in Metolar25. The quality control sample so 
lution containing 50 ug mL"' of the drug was assayed. 1 he 
percent recoveries ± RSD for fixed-time (AA) (100.02 <. 
0.09) and equilibrium methods (100.05 ± 0.08) were found 
to be appreciable, indicating that the proposed methods arc 
robust. 
Ruggedness 
For the evaluation of ruggedness of fixed-time (AAi 
and equilibrium methods, the contents of metoprolol tar 
0 5 10 15 ?0 25 30 36 40 45 60 
Healing time (mm) 
Fig. 3. Effect of heating time on the absorbance of the 
Meisenheimer complex between metoprolol 
tartrate (50 Mg mL') and CDNB (3.36 x 10"' M) 
in DMSO. 
06 1 
04 
0,0 
0,000 0 001 0,002 0 003 0 OC' 
[CDNBI (m 
Effect of the molar concentration of CDNB on 
the absorbance of the colored product keeping 
7.30 X 10 •* M metoprolol tartrate (50 ug mL"'). 
Fig. 4. 
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Tabic 1. Summary of calibration equations at different fixed times 
AA 
Am 
A,. 
A,,, 
A:5 
A, 
A, 
A, 
A, 
AA = 
AA = 
AA = 
AA = 
Calibration equation 
-1.61 X lO"* + 3.96 X lO-'C 
-5.76 X 10-'+ 6.12 X 10-^  C 
-6.52 X 10-' +8.14 X 10'-C 
-5.72 X 10-^+ 1.11 X 10'-C 
r 
0.9996 
0.9995 
0.9993 
0.9999 
8.22 X 10"' 
2.64 X ]b-' 
2.06 X Kr ' 
2.51 X 10-' 
Sb 
2.28 X 10-' 
7.31 X lO-' 
5.71 X lO-' 
6.96 X lO-' 
trate (Metolar-25; Cipla) at 50 |,ig mL ' were assayed fol-
lowing the recommended procedure using Spcctronic 20D* 
and Shimadzu UV 1240 spectrophotometers. The percent 
recoveries ± RSD resulting from the Spectronic 20D* 
spectrophotometer (100.03 ± 0.14 and 100.01 ± 0.1 7 for 
fixed-time (AA) and equilibrium methods, respectively) 
and Shimadzu UV 1240 (100.04 ± 0.13 and 99.99 ± 0.16 
for fixed-time (AA) and equilibrium methods, respec-
tively) were compared. The results agreed well within the 
acceptable limits with permissible bias. 
Analytical Performance: Fixed-Time (AA) Method 
At room temperature, the reaction did not take place; 
hence the reaction leading to the formation of Meisenheimer 
complex was carried out at 100 ± 1 °C. The absorbance of 
the Meisenheimer complex was measured at 420 nm QN a 
function of time and was utilized to develop a tlxed-tinic 
(AA) method for the quantitation of metoprolol tartrate 
(Fig. 5). The change in absorbance (AA) between 10 and ^ 
15 and 5; 20 and 5; 25 and 5 was computed and plotted 
against the initial concentration of metoprolol tartrate at 
seven concentration levels. The corresponding linear re 
gression equations with coefficient of correlations are sum 
marized in Table 1. It is evident from the table that the most 
acceptable linearity was obtained when the change in ab 
sorbance between 5 and 10 min (i.e. AA = Aio - A5) v\as 
plotted against the initial concentration of metoprolol 
tartrate (|ag mL"'). This fixed time was selected for the 
quantitation of metoprolol tartrate in commercial dosage 
forms. 
C 6 -I) - 5 20 26 
Time (min) 
Fig. 5. Absorbance-timc curves for the reaction be-
tween metoprolol tartrate and CDNB in DMSO; 
1.7 mL of 9.87 x 10 ' M CDNB and (a) 5, (b) 10, 
(c) 20, (d) 30. (e) 40. (0 50 and (g) 60 Mg mL"' 
metoprolol tartrate. I:ach set is diluted to 5 mL 
standard flask with DMSO. 
Equilibrium Method 
The reaction between metoprolol tartrate and CDNB 
required 44 min to complete. Therefore, in the equilibrium 
method, the absorbance of the colored product at 420 1111, 
was measured after 46 min of heating. The absorbance w as 
plotted against the initial concentration of metoprolol tar-
trate (ng mL''). 
The linear dynamic range, molar absorptivity, regres-
sion equation, correlation coefficient, confidence limits for 
slope and intercept, limits of detection and quantitation 
and variance of calibration line for fixed-time (AA) and 
equilibrium methods are summarized in Table 2 The high 
values of correlation coefficient indicated the excellent hn-
earity of the calibration graphs. The small values of confi-
dence limit of slope and intercept pointed towards good 
reproducibility of the fixed-time (AA) and equilibrium 
methods. 
Accuracy and Precision 
The intra day and inter day precisions m pure anti 
quality control samples were evaluated and the results are 
summarized (Tables 3 and 4). As can be seen from Tables 3 
and 4, the percent relative error and relative standard devia-
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Table 2. Summary of optical and regression characteristics of fixed time (AA) and equilibrium methods 
Parameters Fixed time method (AA) [equilibrium Method 
Linear dynamic range (pg ml/') 
Molar absorptivity (L mol"' cm') 
Regression equation 
± i S , 
+ tSh 
Correlation coefficient (r) 
LOD(pgmL') 
LOQ(pgml. ') 
Variance (S^ )^ of calibration line 
5-60 
AA = -5.72 X 10"^ + 1.11 X 10-C 
6.45 X 10"' 
1.79 X 10'"' 
0.9999 
1.04 
3.16 
1.23 X 10"' 
5-60 
1.30 X 10' 
A = 7.31 X 10"'' 
4.42 X 10"-' 
1.22 X 10""" 
0.9999 
0.415 
1.26 
5.71 X 10"' 
1.90 X 10"-C 
± t Sa and = t S(, are confidence limits for intercept and slope, respectively. 
Table 3. Summary of accuracy and precision results of the proposed methods in pure form 
Proposed methods 
Fixed time(AA) 
Intra day assay 
Inter day assay 
Equilibrium method 
Intra day assay 
Inter dav assay 
Taken 
10.0 
30.0 
50.0 
10.0 
30.0 
50.0 
10,0 
30.0 
50.0 
10.0 
30.0 
50,0 
Amount 
HgmL"') 
Found ± SD" 
10.01 +0.08 
30.02 ± 0.06 
50.01 +0.10 
9.99 ± 0.09 
29.99 ± 0.08 
49.99 + 0.12 
10.00 + 0.06 
30.00 + 0,07 
50.01 +0.08 
9.99 + 0.06 
29.99 + 0.09 
49,99 ±0.10 
RSD 
(%) 
0,76 
0,21 
0.21 
0.90 
0,27 
0,24 
0,58 
0,23 
0,17 
0.60 
0.29 
0.19 
RE 
(%) 
0.11 
0.07 
0.02 
0.07 
0.02 
0.01 
0.04 
0.01 
0.03 
0.07 
0.02 
0,01 
SAE'' 
0.03 
0.03 
0,05 
0.04 
0.04 
0.05 
0.03 
0.03 
0.04 
0.03 
0.04 
0.04 
C.L.= 
0.09 
0.08 
0.13 
0.11 
0.10 
0.15 
0.07 
0.09 
0.10 
0,08 
0.11 
0.12 
•* Mean for 5 independent analyses. 
*" SAE, standard analytical error. 
' C.L., confidence limit at 95% confidence level and 4 degrees of freedom (t = 2.776). 
tion by intra day precision were in the ranges 0.01-0.11%; 
0.15-0.76 and 0.01-0.04%; 0.12-0.58 for fixed time (AA) 
and equilibrium methods, respectively. Also, the percent 
relative error and relative standard deviation by inter day 
were found to be 0.01-0.07%; 0.21-0.90 and 0.01-0.07%; 
0.10-0.60 for fixed-time (AA) and equilibrium methods, re-
spectively. The results showed that the percent relative er-
ror (< 0.11 %) and relative standard deviation (< 0.90%) 
found in intra and inter day assays can be considered to be 
satisfactory. 
Recovery Studies 
The accuracy of the fixed-time (AA) and equilibrium 
methods was ascertained by recovery studies using the 
standard addition method. The results are summarized in 
Table 5. The mean recoveries ± RSD for fixed-time (AA i 
and equilibrium methods were in the ranges of 99.92 ±0.15 
- 100.02 ± 0.50% and 99.98 ± 0.14 - 100.06 ± 0.32%. re-
spectively. The results agreed well within the acceptable 
limits of ± 2%. There is no interference from excipicnts 
present in tablet formulations. 
Application 
The proposed procedures have been successfully ap-
plied to quantitate metoprolol tartrate in commercial dos-
age forms. The assay of the same batch of samples was also 
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Table 4. Summary of accuracy and precision results of the proposed methods m dosage forms 
Proposed methods 
Fixed time (AA) method: 
Intra day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metoiar-25 (Cipla) 
Inter day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Equilibrium method; 
Intra day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Inter day assay 
Betaloc 25 (AstraZeneca) 
Metapro-25 (Cardicare) 
Metolar-25 (Cipla) 
Taken 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
50.00 
Amount 
(l-igmL ) 
Found + SD" 
50.01 ±0.08 
49.99 ±0.08 
49.99 ±0.10 
50.01 ±0.10 
49.98 ±0.11 
49.99 ±0.12 
49.99 ± 0.06 
50.00 + 0.07 
50.01 ±0.08 
49.98 + 0.10 
49.99 ±0.14 
49.97 ±0.10 
RSD 
(%) 
0.16 
0.15 
0.20 
0.21 
0.22 
0.24 
0.12 
0.14 
0.17 
0.19 
0.28 
0.20 
RE 
(%) 
0.02 
0.01 
0.01 
0.02 
0.05 
0.01 
0.01 
0.01 
0.03 
0.03 
0.01 
0.06 
SAE*' 
0.04 
0.03 
0.04 
0.05 
0.05 
0.05 
0.03 
0.03 
0.04 
0.04 
0.06 
0.05 
C.L.^  
0.10 
0,09 
0.12 
0.13 
0.12 
0.15 
0.08 
0,09 
0.10 
0.12 
0.17 
0,13 
" Mean for 5 independent analyses. 
'' SAE, standard analytical error. 
•^  C.L., confidence limit at 95% confidence level and 4 degrees of freedom (t = 2.776). 
Table 5. Summary of data for the determination of metoprolol tartrate in pharmaceutical preparations by standard addition method 
Formulations 
Tablets 
BetaIoc-25 
(Astra Zeneca) 
Metopro-25 
(Cardicare) 
Metolar-25 
(Cipla) 
Taken 
20.0 
20.0 
20.0 
20.0 
20.0 
20.0 
Amount ( 
Added 
10.0 
30.0 
10.0 
30.0 
10.0 
30.0 
Fixed time (AA)method 
Lig m l / ' ) 
Found ± SD" 
29.99 + 0.08 
49.98 ±0,09 
29.99 ±0.15 
50.01 ±0.10 
29.98 ±0.10 
49.99 ±0,08 
Reco\ery 
(%) 
99.98 
99.95 
99.98 
100.02 
99.92 
99.99 
RSD 
(%) 
0.27 
0.18 
0.50 
0,21 
0.34 
0.15 
SAE 
0.04 
0.04 
0.07 
0.05 
0.05 
0.03 
Taken 
20.0 
20.0 
20.0 
20.0 
20.0 
20.0 
.^lT10Unt (jl! 
Added 
10.0 
30.0 
10.0 
30.0 
10.0 
30.0 
Equlibrium method 
I mL'') 
Found ± SD' 
30.01 +0.05 
50.00 ±0,10 
29.99 ±0.10 
49,99 + 0.09 
30.00 ± 0.09 
50.00 ±0.07 
Recovery 
(%) 
100.06 
100.01 
99.98 
99.99 
100.01 
100.00 
RSD 
(%) 
0.18 
0.20 
0.32 
0.18 
0.29 
0.14 
SAt 
0.02 
(),0> 
0.04 
(1.04 
(1.04 
o.o;! 
' Mean for 5 independent analyses. 
completed by El-Ries's spectrophotometric method."* The 
results of the fixed-time (AA) and equilibrium methods 
were compared with those obtained by El-Ries's spectro-
photometric method in terms of mean recovery, RSD, OL, 
Bu, t- and F- values (Table 6). As can be seen from Table 6, 
the assay results showed good agreement between the pro-
posed methods and the reference method as t- and F- values 
were less than the theoretical ones at a 95% confidence 
level and 9L and 9 ;^ were less than ± 2.0% indicating the 
compliance of the regulatory authorities. 
CONCLUSIONS 
The proposed method is a kinetic spectrophotometric 
method requiring only a single reagent (l-chloro-2.4-di-
nitrobenzene) for colour development in dimethyl sulpho-
xide. The method does not require any pretreatment of the 
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Table 6. Summary of comparison results of the proposed methods with the reference method at 95"i) cont'idcncc level 
Formulations 
Betaloc-25 
(Astra Zeneca) 
Metopro-25 
(Cardicarc) 
Mctolar-25 
(Cipla) 
Recovery 
99.99 
99.95 
99.99 
Fixed time 
RSD' 
0.62 
0.69 
0.78 
(AA) mcthoc 
t-c&F*' 
t = 0.53 
F= !.01 
T = 0.64 
F = 1.20 
T = 0.40 
F - 1.26 
1 
Or^  
Oi) 
OL 
Ou 
e,. 
Of 
& 0 i "•• 
= 0.994 
= 1.004 
= 0.992 
= 1.005 
= 0.992 
= 1.006 
Recovery 
(%) 
99.99 
99.97 
99.96 
Equilibrium method 
RSD" , 
(%) ' - * f 
0.57 
0.64 
0.67 
t = 0.56 
F== 1.19 
T = 0.73 
F== 1.38 
t = 0.29 
F == 1,71 
0, 
01 
OL 
0,. 
OL 
0, 
OL 
& 0 , >• 
= 0.994 
= 1.004 
= 0.992 
= 1.005 
= 0.992 
= 1.006 
Reference mcthcH' 
Rccovcrv RSD 
( " o i [".,' 
99.88 0 (.: 
99.80 0 (^^  
99.88 0 XS 
Mean for five independent analyses 
' Theoretical t-value (v = 8) and F-value (v = 4,4) at 95% confidence level are 2.306 and 6.39, respectively. 
6i = 0.98 and OL- = 1.02 are acceptable bias, based on recovery experiments and are within ± 2%. 
drug or any laborious clean-up procedure for the estimation 
of drug. Fixed-time (AA) and equilibrium methods are 
adopted providing accurate and reproducible recovery re-
sults of metoprolo! tartrate in commercial dosage forms. 
No interferences have been observed with excipients found 
in drug formulations. Both methods are simple and selec-
tive with a detection limit < 1.04 (,ig mL"' and linear dy-
namic range of 5-60 ^g mL"'. Therefore, fixed-time (AA) 
and equilibrium methods can be used in the laboratories of 
research, hospitals and pharmaceutical industries. 
Received March 23, 2007. 
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ORIGINAL RESEARCH 
Optimized and Validated Spectrophotometric Methods 
for the Determination of Enalapril Maleate in Commercial 
Dosage Forms 
Nafisur Rahman and Sk Manirul Hague 
Department of Chemistry, Aligarh Muslim University, Al igarh (U.P.) 202 002, India. 
Abstract: Four simple, rapid and sensitive spectrophotometric methods have been proposed for the determination ot 
enalapril maleate in pharmaceutical formulations. The first method is based on the reaction of carboxylic acid group of 
enalapril maleate with a mixture of potassium iodate (KIO-,) and iodide (KI) to fonn vellow colored product in aqueous 
medium at 25 ± 1°C .The reaction is followed spectrophotometrically by measuring the absorbance at 352 nm. The second. 
third and fourth methods are based on the charge transfer complexation reaction of the drug with p-chloranilic acid (pCA) 
in 1,4-dioxan-methanol medium. 2. 3-dichloro 5. 6-dicyano 1, 4-benzoquinone(DD0) in acetonitnle-1,4 dioxane medium 
and iodine in acetonitrile-dichloromethane medium. Under optimized experimental conditions, Beer's law is obeyed in the 
concentration ranges of 2.5-50. 20-560. 5-75 and 10-200 (ig mL"' , respectively. Al l the methods have been applied to the 
detemiination of enalapril maleate in pharmaceutical dosage forms. Results of analysis are validated statistically. 
Keywords: enalapril maleate. spectrophotometry, validation, commercial dosage forms 
Introduction 
Enalapril maleate is chemically described as 1-[N-[(S) - 1 -carboxy- 3-phenylpropyl] L - proline 
1'- ethyl ester, maleate (1:1). Its molecular weight is 492.53. Enalapril maleate is a prodrug; following 
oral administration, it is bioactivated by hydrolysis of ethyl ester to enalaprilat, which is the active 
angiotensin converting enzyme inhibitor. It lowers peripheral vascular resistance without causing an 
increase in the heart rate. It is an ideal drug for hypersensitive patients who are intolerant to beta-block-
ers. The drug is used for treating high blood pressure or hypertension in adults and children and conges-
tive heart failure. The drug and their tablets are official in USP 24 (1), which describes HPLC method 
for its quantitation. 
The therapeutic importance of enalapril maleate was behind the development of numerous methods 
for its determination. The methods adopted to the analysis of enalapril maleate include high-performance 
liquid chromatography (2-9), capillary electrophoresis (10), liquid chromatography- tandein mass 
spectrometry (11), polarography (12), atomic absorption spectrometry (13) and membrane selective 
electrodes (14). 
Few spectrophotometric methods have also been reported for the determination of enalapril maleate 
in commercial dosage forms. The cited drug after dissolving in distilled water exhibits an absorbance 
maximum at 207 nm and this property has been exploited to develop a UV method for its quantitation 
(15). Enalapril maleate reacts with 2, 4-dinitroflurobenzene at pH 9 yielding a colored product which 
absorbs maximally at 356 nm forming a basis for its determination (12). Spectrophotometric methods 
based on the ternary complex formation between copper (II), eosin (13); palladium (II), eosin (16) and 
enalapril maleate have been reported. The spectrophotometric methods reported for analysis of enalapril 
maleate in commercial dosage forms suffered disadvantage of heating at 100 °C (12) and long analysis 
time (16). Considering this drawback, there was a need to develop more advantageous spectrophoto-
metric methods for its determination in commercial dosage forms. 
This paper describes four sensitive, fast, simple and economical methods for the determination of 
enalapril maleate in dosage forms. The first method is based on the reaction of carboxylic acid group 
of enalapril maleate with a mixture of potassium iodate and iodide. The second, third and fourth meth-
ods are based on the charge transfer complexation reaction of the drug with pCA in 1,4-dioxan-methan(ii 
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002, India. Email: cht17nr_amu@yahoo.com 
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medium. DDQ in acetonitrile-1.4 dioxan medium 
and iodine in acetonitrile-dichloromethane 
medium 
Experimental 
Apparatus 
Spectral mns were made on Spectronic 20D^ Spec-
trophotometer (Milton Roy Company. USA) with 
1 cm matched glass cells. 
Materials and reagents 
• Enalapril maleate was kindly provided by Sunij 
Phamia Pvt. Ltd., Ahmedabad. India and was 
used as received. 
• Pharmaceutical preparations of enalapril 
maleate such as enapril (Intas Pharmaceuticals 
Pvt. Ltd., India), envas (Cadila Pharmaceuticals 
Ltd., India) and enace (Nicholas Primal India 
Ltd.) were purchased from local market. 
• Potassium iodide (s.d. Fine-Chem Ltd, Mumbai. 
India) solution was prepared as 5.0 x 10" M 
solution in distilled water. 
• Potassium iodate (Central Drug House (P) Ltd, 
New Delhi. India) solution was also prepared 
as 3.0 X 10"^  M solution in distilled water. 
• pCA (Central Drug House (P) Ltd, New Delhi, 
India) was prepared as 0.2% (w/v) solution in 
1,4-dioxan. 
• DDQ (Fluka Chemie AG, Germany) was pre-
pared as 0.1% (w/v) solution in 1, 4-dioxan. 
• Iodine (Merck Limited. Mumbai, India) was 
prepared as 0.1%) (w/v) solution in dichloro-
methane. 
Standard drug solutions 
Enalapril maleate standard solutions were prepared 
as 0.5 mg mL~' solution in distilled water for 
Method A, 2.0 mg mL"' in methanol for Method 
B, 0.5 mg mL"' in acetonitrile for Method C and 
1.0 mg mL"' in acetonitrile for Method D. 
Procedure for determination 
each flask, 1 mL of 3.0 x 10"^  M potassium iodate 
and 1.5 mL of 5.0 x 10"' M potassium iodide were 
added and diluted to volume with distilled water. 
The reaction was allowed to proceed at 25 r 1 'C 
and absorbance was measured as a function of time 
at 352 nm against reagent blank prepared simultane-
ously. The calibration curve was constructed b\ 
plotting the A A (absorbance measured at 8.0 
min—absorbance measured at 2 min) against the 
initial concentration of enalapril maleate. The con-
tent of enalapril maleate was calculated either from 
the calibration curve or corresponding regression 
equation. 
Method B 
Into a series of 5 mL volumetric flasks, volumes of 
enalapril maleate standard solution (2.0 mg mL'') 
equivalent to 0.1-2.8 mg of the drug were trans-
ferred. To each flask, 2.5 mL of 0.2% pCA was 
added and brought up to the volume with 1.4 
dioxan . The colored product formed immediate!) 
at room temperature (25 ± 1 °C) and absorbance 
was measured after 2 min of mixing at 510 nm 
against the reagent blank prepared similarly omit-
ting the drug. 
Method C 
The aliquots of enalapril maleate standard solution 
(0.5 mg mL"') equivalent to 25-375 fig of the drug 
were transferred into a series of 5 mL volumetric 
flasks. To each flask, 1.4 mL of 0.1% DDQ was 
added and brought up to the volume with acetoni-
trile.The color developed immediately at room 
temperature (25 ± I °C) and the absorbance was 
measured after 3 min at 565 nm against the reagent 
blank prepared similarly omitting the drug. 
Method D 
The volumes of enalapril maleate standard solution 
(1.0 mg mL"') corresponding to 50-1000 |ig of the 
drug were transferred into a series of 5 mL flasks. 
1.2 mL of 0.1 %) iodine was added in each flask at room 
temperature (25 ± 1 °C) and diluted up to the mark 
with dichloromethane. The absorbance was measured 
after 2 min at 365 nm against the reagent blank. 
Method A 
Aliquots of enalapril maleate standard solution 
(0.5 mg mL"') containing 25-500 |ig were trans-
ferred into a series of 10 mL volumetric flasks. To 
Analysis of pharmaceutical 
formulations 
Twenty tablets (claming for 2.5 mg of enalapril 
maleate per tablet) were finely powdered and 
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extracted separately into sufficient volume of 
water, methanol or acetonitrile with shaking. The 
residue was filtered on Whatmann filter paper No. 
42 and the filtrate was diluted to 50 niL with water, 
methanol or acetonitrile. as the case may be. It was 
further diluted according to the need and then 
analyzed following the proposed procedures. 
Results and Discussion 
Reaction with a mixture of iodide 
and iodate 
It has been reported in the literature (17) that iodine 
is formed as a result of the interaction of a mixture 
of iodide and iodate with inorganic or organic acid 
in accordance with the equation: 
5/" + lO; + 6//^ ^ iHp + 3/, 
In aqueous solution, the iodide ions react 
with the liberated iodine to yield triiodide ion 
(/j + / -^ /" ) which absorbs maximally at 290 nm 
and 360 nm. We thought that this reaction would 
be helpful for developing a spectrophotometric 
method for determination of enalapril maleate as 
it contains -COOH group in its moiety. Keeping 
this in mind, a mixture of potassium iodide and 
potassium iodate was allowed to react with enala-
pril maleate which yielded iodine. Then the liber-
ated iodine reacted with the excess of iodide ion 
resulting in the formation triiodide ion with /V^nax 
at 352 nm. The reaction sequence is shown in 
Scheme 1. 
Ijiiilapril mate;Me 
Aquc^His niedmni 
Scheme 1. 
an ionized structure D r ... I3". The absorption 
spectrum of this charge-transfer complex is identical 
to that oi\{ in dichloromethane as it also absorbed 
at 290 nm and 360 nm. On the basis of our 
experimental findings and the literature background. 
the reaction mechanism is proposed and gi\'en in 
Scheme 2. 
Reaction with 7i-acceptors 
The interaction of enalapril maleate with 7i-acceptors 
such as p-CA and DDQ at room temperature was 
found to yield colored charge transfer complexes. In 
polar solvents, complete electron transfer from 
enalapril maleate (D), as an electron donor, to the 
acceptor moiety (A) takes place resulting in the 
formation of intensely colored radical anions. The 
reaction sequence can be shown as: 
Reaction with o-acceptor 
The absorption spectrum of iodine in dichloromethane 
showed only one peak with maximum absorption 
at 500 nm. The color of iodine changes to yellow 
upon reaction with enalapril maleate.This is due to 
charge transfer complexation reaction between 
enalapril maleate and iodine. The absorption 
spectrum of enalapril maleate-iodine reaction 
product showed absorption peaks at 290 and 365 
nm. The stoichiometry of the reaction was studied 
by Job's method of continuous variations. It was 
observed from the Figure 1 that the combining 
molar ratio between enalapril maleate and iodine 
is 1:1. It has been reported that the charge-transfer 
complex between drug and iodine (18) would have 
Polar solvent 
D + A ( D - A ) 
complex 
D"+A 
radical ions 
The absorption spectra of enalapril maleate- K-
acceptor reaction mixtures showed absorption 
peaks which were similar to the maxima of the 
radical anions of the Ti-acceptors obtained b\ the 
iodide reduction method (19). 
The literature reveals that pCA exists in three 
forms:(i) HjA at very low pH which is yellow-
orange in color, (ii) HA", dark purple, which is 
stable at pH 3, and (iii) colorless A"^  which is 
stable at high pH. The interconversion of these 
species can be represented as: 
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Figure 1. Job's plot for stoichiometric ratio between enalaparil maleate and pCA(4.06 x 10"^ M each), DDQ (2.03 x 10^^ M each) or Iodine 
(3.94 X 10-^ M each). 
H2A ^ H+ + HA" (violet) 
HA~ =^  H+ + A" (colorless) 
The interaction of enalapril maleate with pCA 
in methanol-1,4-dioxan solvent system resulted in 
the formation of violet colored charge transfer 
complex and the absorption spectrum exhibited 
maximum absorption at 510 nm. The reaction 
stoichiometry between enalapril maleate and pCA 
was evaluated by applying Job's method of con-
tinuous variations. The Job's plot (Fig. 1) reached 
a maximum value at a mole fraction of 0.5 which 
suggested a donor (enalapril maleate) to acceptor 
(pCA) ratio of 1:1. On the basis of reaction stio-
chiometry and literature background, the reaction 
mechanism is presented in scheme 3. 
The interaction of enalapril maleate with DDQ 
resulted in the formation of colored charge-
transfer complex. The dissociation of charge-
transfer complex was promoted by the high 
ionizing power of the acetonotrile-1, 4-dioxan 
solvent system where complete electron transfer 
from enalapril maleate to the DDQ moiety takes 
place. This is followed by the formation of the 
DDQ radical anion as predominant chromogen 
which absorbed maximally at 430. 535 and 565 nm. 
In order to avoid the maximum interference from 
the blank, the absorption band at 'k^^^ 565 nm was 
chosen for analytical studies. The Job's plot 
(Fig. 1) indicated a donor to acceptor ratio of 1:1, 
On the basis of this study and literature survey, 
the formation of DDQ radical anion is shown in 
Scheme 4. 
The association constants and apparent molar 
absorptivities of pCA-enalapril maleate, DDQ-
enalapril maleate and iodine-enalapril maleate 
charge transfer complexes have been calculated 
using Ross and Labes equation (20), which depends 
on the experimental condition that acceptor con-
centration should not low enough to be considered 
negligible with respect to donor concentration. 
VA\{D\ I 
• + — 
M] + [Z)] A, / : G , \A\ + {D\ 6, (1) 
where \A\ and \D\ are total concentrations of 
the acceptor and donor, respectively. A^ and e, are 
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for pCA- enalapril maleate system 
Scheme 2. 
the absorbance and apparent molar absorptivity of 
the complex at wavelength X. K is the association 
constant of the charge transfer complex. 
A][D] X ^ is plotted against (Fig. 2) 
which gave a straight line. The intercept and slope 
were calculated and equation (1) is transformed 
into the following equations: 
^ 
|A „ | ,A -
2.173x10 ' x [A] + [D] A, [A]-\D\ , ;) 
+ 8.313x10' 
for DDQ - enalapril maleate system 
3.202 X 10"'X 
Figure 2. Plot of 1/[Do] vs [Aol/A*"^  for Methods B, C and D. 
[A][D] .. 
[A] + [D] A,^ [A] + [D] , ; , 
+ 1.641x10 ' 
for Iodine - enalapril maleate system 
J M ^ x ^ = 8.889 X 10-*^  x ^ -
[A] + [D] A, [A] + [D] (4) 
+ 1.371x10"* 
The association constants and molar absorp-
tivitieswerefoundtobe3.826x 10^and 1.203 x 10' 
Lmor'cm"' for pCA-enalapril maleate complex 
from equation (2), 5.124 x 10^  and 6.095 x 10' 
Lmor'cm"' for DDQ-enalapril maleate complex 
from equation (3) and 1.543 x 10^  and 7.291 x lO' 
Lmor'cm"' for iodine- enalapril maleate complex 
from equation (4). respectively. The free energy 
change was also calculated and lound to 
be -20.44 KJmol"' for pCA-enalapril maleate 
complex. -21.17 KJmol"' for DDQ-enalapril 
maleate complex and -18.19 KJmol"' for iodine-
enalapril maleate complex. 
Optimizations of variables 
The different parameters affecting the color devel-
opment were extensively studied to determine the 
optimum conditions for the assay procedures. The 
optimum values of the variables were maintained 
throughout the determination process. 
Method A 
Effect of the concentration 
of potassium iodate 
The effect of the volume of 3.0 x 10"^  M potassium 
iodate on the absorbance of the product was stud-
ied in the range of 0.2 -1.2 mL. The absorbance 
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Scheme 3. 
increases with increase in the volume of KIO3 and Effect of the concentration 
became constant at 0.8 mL. Further addition of of potassium iodide 
KIO3 does not change the absorbance and therefore. The effect of the volume of 5.0 x 10"^  M potassium 
1.0 mL of 3.0 X 10"^  M KIO3 was chosen as an iodide on the intensity of the colored product was 
optimum value (Fig. 3). studied in the range of 0.2- 1.8 mL, keeping the 
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HOOC 
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Complexation 
N=C 
N^C 
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N ^ C C = N 
n - 71 complex 
HOOC 
in acetonitrile-1,4 dioxan solvent 
O' 
N = r 
(). 
DDQ radical anion 
(colored species) 
Scheme 4. 
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Method B 
Volume of 3 < 10 ' M poUissiiim iodate (niL) 
Figure 3. Effect of the volume of 3,0 x 10"^ M potassium iodate on 
the absorbance of the product (enalapril maleate 50 ng mL^'; 1.5 mL 
of5.0x10-^KI). 
Effect of reaction time 
Optimum reaction time was evaluated b> 
monitoring tlie color development at room 
temperature. It was observed that the reaction got 
stabilized within 2 min. The developed color 
remained stable at room temperature for about a 
further 1 h. 
Effect of pCA concentration 
To study the effect of the volume of the reagent 
on the absorbance of the charge transfer complex, 
varying volumes of 0.2% pCA was mixed with 
1.5 mL of 0.2% drug in a 5 rnL standard flask 
and diluted to volume vvith 1. 4-dioxan. The 
results (Fig. 5) showed that the highest absorbance 
was obtained with 2.2 mL, which remained unaf-
fected by further addition of pCA. Hence. 2.5 mL 
of the reagent was used for the determination. 
constant concentrations of enalapril maleate 
(50 |lg mL-')andKIO3(3.0 x 10~*M). The maximum 
absorbance was obtained with 1.2 mL; further 
addition caused no change on the absorbance. 
Thus, 1.5 mL of 5.0 x 10"^  M potassium iodide 
was used throughout the experiment (Fig. 4). 
Method C 
Effect of reaction time 
The interaction of DDQ with enalapril maleate 
resulted in the formation of colored product which 
stabilized within 2 min.The developed color 
A 
b 
0-0 0,2 1J,4 0,f> OS 1,0 I . ; I J 16 IK : o :,2 24 2.f> 2 - , '0 
Volume of (a) 0.2% pCA (b) 0,1 % DDQ (c) 0.1 % iodine (niL) 
Figure 5. Effect of the volume of 0.2% pCA, 0.1% DDQ and 0.1% 
Iodine on the absorbance (600 ng mL ' enalapril maleate for pCA, 
the absorbance ofthe product (enalapril maleate 50 ngmL"^ 1.0 mL 50 ng mL"' enalapril maleate for DDQ and 100 \xg mL"' enalapril 
Volume of 5 • 10 " .M potassium iodide (mL) 
Figure 4. Effect of the volume of 5 0 x 10"^ M potassium iodide on 
ofS.OxlO^^KIOj) maleate for iodine). 
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remained stable at room temperature for about a 
further 2 h. 
Effect of DDQ concentration 
To establisli tlie optimum experimental condition, 
enalapril maleate (250 |ig) was allowed to react 
with different volumes (0.05-1.8 mL) of 0.05% 
DDQ. The results (Fig. 5) showed that the highest 
absorbance was obtained with 1.0 mL, which 
remained unaffected by further addition of DDQ. 
Hence, a volume of 1.4 niL of the reagent was used 
for the determination. 
Method D 
Effect of reaction time 
In method D, the colored product was formed 
immediately and remained stable at room tem-
perature for about 1 h. The absorbance was mea-
sured after 2 min. of mixing the reagent. 
Effect of iodine concentration 
In order to study the effect of the volume of 0.1% 
iodine on the absorbance of the charge transfer 
complex, varying volumes (0.05-1.2 mL) were 
treated, separately with 500 |ig of enalapril maleate. 
The results are shown in Fig. 5 which indicated that 
0.8 mL of 0.1% iodine gave the maximum absor-
bance and remained constant by further addition of 
iodine. Therefore, a volume of 1.2 mL was chosen 
as an optimum value for the determination. 
Validation of proposed methods 
Under the optimum experimental conditions, 
the calibration graphs were constructed by 
plotting A A (A A = absorbance measured at 
8.0 min—absorbance measured at 2 min) or 
absorbance as a function of initial concentration 
of enalapril maleate for methods A; and B. C and 
D, respectively. The method of least square was 
applied to yield the regression equations. Results 
are summarized in Table 1. It is apparent from 
the table 1 that the sensitivity of the proposed 
methods follows the order: A > C > D > B . In all 
cases, calibration plots (n = 11 ) were linear with 
small intercepts (1.32 x 10""* ± 6.52 x 10'"*), 
(9.36 X 10'^ ± 2.43 x 10"-^). (6.98 x 10"^ ± 
1.55 X 10"^) and (-8.76 x lO"'* ± 4.12 x 10"^) 
and good correlation coefficients (0.9998-0.9999). 
The LCD values obtained for methods A. B ( 
and D were 1.13. 3.07. 0.39 and 3.20 jig ml/ 
respectively. The small values of the \arianc: 
2.13 x \{}-\ 3.03 x 10"'. 1.04 x 10"' and 
9.06 X 10"' |Jg mL'for methods A. B. C and D 
respectively (Table 1) confirmed the smali 
degree of scatter of experimental data points 
around the line of regression. 
Accuracy and precision 
The within day precision was evaluated through 
replicate analvsis (n = 5) of quality control samples: 
20. 35 and 50 \xg mL"' for method A and 120. 280 
and 440 )Ltg niL"' for method B and 20.40 and 60 ug 
mL'' for method C and 40. 100 and 160 |Jg mL"' for 
method D. The percentage recoveries ranged 
fi-om99.9^I00.08%withRSDfi-om0.284y,^~0.845%. 
99.96%^-l 00.02% with RSD from 0.122O/,r-0.242%. 
99.96%-l00.04% with RSD from 0.250%-
0.481% and 100.01 100.06% with RSD from 
0.142%-0.440%for methods A. B. C and D 
respectively. The interday precision was also 
evaluated through replicate analysis of the qualit} 
control samples for five consecutive days at the same 
concentration levels as used in within day precision. 
The percentage recoveries for methods A. B. C and 
D ranged from 99.98o/^I00.11% with RSD from 
0.482%^1.098%, 99.910/(^99.96% with RSD from 
0.184%-0.373%, 99.89%-I00.00% with RSD 
from 0.373°/<r-0.872% and I00.0P/(^I00.06% with 
RSD from 0.318°/(y-0.918% respectively (Table 2). 
The results in the Table 2 indicated the high precision 
of the proposed methods. The selectivity of the 
proposed methods was investigated by observing any 
interference encountered from the excipients of the 
tablets such as lactose, starch, cellulose, magnesium 
stearate, ferric oxide, talc and calcium carbonate and 
hydrochlorothiazide which is present with enalapnl 
maleate in pharmaceutical products. It was observed 
that the excipients and hjdrochlorothiazide did not 
interfere with the proposed methods. 
The proposed methods were applied to the 
determination of enalapril maleate in commercial 
tablets such as Enapril 2.5, Envas 2.5 and Enace 
2.5. The same batch of the commercial dosage 
forms was also analyzed by the reference methot. 
(12). The results of the proposed methods were 
compared with those obtained by the reference 
method. Statistical analysis of the results using 
Student's t-test, variance ratio F-test and interval 
hypothesis test (21) revealed no significant 
difference between the proposed method (A, B. C 
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Table 1. Optical characteristics and statistical data of the regression equations for methods A, B, C and D. 
Parameters 
A,max (nm) 
Beer's law limit (|i.g mL )^ 
Linear regression 
equation 
tSa 
tSb 
Correlation coefficient (r) 
Variance (S^^ ) 
Detection limit (n,g mL"^ ) 
± t S, Confidence limit for intercept. 
± t S, Confidence limit for slope, 
n = 11, t (0 = 10) = 2.228 
IVIethod A 
352 
2,5-50 
AA=1.32x10"''-t 
1.35x10-^C 
6.15x10-" 
2,11 xlO"^ 
0.9998 
2.13 xlO"^ 
1.13 
Method B Method C 
510 565 
20.0-560 
A = 9.36x10-^ + 
1.87x10-^C 
2.30x10-2 
6.37x10-^ 
0.9999 
3.03x10-^ 
3.07 
5-75 
A = 6 .98X10- ' 'H 
8.70x10 ^C 
1.46x10-2 
3 . 1 3 X 1 0 - ^ 
0.9999 
1.04x10-^ 
0.39 
Method D 
365 
10-200 
A = -8.76x10' ' 
3.11x10"C 
3 .88x10 2 
6.53x10-2 
0.9999 
9.06x10-*^ 
3.20 
Table 2. Test of precision of the proposed methods A, B, C and D. 
Proposed methods 
Method A 
Intraday assay 
Interday assay 
Method B 
Intraday assay 
Interday assay 
Method C 
Intraday assay 
Interday assay 
Method 0 
Intraday assay 
Interday assay 
Concentration, (n.g mL )^ 
Taken 
20 
35 
50 
20 
35 
50 
120 
280 
440 
120 
280 
440 
20 
40 
60 
20 
40 
60 
40 
100 
160 
40 
100 
160 
Found ±SD 
19.99 + 0.169 
35.03 + 0.133 
50.01 ±0.142 
20.02 ±0.220 
35.00 ±0.169 
49.99 ±0.270 
119.99 ±0.290 
279.89 ±0.478 
440,10 ±0.535 
119.89 ±0.447 
279.89 ±0.610 
439.78 ±0.811 
20.00 ±0.096 
40.01 +0.113 
59.98 ±0.150 
19.98 ±0.174 
39.99 ±0.149 
60.00 ±0.244 
40.02 ±0.176 
100.05 ±0.269 
160.02 ±0.228 
40.02 ±0.367 
100.05 ±0.420 
160.02 ±0.509 
Recovery 
(%) 
99.96 
100.08 
100.03 
100.11 
100.00 
99.98 
99.99 
99.96 
100.02 
99.91 
99.96 
99.95 
100.00 
100.04 
99.96 
99.89 
99.98 
100.00 
100.06 
100.06 
100.01 
100.06 
100.06 
100.01 
RSD^ 
(%) 
0.845 
0.378 
0.284 
1.098 
0.482 
0.538 
0.242 
0.171 
0.122 
0.373 
0.217 
0.363 
0.481 
0.283 
0.250 
0.872 
0.373 
0.406 
0.440 
0.269 
0.142 
0.918 
0.420 
0.318 
SAE" 
0.076 
0.059 
0.063 
0.098 
0.076 
0.120 
0.130 
0.214 
0.239 
0.200 
0.273 
0.363 
0.043 
0.051 
0.067 
0.078 
0.067 
0.109 
0.079 
0.121 
0.102 
0.164 
0.188 
0.228 
CL^ 
0.210 
0.165 
0.176 
0.273 
0.210 
0.334 
0.360 
0.594 
0.664 
0.555 
0.757 
1007 
0.119 
0.141 
0.186 
0.216 
0.185 
0.303 
0.219 
0.335 
0.283 
0.456 
0.521 
0.632 
''RSD, relative standard deviations (n = 5). 
''SAE, standard analytical error 
'^ CL, confidence limit at 95% confidence level 
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Table 4. Application of the proposed spectrophotometric methods to the determination of enalapril maleate in 
spiked human urine. 
Method A 
Method B 
Method C 
Method D 
Amount added (^g/mL) 
10,0 
250 
40.0 
.V 
RSD 
80.0 
320.0 
480.0 
X 
RSD 
20.0 
40.0 
100.0 
X 
RSD 
40.0 
80.0 
160.0 
X 
RSD 
Amount found (|ig/mL) 
9.83 
24.63 
39.56 
79.14 
319.25 
474.28 
19.45 
38.78 
99.52 
39.57 
79.83 
158.70 
% Recovery 
98.30 
98.52 
98.91 
98.58 
031 
98.92 
99.76 
98.81 
99.16 
0.52 
97,25 
96.96 
99.52 
97.91 
1.43 
98.93 
99.78 
99.19 
99.30 
0.44 
and D) and reference method al 95% coniidence 
level regarding accuracy and precision. The results 
are summarized in Table 3. The proposed methods 
have been extended to the determination of enala-
pril maleate in spiked human urine samples. The 
results of analysis of urine samples are summarized 
in Table 4. 
Conclusion 
The proposed method does not require any labo-
rious clean up procedure before measurement. In 
addition, the method has wider linear dynamic 
range with good accuracy and precision. The 
methods show no interference from the common 
excipients and additives. The statistical parame-
ters and recovery data reveal the good accuracy 
and precision of the proposed methods. Therefore, 
it is concluded that the proposed methods are 
simple, sensitive and rapid for the determination 
of enalapril maleate in commercial dosage 
forms. 
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